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Abstract 
Throughout our life cycle, the human body is exposed to harmful microorganisms. The 
innate immune system is a fundamental factor in the human body, which helps 
eliminate foreign organisms through specific signalling pathways with the 
involvement of immune receptors and signalling molecules.  
Viruses have evolved to infect the host and bypass the host immune responses, 
however a plethora of Pattern recognition receptors exist in the cell that are capable of 
detecting viral pathogens and mounting an innate immune response.  
Herpes simplex Virus Type 2 and Cytomegalovirus are common human pathogens 
that cause genital ulcerations, organ failure and mental health problems like 
encephalitis. In this study, we have aimed to identify the host’s innate immune 
response to HSV2 and HCMV infection in primary vaginal cells as well as Hela cells. 
Our data have shown that these viruses are recognized by TLR2 on the cell surface 
followed by intracellular PRRs such as TLR9, DAI, and IFI16, which trigger cytokine 
activation and release. Confocal imaging has revealed that these PRRs are located in 
different cell compartments and during viral cell entry and replication they can 
identify viral presence at specific parts of the cell. Therefore it seems that different 
PRRs are strategically placed in different cell locations to detect virus invasion and 
replication in order to activate cytokine secretion and protect the host. 
When different agonists for PRRs were used it was revealed that they were effective 
against Herpes virus infection thus indicating that a combination of PRRs agonists 
especially ones that trigger different cytokines could provide a wider spectrum 
prophylaxis to the host and they can be used to generate efficient treatment against 
HSV2 and HCMV infection.  
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1.1 The Immune System 
Immunology is a branch of biology and medicine, which is concerned about the 
immune system. This system gives the ability to the organism to be able to distinguish 
between self and non-self entities. From the beginning of human life, the human body 
has to defend itself from life-threatening organisms to stay alive. This highly specific 
defense mechanism against foreign microorganisms, which is provided by the immune 
system, is called immunity. The word immunity is derived from the Latin word 
immunitas that means, “to be exempt from”. The human body will be protected from 
particular disease causing infectious microorganism, known as pathogen, by 
triggering the certain mechanisms to eliminate this foreign organism. The immune 
system is divided into two different groups; innate immunity and adaptive (acquired) 
immunity. 
1.1.1 Innate Immunity 
In innate immunity the basic resistance will be exerted against the foreign organisms, 
innate immunity is present in the body since the birth of the person. It is the first line 
of defence, which has no self/nonself discrimination. This nonspecific immunity 
functions through three stages; atomic (mechanical) barriers, physiological (humoral) 
barriers and cellular barriers respectively. Anatomical barriers are skin and mucous 
membranes, whereas physiological barriers are temperature, pH and various soluble 
factors. If the pathogen is still able to survive, immune molecules phagocytes such as 
macrophages, dentritic cells appear and reactions like phagocytosis, endocytosis and 
inflammation takes place in order to destroy the infectious particle (Medzhitov, 2007). 
The innate immunity is able to identify vast variety of microorganisms from their 
particular patterns through innate immune receptors that distinguish these motifs. 
Pathogen-associated molecular patterns (PAMPs) and pattern recognition receptors 
 3 
(PRRs) were first referred by Janeway during Cold Spring Harbor Symposia on 
Quantitative Biology held in 1989. Primitive immune system, the evolvement of 
clonally distributed immunity from the innate immunity and how innate immunity can 
possibly operate, were the main topics that Janeway pointed out and discussed in depth 
(Janeway, 1989). He had a theory that other than foreign molecules modified proteins 
could also initiate antibody production in the host.  He suggested that immune system 
cannot only identify self/non-self, but also infectious and non-infectious molecules. He 
speculated that innate immunity and its’ receptors were responsible for this self/non-
self discrimination. This idea was in opposition to the  current belief of immunologists 
in those years. They believed that B and T-cells, were responsible for the recognition 
of these microbes. Janeway’s idea was supported by studies on the the immune 
mechanisms of invertebrates, since they can initiate an immune response against 
pathogens even though they lack the adaptive immunity. Lemaitre et al. supported 
Janeways’ hypothesis in a study in 1996, he showed that the‘Toll’ gene mutant 
drosophila was susceptible to fungal infection (Lemaitre et al., 1996). Innate immunity 
receptors of the host organism recognize these highly conserved motifs and activate 
the downstream signalling cascades. Each pathogen-associated molecular pattern is 
unique to that class of infectious microorganism and they are vital for the microbe 
survival. For this reason they are always conserved on the pathogen and they do not 
change structurally, resulting in the constant recognition by the innate immune system 
of the host cell.  
1.2 Pattern Recognition Receptors 
Pattern recognition receptors (PRRs) are proteins expressed by cells of the innate 
immune system to identify pathogen-associated molecular patterns (PAMPs), which 
are associated with microbial pathogens or cellular stress. PRRs can be divided into 4 
 4 
groups, which are: Toll-like Receptors (TLRs), Retinoic acid-inducible Gene-like 
Receptors (RLRs), Cytosolic DNA Sensors and Nod-like Receptors (NLRs). 
Toll-Like Receptors are the first pattern recognition receptors that have been identified 
in innate immunity. They are transmembrane proteins possessing a leucine rich 
repeated-domain (LRR-domain) at the extracellular amino-terminal (N-terminal), 
followed by a cysteine-rich domain that is a cytosolic carboxyl-terminal (C-terminal).  
Currently there are 13 TLRs that have been distinguished by the scientists (Figure 1.1). 
Human TLRs are TLR1-10, mice have TLR1-9, TLR11-13 but not TLR10. They 
recognise different pattern associated molecular patterns such as bacterial motifs, 
fungal proteins and viral protein structures. 
RLRs are cytosolic receptors that recognise viral RNA molecules. Retinoic-acid-
inducible protein 1 (RIG-I) and melanoma-differentiation-associated gene 5 (MDA-5) 
are responsible for dsRNA recognition (Yoneyama and Fujita, 2007). Even though 
LGP2 (laboratory of genetics and physiology 2) is a member of RLRs, it functions as a 
RIG-I and MDA-5 negative feedback regulator by acting on RIG-I repressor domain 
or by interacting with MAVS adaptor molecule (Komuro and Horvath, 2006;Saito et 
al., 2007;Yoneyama et al., 2005). 
Cytosolic DNA sensors are responsible for the cytosolic DNA recognition. DNA-
dependent activator of IFN-regulatory factors (DAI) interacts with cytosolic dsDNA to 
trigger type I IFN production (Takaoka et al., 2007), whereas another DNA sensor 
IFI16 (Interferon inducible protein 16) in the nucleus leads to IFN-β production by 
interacting with a signalling adaptor protein STING (Stimulator of interferon genes) 
(Unterholzner et al., 2010). Besides of IFI16, during cytosolic DNA detection, DDX41 
(DEAD box polypeptide 41) signals through STING as well (Zhang et al., 2011). 
Absent in melanoma 2 (AIM2) is a cytosolic DNA that causes inflammasome pathway 
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activation via adaptor molecule ASC (Apoptosis-associated speck-like protein 
containing a CARD), leading to caspase-1 activation and IL-1β, IL-18 secretion from 
the cell (Hornung et al., 2009). LRRFIP1 (Leucine rich repeat (in FLII) interacting 
protein 1) can sense cytosolic nucleic acids and start type I IFN production through 
beta-catenin-dependent pathway (Yang et al., 2010). P202 binds cytoplasmic dsDNA 
to inhibit caspase activation (Roberts et al., 2009). 
 NLRs are in the cytosol and are responsible for the recognition of PAMPs and 
endogenous molecules from bacteria. Depending on their N-terminal structures, NLRs 
can be divided into groups: NLRA, NLRB, NLRC, NLRP, and NLRX. 
1.3 The Discovery of Toll-like Receptors 
In 1985 Anderson and her group have discovered the gene called Toll in the 
Drosophila, which was playing an important role during the dorsal-ventral polarity 
development of the Drosophila embryo (Anderson et al., 1985). The relation of the 
toll-gene with the immunity was introduced in 1991 by Gay and Keith, mentioning 
that there were matching amino acid sequences between the cytoplasmic domain of 
Toll protein and the human interleukin-1 receptor (IL-1R) (Gay and Keith, 1991).  In 
1996 Lemaitre et al discovered that Toll gene in Drosophila, was functioning as a 
defence mechanism against fungal infections in the organism. Flies lacking the toll-
gene died in a couple of days after the infection (Lemaitre et al., 1996). This was 
followed by the discovery of hToll, the first human homologue of Toll, in 1997 by 
Medzhitov and Janeway and the discovery of 5 homologues of Drosophila Toll by 
Rock et al in 1998 (Medzhitov et al., 1997;Rock et al., 1998). Those five human toll-
like receptors were named TLRs 1-5, and it was TLR4 that was named as hToll by 
Medzhitov & Janeway. Experiments, carried out by Poltorak et al on TLR4 deficient 
mice, have shown that lipopolysaccharide (LPS) from gram-negative bacteria its the 
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ligand for TLR4 (Poltorak et al., 1998a). New studies indentified new TLRs thus after 
screening the murine genomic library in 1999 Takeuchi & Akira discovered a novel 
TLR that showed similarities to human TLR1, so they called it TLR6 (Takeuchi et al., 
1999b). Chuang and Ulevitch discovered TLR 7-9 in 2000 and TLR10 in 2001 
(Chuang and Ulevitch, 2001;Chuang and Ulevitch, 2000). TLRs are highly expressed 
in cells and tissues where immune response takes place. This includes macrophages, 
neutrophils, dentritic cells, cells in the lung, placenta, peripheral blood leukocytes, 
bone marrow, spleen, lymph node, thymus and tonsils. TLRs are either expressed on 
the cell surface or in the intracellular compartments of the cell. Receptors that are 
expressed on the cell surface are TLR1, TLR2, TLR4, TLR5 and TLR6. TLR3, TLR7, 
TLR8 and TLR9 sit in the intracellular part of the cell (Figure 1.1). TLRs are 
transmembrane proteins, which adopts two parts; ectodomain, made up of leucine rich 
repeats (LRR) at N-terminus where the ligand interacts with and intracellular 
cytoplasmic IL-1R homologous domain at C-terminus that initiates the inflammatory 
response in the cell.  
1.3.1 Toll-like Receptor Structure 
TLRs are type I transmembrane proteins, with pathogen binding domain forming the 
ectodomain, a transmembrane domain and Toll/IL-1R (TIR) domain that forms the 
endodomain. Leucine-rich-repeat (LRR) motifs sit at the ectodomain part where the N-
terminal is, whereas C-terminal owns TIR domain that is a homologue of that of IL-1R 
and this signalling domain triggers the downstream signalling cascade in the cell 
(Bowie A. 2000). A horseshoe shaped LRR domain, which is made of 19-25 tandem 
copies of LRR motifs, is approximately 20-30 amino acid residues long. LRR domain 
can be found in structures where protein-protein interaction is needed, it owns 
LxxLxLxxNxL conserved motif and xxLPxxxFx variable region. LxxLxLxxNxL 
forms parallel β-strands via “N” asparagine residue. Asparagine network is important 
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to create hydrogen bonds with neighbouring carbonyl groups, cysteine, threonine and 
serine residues can also form hydrogen bonds. Formation of H-bonds in the protein is 
important, because it maintains the shape of the ectodomain. Variable region 
xxLPxxxFx forms α helices and β-turns. This extracellular domain part is connected 
to cysteine rich residue and then to the TIR domain via a single transmembrane α 
helix. Toll/IL-1R (TIR) domain is approximately 160 amino acid residues long and it 
has 3 sequence boxes; Box 1, 2, and 3. The functional sides where the interaction of 
the TIR domain with its’ adaptor molecule occurs are at Box 2 and 3.  
1.3.2 Toll-like Receptor Signalling Pathways 
 During the recognition of PAMPs, TLRs function as a homodimer or heterodimer to 
generate the signalling cascade in the cell. TLR 1, 2, and 6 form heterodimers with 
each other whereas rest of the TLRs form homodimers. During this process adaptor 
molecules play an important role between the TIR domain of the TLRs’ and 
downstream signalling molecules. Adaptor molecules which are: Myeloid 
differentiation primary response gene-88 (MyD88), TIR associated protein (TIRAP), 
TIR-domain-containing adaptor protein-inducing IFN-β (TRIF) also known as TIR-
domain-containing molecule 1 (TICAM1), TRIF-related adaptor molecule (TRAM) 
functions in the downstream signalling cascades of TLRs. Once the LRR-domain 
recognizes and binds the pathogen, this leads to the conformational change of TIR-
domain that enables the adaptor molecules to associate with the TIR-domain in the 
cytosol. There are two pathways that TLRs are signalling through, which are MyD88-
dependent and TRIF-dependent signalling pathway (Figure 1.1). TLR 1, 2, 4, 5, 6, 7, 8, 
and 9 initiates the signalling cascades via adaptor molecule MyD88, whereas TLR 3 
signals through TRIF. TLR 4 uses both of the signalling pathways.  
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MyD88 molecule functions together with IRAK family members which are IRAK-4, 
IRAK-1, IRAK-2 and IRAK-M, they contain death domain at the N-terminus and a 
serine/threonine kinase domain (Janssens and Beyaert, 2003). IRAK family members 
act through MyD88 pathway and also triggering mitogen-activated protein kinase 
pathway (MAPK). MyD88 recruits IRAK-4 (IL-1 receptor-associated kinase-4) and 
IRAK-1 via their death domains, IRAK-4 is the one that phosphorylates IRAK-1, 
which leads to the activation of TRAF6 (TNF receptor associated factor 6) (Burns et 
al., 2003;Cao et al., 1996). TRAF6 and UBC13/UEV1A functions as a ubiquitin 
protein ligase E3 and E2 respectively. They catalyze the polyubiquitin chain on 
TRAF6 itself and on IΚΚ-γ/NEMO (NEMO: ΝF-κΒ essential modulator) by creating 
a complex made of TRAF6, TAK1/TAB1/TAB2/3, NEMO/IΚΚ-γ/IΚΚ-β/IΚΚ-α. 
Besides of this, IRF-5, which is the transcription factor, moves into the nucleus to 
trigger synthesis of cytokine genes. TAK1 (TGF-β activated kinase 1) gets activated 
via interaction of TAK1 binding proteins TAB1, TAB2/3 complex (Jiang et al., 
2002;Takaesu et al., 2000). TAB2 and TAB3 use their ZnF (zinc finger) at their C-
terminal to be able to bind K-63 linked polyubiquitin chains in order to activate TGF-β 
activated kinase 1 and IKK (Kanayama et al., 2004). After Lysine 63-linked 
polyubiquitin chains on NEMO have been catalyzed by E3 and E2, in IΚΚ complex, 
which consists NEMO/IΚΚ-γ/IΚΚ-β/IΚΚ-α, TAK1 phosphorylates IΚΚ-β. This is 
followed by the phosphorylation of IκΒ which is bound to ΝF-κΒ, K48 ubiquitinates 
IκΒ, leading to its’ degradation. When IκΒ is degraded ΝF-κΒ is free, so it gets 
translocated in to the nucleus to initiate the proinflammatory cytokine gene expression. 
TAK1 also activates MAPK pathway (mitogen-activated protein kinase pathway) 
which causes the phosphorylation of Jun Kinases (JNKs), p38 and CREB (cyclic 
AMP-responsive element-binding protein). At the end AP-1 (activator protein 1) 
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transcription factor also moves into the nucleus and function with ΝF-κΒ and IRFs to 
trigger transcription of proinflammatory cytokine genes.  
TRIF-dependent signalling pathway is achieved via TRAM, which is known as TRIF-
related adaptor molecule, functioning between TIR-domain of TLR and TRIF. TRIF is 
an essential adaptor molecule during TRIF dependent signalling pathway of TLR3 and 
TLR4 (Yamamoto et al., 2003;Yamamoto et al., 2002). TRAM and TRIF are TIR-
domain containing molecules, which leads to production of IFN-β and IFN-inducible 
genes (Yamamoto, M., 2002; Oshiumi H., 2003). TRIF acts together with TRAF6 and 
RIP1 (receptor-interacting protein 1) on IΚΚ-i and TBK1 (TRAF-family-member-
associated ΝF-κΒ activator (TANK) binding kinase 1). TRAF interacts with N-
terminal of TRIF, whereas RIP interaction takes place at the C-terminal of a RIP 
homotypic interaction motif (RHIM) of TRIF (Meylan et al., 2004). IRF-3 
phosphorylation by IΚΚ-i/TBK1, leads to the translocation of IRF-3 into the nucleus 
to trigger type I interferon production. 
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Figure 1.1: The diagram shows the distribution of the TLRs on the surface and inside of the cell in 
mammals. Specific ligands for each TLR and signalling cascade pathways they activate, is clearly 
represented in the diagram. Adapted from a nature review O'Neill et al. (2013). 
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1.3.3 Toll-like Receptors 
1.3.3.1 TLR2, TLR1 AND TLR6 
TLR2 can form heterodimers with TLR1 or with TLR6 to recognize a wide range of 
PAMPs and DAMPs on the cell surface where they are expressed (Figure 1.1). When 
TLR2 pairs up with other receptors, they can recognize bacterial PAMPs like triacyl 
lipopeptides from bacteria and mycobacteria, diacyl lipopeptides from mycoplasma, 
atypical lipopolysaccharides (LPS), lipoarabinomanan from mycobacteria, soluble 
factors, OspA, Porin PorB, proteoglycans, heat shock proteins (HSP 60, 70, GP96), 
high mobility group proteins (HMGB1), glycolipids, lipoteichoic acid (LTA) and 
peptidoglycans from Gram-positive bacteria. Fungal structures like yeast/zymosan, 
glycosylphosphatidyl inositol like proteins that belong to parasites. TLR2 can 
recognize viral particles from cytomegalovirus and from HSV which trigger 
downstream signalling cascades (Compton et al., 2003;Kurt-Jones et al., 2004). 
TLR2 and TLR6 can associate together to recognize diacyl lipopeptides from bacteria 
and lipoteichoic acid (LTA) from gram-positive bacteria cell wall, yeast/zymosan 
from fungi, glycosylphosphatidyl inositol linked proteins from parasites (Triantafilou 
et al., 2006). The association of the TLR2 and TLR6 forms an ‘m’ shaped heterodimer. 
This heterodimer structure has two N-terminals that extends away from each other to 
the opposite direction. Ligand-binding sites sit at the central parts and C-terminals of 
the receptors overlapping parts. The difference in the structure of the ligand binding 
sites of TLR1 and TLR6 lead to the discrimination between the diacylated and 
triacylated lipopeptides. The structural difference of TLR1 and TLR6 lies in the 
ligand-binding site of TLR6 where side chain residues of Phenylalanine partially block 
the binding site. Thus the TLR6 ligand-binding site is half the length of the TLR1. 
TLR2 and TLR1 heterodimer ligands  
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1.3.3.2 TLR3 
TLR3 forms a dimmer structure to recognize its’ ligands. TLR3 is another receptor 
that recognises viral dsRNA as well as the synthetic dsRNA poly (I:C) (polyinosine-
polycytidylic acid) (Alexopoulou et al., 2001). TLR3 resides in endosomes and 
triggers type 1 interferon and ΝF-κΒ production after the recognition of dsRNA, 
TLR3 is expressed in B cells, T cells, natural killer cells, dendritic cells at the 
endosomal/lysosomal compartment of the cell. TLR3 triggers IFNα/β and 
inflammatory cytokine secretion through the TRIF-dependent signalling pathway via 
TRIF and TRAM signalling adaptor molecules.  
1.3.3.3 TLR4 
TLR4 recognizes  bacterial lipopolysaccharide (LPS), which is found in the structure 
of a Gram-negative bacteria cell wall and is the main cause of septic shock (Poltorak 
et al., 1998b;Takeuchi et al., 1999a). (Bryant et al., 2010;Mullarkey et al., 2003). 
Recognition of LPS is achieved with the help of lipopolysaccharide-binding protein, 
CD-14 and MD-2 (Schumann et al., 1990;Shimazu et al., 1999;Wright et al., 1990). 
(Miyake, 2007;Shimazu et al., 1999). The main PAMP of TLR4 is bacterial LPS, but 
it has been shown to interact with several different viruses as well. Using TLR4-
deficient mice, it was found that TLR4 is involved in the innate immune response to 
RSV, through an interaction with the viral envelope fusion protein  Mouse mammary 
tumour virus (MMTV) and Coxsackievirus (Kurt-Jones et al., 2000; Haynes et al., 
2001]. 
1.3.3.4 TLR5 
TLR5 is synthesized on the cell surface of epithelial and endothelial cells where it 
detects bacterial flagellin, leading to the activation of MyD88 pathway (Hayashi et al., 
2001;Zhang et al., 2005).  
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1.3.3.5 TLR7 and TLR8 
TLR7 and 8 are expressed in the cells of lungs, placenta, spleen, lymph node and bone 
marrow (Chuang and Ulevitch, 2000). They are located in the endosomal 
compartments where they recognize single-stranded RNA which leads to the 
activation of the MyD88 pathway, the synthesis of ΝF-κΒ followed by inflammatory 
cytokine and type 1 interferon secretion. These endosomal receptors have their 
pathogen recognition site inside the endosome whereas the TIR domain is in the 
cytoplasm of the cell. They detect the uridine-rich or both uridine and guanosine-rich 
single-stranded RNA from viruses like HIV, VSV, Influenza virus as well as 
imiquimod and resiquimod (R-848) analogues which are derived from 
imidazoquinoline (Diebold et al., 2004;Heil et al., 2004;Hemmi et al., 2002). 
1.3.3.6 TLR9 
Endosomal compartments of B and T cells, dentritic cells, monocytes and 
macrophages express TLR 9. This receptor size is 1032 a.a. residues long and it has a 
molecular weight of 115.9 kDa (Chuang and Ulevitch, 2000). TLR 9 plays an 
important role in the recognition of viral unmethylated CpG DNA from HSV-2 and 
bacterial unmethylated dinucleotide CpG DNA (Hemmi et al., 2000;Krieg, 2002;Lund 
et al., 2003). TLR9 can detect A/D type CpG DNA from synthetic oligonucleotides to 
initiate synthesis of type 1 interferon α\β in the plasmacytoid dentritic cells and IFNα 
production in human peripheral blood cells (Krug et al., 2001;Verthelyi et al., 2001). 
TLR9 can bind its’ ligand directly which lead to conformational changes on the 
ectodomain of the TLR9 (Latz et al., 2004;Latz et al., 2007).  
Studies have shown that recognition of CpG DNA from HSV 1 and HSV-2 leads to 
IFNα secretion in plasmacytoid dentritic cells (Krug et al., 2004a;Krug et al., 
2004b;Lund et al., 2003). TLR9 can activate the immune response in the cell when it 
 14 
detects viral DNA but not self-DNA; this recognition of “self” and “non-self” is 
because its localisation (Stetson et al., 2006). Conformational change of TLR9 is 
achieved when the CpG DNA binds to its’ LRR domain, this structural change leads to 
the activation of the TLR9 dimer by bringing the TIR-domains closer which allows the 
signalling adaptor molecule to bind to the receptor.   
TLR9 signalling is through the adaptor molecule MyD88 which recruits transcription 
factor IRF-7 leading to type 1 IFN production (Honda et al., 2005a). Activation of this 
MyD88\ IRF7 pathway, leads to the expression of  TNFα, IL-6, IL-1 and type 1 IFNs.  
1.3.3.7 TLR10 
TLR 10 does not exist in mice but in humans, it is expressed on the cell membrane but 
the ligand for TLR10 is unknown. Human TLR10 is closely related to human TLR1 
with 50% amino acid equality and to human TLR6 with 49% amino acid equality 
(Chuang and Ulevitch, 2001). 
1.3.3.8 TLR11 and TLR12 
TLR 11 and TLR12 exist in mice whereas humans do not have these receptors. Studies 
have shown that TLR11 knockout mice, die from kidney infection from uropathogenic 
bacteria, thus confirming its importance (Zhang et al., 2004). Toxoplasma gondii is 
also recognized by TLR11, leading to the production of IL-12 through MyD88 
pathway (Yarovinsky et al., 2005). (Andrade et al., 2013). 
1.3.3.9 TLR13 
TLR13 exists in mice and is located in the endosome and functions during recognition 
of bacterial 23S ribosomal RNA, a binding side for antibiotics (Oldenburg et al., 2012). 
Moreover at the recent experiments done by Hidmark et al. on CHO (Chinese hamster 
ovary) cells, it was clear that TLR13 could bind to the bacterial RNA to activate ΝF-
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κΒ, when TLR7 did not exist in the cell (Hidmark et al., 2012). TLR13 triggers IL-1β 
production after the recognition of rRNA from bacteria via the adaptor molecule 
MyD88 pathway and through endoplasmic reticulum transmembrane protein UNC93b 
(Li and Chen, 2012).  
1.3.4 Toll-like Receptors Viral recognition and Modulation in 
the Cell  
TLRs are expressed in variety organs and tissue types and have different location in 
the cell. Innate immunity cells like macrophages, dentritic cells, mast cells, neutrophils 
have these TLRs as well. Once viruses manage to pass through the physical barriers it 
will be recognized since it displays PAMPs, which are non-existent in eukaryotic cells. 
The innate immune cells will recognize the glycoproteins on the surface of the virus, 
as well as the nucleic acid in the nucleocapsid of the virus. Virus cell entry will trigger 
activation of signalling cascades leading to the interferon and proinflammatory 
cytokine secretion from the host. Secretion of these, leads to the magnification of the 
immune response, by initiating chemokine synthesis, cell apoptosis, by gathering 
immune effector cells, memory cells to the point of infection. They can either bind to 
the specific receptors in the same the cell or on other cells.  
The first transmembrane receptors that will come into a contact with a virus are the 
ones that are expressed on the cell membrane such as TLR1, TLR2 and TLR6  It was 
shown that TLR2 binds to gH/gL and gB glycoproteins of HSV, binding of gh/gL 
leads to the activation of the ΝF-κΒ signalling cascade (Leoni et al., 2012). In addition 
HSV gB binds to TLR2 and initiates ΝF-κΒ via MyD88 adaptor molecule and TNF 
receptor associated factor 6 (TRAF6) dependent pathway (Cai et al., 2013).   
After the internalisation of the virus TLRs that are located in the endosomal 
compartments of the cell take action. TLR3 is one these receptors and it recognizes the 
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dsRNA molecule of the virus, which lead to further activation of the ΝF-κΒ and IRF3 
transcription factors, followed by pro-inflammatory cytokine and type I interferon 
synthesis (Alexopoulou et al., 2001). TLR3 uses TRIF-dependent signalling pathway 
for initiating the immune response in the cell.  
Other receptors that function during the antiviral response are TLR7 and TLR8 which 
recognize the single stranded viral RNA and activate pro-inflammatory cytokine and 
type I interferon secretion (Heil et al., 2004;Hemmi et al., 2002;Lund et al., 2004). 
Un-methylated CpG motifs of viral and bacterial genome are recognized by 
endosomal TLR9. TLR9 will bind to its ligand and interact with its adaptor molecule 
MyD88 and activate type I IFN and pro-inflammatory cytokine production (Hemmi et 
al., 2000;Krug et al., 2004a;Krug et al., 2004b;Lund et al., 2003). 
1.4 Innate Immunity and DNA sensors 
The viral and bacterial PAMP and genome recognition takes place in the endosomes 
as well as in the cytosol. The DNA of the pathogen is released into the cytosol, either 
through lysosomes, or through TREX1 (three prime repair exonuclease 1). When the 
pathogenic DNA has to be metabolized it ends up in the lysosomes where it is digested 
by DNase II. However in cells which lack the mechanism of DNase II, digestion the 
DNA enters into the cytoplasm (Okabe et al., 2005). TREX1 is a cytosolic DNase that 
sits on the endoplasmic reticulum and functions during the endogenous DNA 
degradation. The cells lacking TREX1 protein have pathogenic protein build up in the 
cytosol, which initiates the immune response (Stetson et al., 2008;Yang et al., 2007) 
When DNA virus replication takes place in the nucleus degradation is prevented. 
However in the cytoplasm ubiquitinalation of the HSV capsid occurs leading to 
degradation and viral genome exposure, leading to recognition by DNA sensors in the 
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cytosol (Horan et al., 2013). Cytosolic DNA sensors give a new insight in pathogen 
recognition in the cytosol and the DNA sensing mechanisms of the host. 
1.4.1 DAI 
This receptor was first discovered by Fu et al. and was named DLM-1 (Fu et al., 1999). 
DAI is a dsDNA sensor protein in the cell cytoplasm that initiates interferon 
production in the cell after HSV-1 infection (Takaoka et al., 2007). Besides HSV-1, 
DAI can also detect HCMV as well (DeFilippis et al., 2010a). DAI can also form 
complexes with RIP-3 to initiate necrosis in fibroblasts (Upton et al., 2010;Upton et al., 
2012). The murine cytomegalovirus can interact with DAI through its M45 protein 
RHIM domain and inhibit DAI functioning to stop the immune response (Rebsamen et 
al., 2009). There are two RIP (receptor-interacting protein) homotypic interaction 
motifs (RHIMs) in DAI, which are conserved in the genome. Deletions or mutations 
on RHIM domains cannot initiate NF-kβ expression. RHIMs are the motifs which RIP 
kinases RIP1 and RIP3 can interact with. RIP2 and RIP4 lack RHIMs thus DAI cannot 
interact with them directly. In 2001 it was shown that DLM-1/DAI has Z-DNA 
binding domain at amino terminus where the receptor binds to Z-DNA. This domain is 
homologous to Zα and Zβ domains of ADAR1 (adenosine deaminase RNA-specific 1) 
(Schwartz et al., 2001) (Figure 1.2). 
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Figure 1.2: The detailed structure of the Z-DNA binding domain of DAI/DLM-1/ZBP-1 to Z-DNA. a) 
The structure of Z-DNA and Zα-DLM complex, grey helix is the DNA molecule attached to the domain, 
green dots are water molecules and hydrogen bonds between two proteins are shown as dashed lines. b) 
Representation of the Zα and Zβ domains of DAI (blue) with a C-terminal domain (grey). c) The 
detailed structure showing the residues involving and the type of the bonds forming between the binding 
domain and Z-DNA. The binding domain is represented on the left hand side and the Z-DNA is 
represented on the right hand side. Green ‘W’ are water molecules, white circled lines are Van der 
Waals, pink circles are phosphate groups of the DNA, dashed lines are hydrogen bonds and black 
circled line is CH-π which is located at the centre of the hydrophobic core Schwartz et al. (2001). 
 
 During the detection of the dsDNA, IRF3 (Interferon Regulatory Factor 3) 
transcription factor and the TBK1 serine/threonine kinase is recruited by DAI 
cytosolic receptor. Activation of IRF3 leads to the activation of type 1 interferon 
synthesis without initiating ΝF-κΒ and MAP kinase pathway (Stetson and Medzhitov, 
2006). According to the experiments done on bone marrow pDCs, macrophages, 
viruses like HSV type 1 and type 2 can trigger type 1 IFNα and type 1 IFN-β 
production through TLR dependent or independent manner (Hochrein et al., 
2004;Malmgaard et al., 2004). HSV-2 was shown to signal through IRF3 and ΝF-κΒ 
to initiate the IFNα/β in macrophages and type 2 triggers higher amounts of IFNα/β 
synthesis compared to type1 Herpes Simplex Virus.  
1.4.2 AIM2 and IFI-16 
 AIM-2 and IFI-16 are from the PYHIN protein family; other members of this group 
are IFIX and MNDA. This family shares structural common features, which is a pyrin 
domain and two DNA binding HIN-200 domain. However AIM-2 pyrin domain shares 
more similarities to those of NLRPs and of ASC. After the sequence analysis it was 
understood that other PYHIN family members are located in the nucleus whereas AIM 
is located in the cytosol (Bürckstümmer et al., 2009;Hornung et al., 2009). AIM-2 
gene was first discovered in 1997 and they named it Absent In Melanoma gene 2, the 
name was representing the gene that was missing in malignant melanoma chromosome 
1 which was coding for a protein that had common amino acid residues as the 
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interferon-inducible gene family (DeYoung et al., 1997). AIM-2 recognizes the 
dsDNA and interacts with ASC to initiate IL-1β secretion in THP-1 monocytic cells. 
Moreover the inflammasome response was attained in unresponsive HEK293 cells by 
introducing AIM-2, ASC, caspase-1 and IL-1β (Bürckstümmer et al., 2009). The 
detection of the cytosolic bacterial, viral and host DNA takes place independent of 
NALP3 but not ASC, as a result activating the inflammasome response (Muruve et al., 
2008). The AIM-2 protein interacts with the cytoplasmic DNA directly through its 
HIN-200 domains to oligomerize, followed by binding to its adaptor molecule ASC 
(also known as PYCARD, CARD5) forming pyroptosome to activate Caspase-1 
leading to pro-inflammatory cytokine expression also leading to pyroptosis 
(Fernandes-Alnemri et al., 2009;Roberts et al., 2009b). HEK293 cells gain 
responsiveness to cytoplasmic DNA after the continuous expression of the AIM-2 
inflammasome, in addition to that silenced AIM-2 results in reduced inflammasome 
and pyroptosis in macrophages (Fernandes-Alnemri et al., 2009). ASC has PYD (pyrin 
domain) at the N-terminal and CARD (caspase recruitment domain) domain at the C-
terminal, which is the effector domain for the caspase-1 activation (Srinivasula et al., 
2002). AIM2 interacts with this adaptor molecule through their pyrin domain via 
homotypic interactions. The AIM-2 and ASC complex is called AIM-2 inflammasome 
(Hornung et al., 2009). Pro-caspase-1 is the inactive form of the Caspase-1 and the 
interaction with the ASC through the CARD domains, activates Caspase-1. This active 
protein cleaves the inflammatory cytokines pro-IL-18 and pro-IL-1β into IL-18 and 
IL-1β, which are then secreted out of the cell (Hornung et al., 2009). The AIM-2 
inflammasome complex formation can trigger pyroptosis  through ASC and caspase-1. 
Pyroptosis is a programmed cell death that is triggered as a result of infectious or non-
infectious agent entry by an inflammasome complex and caspase-1 interaction and 
activation.  
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IFI-16 is another innate immune receptor that recognizers viral DNA in the cell. This 
PYHIN protein binds to dsDNA to induce the IFN-β expression by recruiting STING 
adaptor molecule (Unterholzner et al., 2010). HIN A and HIN B domains of IFI-16 are 
formed from α helices and β strands, each domain possess two 
oligonucleotide/oligosaccharide binding (OB) sites (Liao et al., 2011). OB1-OB2 
linker that links the OB sites also OB2 owns most of the DNA binding-residues in the 
HINB domain of IFI-16, forming hydrogen bonds, Van der Waals with the phosphates 
groups of the DNA backbone (Jin et al., 2012) (Figure 1.3).  
 
 
Figure 1.3: The detailed representation of IFI-16 HINb (on the right) and DNA complex (on the left) 
interaction. Grey and yellow DNA strands on the left-hand side are forming main and side chain 
hydrogen bonds (grey dashed lines) with the HINb domain of IFI-16. Pink coloured dashes indicate the 
boundary of OB1 and OB2. Minor and major grooves are illustrated in grey. Residues that are forming 
bonds with the DNA molecules are written in black. Adapted from Jin et al. (2012).   
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Experiments using dsDNA vaccinia virus motifs and HSV DNA fragments showed 
that IFI16 directly binds to the DNA of the virus. This interaction takes place via its’ 
HIN domains HINa and HINb colocalize with DNA, leading to IFN-β production 
(Unterholzner et al., 2010). In HSV-1 infection the IFN-β expression is dependent on 
STING, which is a signalling adaptor. Imaging experiments tagging HSV-1 DNA 
showed that while the viral capsid was in the cytosol, HSV-1 replication took place in 
the nucleus (Ishikawa et al., 2009;Unterholzner et al., 2010). Since IFI-16 is expressed 
in the cytoplasm and the nucleus, the viral DNA can be recognized by IFI-16 either in 
the cytoplasm or in the nucleus where the replication takes place (Li et al. 2012)  
NSL acetylation has been identified as a mechanism underlying the dynamic 
localization of IFI16 that extended its range of DNA surveillance. Phosphorylation 
clusters occur within two regions of IFI16: the linker region and C-terminus and lysine 
acetylation sites?(S724) The two major NLS motifs, Δmotif-1 and Δmotif-2, contained 
acetylations at K99 and K128. It was shown that the phosphorylations within the 
linker region (S95, S106 and S153) had only minor roles in IFI16 localization. Since 
both lysine sites are highly conserved among IFI16 homologs and HIN-200 family 
members that suggests that acetylation is a common regulator of subcellular 
localization (Li et al. 2012).  
In a recent study, HCMV and HSV-1 were shown to colocalize with the IFI-16 
receptor in the cytoplasm, followed by induction of IFN-β expression in human 
macrophages (Horan et al., 2013). Ubiquitinalation of the HSV capsid triggered the 
proteasomal degradation and the release of the HSV DNA to the cytoplasm, which 
was recognized by IFI-16 in the cytoplasm (Horan et al., 2013).  Another study has 
shown that Kaposi Sarcoma related herpesvirus infection leads to the IFI-16/ASC 
inflammasome complex formation in the nucleus of the endothelial cells (Kerur et al., 
2011). 
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1.4.3 STING 
 
STING (also known as MPYS, ERIS, TMEM173, MITA) signalling molecule has an 
important role during the type 1 interferon induction after the cytosolic DNA sensing 
(Ishikawa and Barber, 2008;Sun et al., 2009;Zhong et al., 2008). This membrane 
protein was first described by Jin et al in 2008 interacting with MHC class 2 molecules 
to initiate a death signal in B lymphoma cells by activating the extracellular signal 
regulated kinase (ERK) pathway (Jin et al., 2008). STING is 4 transmembrane regions 
where it binds to the ER membrane and it has an N-terminal, which is 130 amino acids 
long with 250 amino acids long globular shaped C-terminal. Inactive state of STING 
CTD is a dimmer and this structure is not dependent on the ligand binding (Ouyang et 
al., 2012;Shang et al., 2012;Shu et al., 2012;Yin et al., 2012). C terminal globular 
region of STING is located in the cytoplasm, where it responds to the cytosolic 
dsDNA and cyclic dinucleotides. The recognition of the B-DNA, HSV-1 DNA, 
bacteria Listeria monocytogenes, cytomegalovirus, vaccina virus and baculovirus in 
the macrophages, dentritic cells, acquires STING to trigger an immune response and 
initiate IFN production (Ishikawa et al., 2009). During this research it was observed 
that STING was relocalizing with the TBK1 from ER to the perinuclear vesicles. 
Besides of STING functioning as a downstream signalling molecule during the 
intracellular DNA recognition, STING was shown to be the direct immune sensor for 
the cyclic dinucleotides, such as cyclic di-GMP (Burdette et al., 2011). The ligand 
interaction enables the TBK1 and IRF3 binding at the globular C-terminal for IRF3 
phosphorylation by TBK1 (Tanaka and Chen, 2012). The mutations at the residues 
Ser366 and Leu374 in the binding site of CTD-STING destroyed the IRF3 binding to the 
CTD, but did not affect the TBK1 interaction, thus stopping the IRF3 phosphorylation 
and activation by TBK1 (Tanaka and Chen, 2012). However these mutations did not 
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affect the TBK1 binding to the CTD-STING. The nucleic acid binding is followed by 
recruitment and activation of TBK-1, leading to relocalization of STING moves from 
the endoplasmic reticulum to the different part of the cytoplasm. TBK1 phosphorylates 
IRF3 transcription factor, which enters into the nucleus to initiate IFN-β production.  
1.5 Signalling Pathways of Intracellular DNA Sensors 
Several signalling receptors have evolved to detect nucleic acids in viruses and other 
microorganisms. DNA is not unique to pathogens and so it is more difficult to 
distinguish microbial nucleic acids from self nucleic acids; multiple sophisticated 
mechanisms have evolved to carry out this task. Recent advances in the field have 
identified DNA sensors IFI-16, DAI, AIM2 inflammasome and DExD/H box helicases. 
As well as the STING adaptor molecule, which recognize viral DNA. 
IFI-16 can be found in the cytoplasm or at the nucleus and initiates IFNα/β production 
via the adaptor molecule STING. STING resides at the endoplasmic reticulum 
membrane where it is in its’ inactive form. Viral invasion and detection of the nucleic 
acids in the cytoplasm leads to the colocalization of STING with TBK1 to the 
perinuclear vesicles. TBK1 phosphorylates IRF3, which moves to the nucleus to 
initiate type I interferon response. 
The recognition of the viral DNA by the Z-DNA binding domain of DAI, also 
includes TBK1 and IRF3 molecules, HSV1 and HSV2 infection in macrophages, 
triggers IFN α/β production through IRF3.   
AIM2 links with ASC via homotypic interactions, to form an inflammasome complex, 
which binds to the pro-caspase1 and cleaves it. Active caspase 1 cleaves the 
inflammatory cytokines pro-IL-18 and pro-IL-1β into IL-18 and IL-1β. Besides of the 
inflammatory response, this inflammasome complex formation triggers pyroptosis 
(cell death). 
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1.6 The Discovery of Viruses 
The word virus comes from the Latin, which means poison, a potent juice. These small 
infectious entities were first discovered in 1892, by a Russian botanist Dmitri 
Iosifovich Ivanovsky, in a tobacco plant. Former to this discovery, a German chemist 
Adolf Mayer was working on tobacco mosaic disease, where he reported the juice 
extract of the infected plants was infectious for the healthy ones. He also used a term 
‘mosaic’ to name the disease, because of the mosaic of dark and light spots on the 
leaves of an infected tobacco plants. In 1892 Ivanovsky mentioned that, a filterable 
infectious agent caused the tobacco mosaic disease. He used a filter, to filter the 
extract from the infected tobacco plants, then he injected this liquid to the healthy 
plants. As a result healthy tobacco plants were infected with the mosaic disease as well. 
Besides of Ivanovskys’ studies, Martinus van Beijerinck has performed similar 
experiments to that of Ivanovskys’. He came to a conclusion that, this infectious 
substance was multiplying in living plants where there is a continuous cell division, 
the extract had living contagious fluid inside and this fluid could keep its’ virulent 
property for years. Beijerinck was not able to see this infectious filterable agent under 
the light microscope and with the findings of Ivanovsksy, he was convinced that it was 
a ‘contagium vivum fluid’ (contagious living fluid). After many years in 1935, 1936 
and in 1939, the crystallization, X-ray crystallography and the electron microscopy 
images of the tobacco mosaic virus (TMV), lead to a better understanding of the 
structure of this filterable virulent particles.  
Viruses are small infectious pathogens that can only replicate in the cells of living 
organism that they infect. Their size and complexity varies but they all have common 
features. The viral genome has either single stranded or double stranded DNA or RNA, 
and depending on the genome the replication process varies from virus to virus.  
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 A typical virion structure is made up of a core that consists of a nucleic acid, a capsid 
protein that encloses the nucleic acid, a tegument, which is the part between the core 
and the envelope which has all essential enzymes and proteins for the first stages of 
viral replication, a lipid envelope that is used forl entry into the host cell.  
Electron microscopy studies showed that viruses have different complexity, shapes 
and sizes, thus in the past they were classified using the Linnaean hierarchical system 
or the Baltimore classification system, according to their nucleic acids in the core, the 
lipid membrane, the size and the symmetry of the capsid and the virus. They were also 
separated according to the disease type they were causing and the type of cells they 
were infecting. Nowadays viruses are classified with the help of sequencing 
technologies, depending on their genomic sequences (Table 1.1).  
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Table 1.1: Virus classification according to their nucleic acid 
 
 
 
 
 
1.6.1 Herpes Simplex Viruses 
Herpesviridae family members are linear DNA viruses that have a core enclosed in a 
capsid, a tegument, an envelope and glycoproteins (Table 1.1). These large viruses 
have a large genomic size. Herpesviruses are divided into three subfamilies, depending 
on their tissue tropism. These are alpha-Herpesviridae which infect the nervous tissues 
(neurotropic), beta-Herpesviridae and gamma-Herpesviridae which infect the 
lymphatic system (lymphotropic).  Herpes simplex virus types 1 and 2 (HSV-1 and -2), 
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and varicella-zoster virus (VZV) belong to alpha-Herpesviridae, (McGeoch et al., 
1995). Beta-Herpesviridae include cytomegalovirus (CMV, also known as HSV-5), 
human herpes virus 6 (HSV-6), human herpes virus 7 (HHV-7). The gamma-
Herpesviridae subfamily consists of Epstein-Bar virus (EBV) and Kaposi’s sarcoma 
herpesvirus (KSHV) (human herpesvirus-8 (HHV-8)).  
Herpes simplex viruses type 1 and type 2 both belong to the alpha-Herpesviridae 
subfamily, both types share almost half of their DNA. HSV 1 causes facial herpetic 
lesions, whereas HSV 2 leads to genital herpetic lesions, but both types infect mucosal 
surfaces and they have the ability to stay latent in the nervous system. The viral genes 
that are expressed at very first stages of the viral replication cycle maintain continuous 
latency of these viruses. Latency associated transcripts are the viral proteins sustaining 
the latency. LATs trigger the reactivation of the virus, however this cycle can be 
triggered due to a stress as well. The difference between these types is the tissue and 
organ that they infect in the organism. Usually the latency period of HSV-1 takes 
place in the nerve cells near the ear.  HSV-1 can cause serious damage depending on 
the part it is infecting. Viral infection can either take place in the eye (ocular herpes) 
causing blindness or in the brain (herpes encephalitis), which can be lethal.  However 
HSV-1 usually takes place on the face, chest and lips. HSV-2 stays latent in the base 
of the spine, and then moves to the genital area. This type does not spread as much as 
type-1 and usually it is not lethal, unless it is affecting newborns. Most people do not 
realize that they actually have the virus until the symptoms of the viral infection 
appear. Both types can be transmitted orally or sexually.  
HSV-1 has a total genome length of 152,260 residues with 68.3% G + C base 
composition (McGeoch et al., 1988) (Table 1.2).  
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HSV-2 has 70.4% G + C composition with a total genome size 154,746 bp (Dolan et 
al., 1998) (Table 1.2). 
 
Table 1.2: Genome length and composition of different regions of HSV-1 and HSV22. Adapted from 
Dolan et al. (1998). 
 
There are twelve glycoproteins in the lipid bilayer of the herpesviruses, not all of their 
functions are understood, however the main glycoproteins that function during viral 
infection are gB, gC, gD, gH and gL. Glycoproteins B, D, H and L play an important 
role during the fusion of the virus with the host cell membrane (Cai et al., 
1988;Forrester et al., 1992;Roop et al., 1993) (Table 1.3). 
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Table 1.3: List of glycoproteins in the lipid bilayer of herpesviruses and their functions 
 
Glycoprotein B is needed during the viral entry of herpes simplex virus. All 
herpesviruses do have glycoprotein B and it works together with gH/gL for fusion of 
the virus in to the host cell. These glycoproteins are highly conserved in almost all 
herpesviruses. Glycoprotein B does not have fusion peptide, however the research on 
cytoplasmic domain mutant gB protein does suggest that this protein does have an 
effect on the fusion of the virus (Cai et al., 1988). The ectodomain of glycoprotein B 
consists of three promoters A, B and C coiled around each other with a left-handed 
twist and each promoter has 5 different domains (Heldwein et al., 2006) (Figure 1.4). 
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Figure 1.4: The structure of glycoprotein B. A) Is the crystal structure of full-length of ectodomain of 
one promoter of gB. Different colours are given for each domain. B) Single gB promoter represented in 
ribbon diagram. Colours and numberings are referring to the promoter in figure A. Dots are disordered 
segments. C) Trimer structure of gB, white and grey structures are referring to other two promoters B 
and C respectively. D) gB trimer. Adapted from Heldwein et al. (2006) 
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Glycoprotein C functions during the host cell recognition, and this non-essential 
binding of the virus is supported with the cell surface receptor heparan sulphate. It 
does not have a big effect on virus binding however when gC and gB are both absent, 
the viral binding to the host cells is severely reduced (Herold et al., 1994). 
The interaction of the virus with the host cell and to initiate the endocytic pathway in 
some cells glycoprotein D is essential. This glycoprotein works with one of the three 
cellular receptors, which are nectin-1, herpesvirus entry mediator (HVEM also known 
as HveA; ATAR; TR2; TNFRSF-14), or heparan sulfate (Carfí et al., 2001). 50 
residues long C-terminus of gD has an important role during the viral entry, this 
terminus is attached near the N-terminal to block the receptor-binding sites. 18 
residues of C-terminal occupy the space at the N-terminal where HVEM-binding takes 
place (Carfí et al., 2001). When gD is bound to HVEM, first residues at the N-
terminus forms a hairpin and it is supported by an α-helix and by the IgV (V-like 
immunoglobulin) core, this hairpin structure binds to the nectin-1 receptor (Figure 
1.5). However the primary entry receptor for HSV-1 and HSV-2 on neurons, 
keratinocytes and on epithelial cells is nectin-1 (HveC, CD111) (Galen et al., 
2006;Huber et al., 2001;Krummenacher et al., 2004;Simpson et al., 2005). Nectin-1 
and nectin-2 are both from nectin family, which have three extracellular 
immunoglobulin (Ig)-like structures, a transmembrane region and cytoplasmic region. 
Both Nectin-1 and HVEM are used by both HSV-1 and HSV-2. Nectin-2 is preferred 
by HSV-2 but not by HSV-1. 
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Figure 1.5: Glycoprotein D and human Nectin-1 complex. a) Nectin-1 structure is represented in pink 
on the left-hand side; herpes simplex virus type 1 glycoprotein D is yellow coloured on the right. 
Transmembrane regions are black-white boxes, N-glycosylation parts are dotted lines, and white boxes 
are signal peptides. The interaction point of Nectin-1 and gD is shown in red. b) The same colour 
coding was applied as in a). Hairpins that bind to HVEM are shown in green. Adapted from Di Giovine 
et al. (2011). 
 
The last known receptor that gD binds to is heparan sulfate (HS) and again this is 
achieved by the first N-terminal residues of gD. After the interactions with 
glycoproteins B and C, heparan sulfate is modified by multiple D-glucosaminyl 3-O-
sulfotransferase isoforms. This includes enzymatic reactions like: de-acetylation of 
glucosamine, sulphation of the amino group, epimerization, O-sulphations in the 
iduronic acid and in the amino sugar. At the end of this, the high affinity binding sites 
appear for gD to interact with.  UA-GlcNS-IdoUA2S-GlcNAc-UA2S-GlcNS-
IdoUA2S-GlcNH23S6S is the octasaccharide structure that is represented on heparan 
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sulphate (Liu et al., 2002), which gD can actually bind to increase the susceptibility of 
the cells to the HSV (Shukla et al., 1999). 
Glycoprotein H and Glycoprotein L is found on the envelope as hetero-oligomers 
(Hutchinson et al., 1992;Kaye et al., 1992) (Figure 1.6). In the research done by 
Hutchinson et al., it was mentioned that for gL to be processed and expressed on the 
cell surface the expression of gH is needed, when they are expressed together they are 
carried to the cell surface at the end. Thus to achieve the fusion of the virus with the 
cell, the expression of these two glycoproteins together is needed. Moreover the 
experiments, which were done with the shortened gH that does not have trans-
membrane and cytoplasmic domain, showed that the gL was still transformed out of 
the cell with this gH mutant (Dubin and Jiang, 1995). For this reason gH trans-
membrane domain is the main part that attaches gL glycoprotein on to the surface as 
gL lacks trans-membrane domain. After the experiments that have been done on HSV 
type 2 gH-gL protein complex, it was revealed that glycoprotein H contains three 
domains, which are H1, H2 and H3 (Figure 1.6). H1 domain enables gH binding to the 
glycoprotein L, H2 domain is a central helical domain and the last domain H3 is C-
terminal β-sandwich domain. H1 domain is divergent whereas H2 is the second most 
conserved domain after H3 (Chowdary et al., 2010). Disulfide bonds link the cysteine 
residues with each other both in gH and in gL. Glycoprotein L binding site (H1 
domain) has two subdomains, which are H1A and H1B, connected with Gly116 to 
Pro136 residues. Subdomain H1A is the part where gL β-sheets interacts with that of 
gH. H1B subdomain interacts with H1A subdomain and H2 domain only.   
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Figure 1.6: The individual structures of gH and gL and 180° representation of gH-gL complex of HSV 
type 2. a) Different colours are given to individual domains of gH and gL. Cysteines residues 
numbering of gH complex was done according to HSV type 1 structure, however in this representation 
C3 was not shown, because HSV type 2 does not have cysteine residue 3. b) The gH-gL complex 
structure; including the disulfide bonds (red sticks & spheres in yellow), disordered segments (dashed 
lines) and sugars (grey colour). The same colour coding of part a) applies in part b) as well. c) 180° 
surface representation of gH-gL complex, the same colour coding of part a) applies in part c) as well. 
Adapted from Chowdary et al. (2010) . 
 
During the replication of the herpes simplex virus, proteins in the tegument part of the 
viruses play an important role. Once the gB, gD and gH/gL complex interacts with the 
cell surface receptors, they lead the fusion of the membrane and tegument part to be 
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transferred into the host cell cytoplasm. Tegument part of the HSV1 virus has 23 
tegument proteins (Loret et al., 2008), which functions during the outer tegument 
disconnection, the early and late replication cycle of the virus (Table 1.4). These viral 
proteins were named depending on their open frame readings, unique short (US), 
unique long (UL) and infected cell protein (ICP) are the names given to them. Most of 
these tegument proteins are preserved in the viruses within the same subfamily 
whereas it can show some variation with the other subfamilies.  In 1991 novel L 
particles of HSV1, which lacks the nucleocapsid and the core, indicated that tegument 
part could still form independently of the viral capsid structure (Szilágyi and 
Cunningham, 1991).  
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Table 1.4: Tegument genes were tabulated in the table. The first column represents the tegument gene 
followed by the protein product it encodes, the number of the amino acids it is made of & the molecular 
weight, the requirement of these tegument genes, and their function during the invasion of the host cell 
and the replication of the virus in the cell cytoplasm. Table content information was obtained from 
Kelly et al. (2009). 
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The viral linear dsDNA is enclosed in a spherical shaped capsid, which has symmetry 
with 2-5 fold axes. This icosahedral capsid of HSV1 contains viral proteins (VP) that 
are VP5, VP19c (50 kDa), VP23 (34 kDa), VP24 and VP26 (12 kDa) (Zhou et al., 
2000) . The major capsid protein of them all is VP5, which has a molecular weight of 
149 kDa and is encoded by UL19 gene. This structure has to be stable to make sure the 
viral genome is protected until it is released to the host nuclear cytoplasm. Pentons and 
hexons are the structures that form the capsid, which are made of VP5 monomers. 
These capsid structures interact with each other to form triplex with the help of other 
capsid proteins VP23 and VP19C (Bowman et al., 2003;Spencer et al., 1998). In a 
research done by Zhou et al in 1999, these pentons and hexons were shown to interact 
with the teguments proteins of HSV1 (Zhou et al., 1999). 
1.6.1.1 HSV binding and entry  
This process includes gC, gD, gB and gH/gL complex. During the binding of the virus 
to the cell surface, interaction of the cell surface proteoglycans with the glycoprotein C 
is followed by the gD binding to the cell surface receptors like HVEM which 
strengthens the binding of the virus to the cell surface. The fusion of the virus 
membrane with the cell membrane occurs after the involvement of the gB and gH/gL 
complex.  The viral capsid is transferred next to the nucleus where the viral genomic 
DNA can be released into the nucleus through the nuclear pores. The phosphorylation 
of the tegument proteins by pUL13, pUS3 and by cellular kinases triggers the 
dissociation of the tegument part from the viral capsid (Morrison et al., 
1998a;Morrison et al., 1998b). HSV-1 viral capsid was shown to colocalize with 
cytoplasmic microtubules, dynein and dynactin, dynein-dependent viral capsid 
transportation takes place possibly with the help of pUL36 and pUL37 (Antinone et al., 
2006;Döhner et al., 2002;Wolfstein et al., 2006). Besides of pUL36 and pUL37, a 
research done in 2004, has shown that HSV1 viral capsid protein pUL35 interacts with 
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RIP3 and Tctex1, which are the light chains of the cellular dynein (Douglas et al., 
2004). pUL36 was also needed for the transportation of the viral capsid to the nucleus, 
for the interaction between the capsid and the nuclear pore complex (NPC) (Copeland 
et al., 2009;Ojala et al., 2000).  
 1.6.1.2 Immediate-early Gene Expression 
 The protein synthesis and the viral gene expression is attained with the help of the 
tegument protein α-TIF (pUL48). It interacts with the transcription factors of the cell 
to initiate the early α gene expression in the nucleus. Once the viral nucleocapsid 
enters the nucleus, viral immediate early (IE) gene expression starts with the α-TIF 
(pUL48; α-transinducing factor) (Campbell et al., 1984;Pellett et al., 1985;Post et al., 
1981). Binding of pUL48-induced transcriptional complex to immediate early gene 
promoters leads to the expression of IE genes like ICP0, ICP4, ICP22 and ICP27 in 
Alphaherpesvirinae. These genes trigger early and late gene expression in the cell 
which are β and γ (Roizman et al., 2005). This stage does not take place during the 
latent infection, before the transcription of the early genes genomic DNA interacts 
with histones to shut down the transcription except from the latency-associated 
transcript (LAT) expression. LAT expression is important for the reactivation of the 
viral cycle by initiating immediate early gene transcription. 
The transcriptional machinery initiates the expression of the early genes, which are β, 
βγ and γ genes. These genes encode for the enzymes that will function during the viral 
DNA replication and they encode for the virion structures. This process takes place in 
the nucleus (Field and Wildy, 1978;Pyles et al., 1992).  
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1.6.1.3 HSV Assembly and Release 
This process is achieved first by the primary envelopment of the virus, followed by the 
de-envelopment outside of the nucleus and secondary envelopment of the virus after 
the attainment of the tegument parts of the virion. The structure is transported to the 
Golgi for the addition of the glycoproteins and it leaves the cell by exocytosis. UL31 
and UL34 form a complex with each other during the budding of the nucleocapsid into 
the perinuclear parts of the nucleus (Fuchs et al., 2002b;Roller et al., 2000). The 
mutation in these genes can stop the primary envelopment leading to the accumulation 
of the viral capsids in the nucleus. Deenvelopment of the virus includes pUS3, gB and 
gH proteins (Farnsworth et al., 2007;Klupp et al., 2001;Reynolds et al., 
2002;Ryckman and Roller, 2004). As a result it was shown that deletion of these 
proteins from HSV-1 virion resulted in primary enveloped virion accumulation at the 
perinuclear parts of the cell. Secondary envelopment involves several proteins, which 
are pUL11, pUL16, pUL21, pUL36, pUL37, pUL46, pUL47, pUL48 and pUL49. The 
membrane associated protein UL11 has been shown to interact with pUL21 and 
pUL16 proteins and this tegument complex function during the secondary 
envelopment of the virus. The deletion of pUL11 stopped the secondary envelopment 
in HSV-1 and in HCMV cycle (Baines and Roizman, 1992;Seo and Britt, 2007). 
During the tegumentation of the capsid pUL36 and pUL37 proteins are needed 
(Roberts et al., 2009a). pUL36 is needed for the pUL37 trafficking to the Golgi 
apparatus, deletion of this protein resulted in the disruption in the pUL37 trafficking to 
the Golgi  (Desai et al., 2008). pUL48 is needed for joining all of the viral parts 
together to initiate the secondary envelopment (von Einem et al., 2006). Interactions 
between pUL48 with pUL35, pUL38, pUL36, pUL41, pUL46, pUL47 and pUL49, 
which are capsid, inner tegument proteins and outer tegument proteins, have been 
shown (Elliott et al., 1995;Lee et al., 2008;Vittone et al., 2005). These interactions in 
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between the tegument proteins are completed by the interaction of pUL48 and pUL49 
tegument proteins with the glycoproteins’ cytoplasmic tails (Chi et al., 2005;Fuchs et 
al., 2002a;O'Regan et al., 2007).   
1.6.2 Cytomegalovirus 
Cytomegalovirus belongs to the beta-Herpesviridae subfamily of the Herpesviridae 
family. Cytomegalovirus infection symptoms are flu; sore throat, tiredness, high 
temperature, muscle pain can be the result of the viral infection. The transmission 
routes for the virus are through saliva, urine, milk, semen and cervical secretions. The 
virus can enter the body but stay latent without any distinct symptoms. More serious 
symptoms can occur when there is a congenital infection or when the infected person 
has an immune deficiency leading to organ damage such as pneumonia, hepatitis. 
Congenital infection is caused by the transmission of the virus from the mother to the 
unborn baby through placenta (Pass, 1985). The transmission of the virus can be 
through the placenta from the mother to the baby. The congenital infections can result 
in rare physical health problems such as blindness, hearing loss, epilepsy. Same as 
other herpesviruses, HCMV does stay latent in the host organism after the primary 
infection. During this latent phase the detection of the virus is not possible. The 
reactivation of the virus depends on the viral machinery that includes latency-
associated transcript (LAT), triggering early genes expression. The viral genome is the 
largest among the herpesviruses, with 230 kbp long linear double-stranded DNA, 
enclosed in an icosahedral nucleocapsid which is surrounded by a tegument part and 
by a lipid bilayer. The viral genome has open reading frames (ORFs) like HSV-1; they 
include unique long (UL) and unique short (US) regions as well. The lipid bilayer is 
coated with more than 25 glycoproteins but most important ones are only 6 of them, 
which are gB, gH, gL, gM, gN and gO. Glycoprotein B, H and L are conserved in all 
herpesviruses, different from herpes simplex virus cytomegalovirus has glycoprotein 
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O encoded by UL74 gene that forms a trimer structure with glycoprotein H and L 
(Huber and Compton, 1998). After the viral entry the tegument part of the virus is 
released into the cell with the viral capsid. Same as HSV the HCMV viral capsid is 
transported to the host nucleus where the viral genome is released into the nucleus. 
The viral replication starts with the immediate early gene expression. The viral 
replication cycle follows the same cascade of gene expression of herpes simplex virus, 
however the viral proteins that function during this process are either conserved in all 
herpesviruses or just belong to betaherpesvirus subfamily.  
The interaction of the glycoprotein B with the host cell is achieved via the interaction 
with the cell surface heparan sulfate glycosaminoglycans (Compton et al., 1993). 
HCMV was unable to bind the Chinese hamster ovary cells, which were deficient in 
heparan sulfate glycosaminoglycans. Further binding of glycoprotein B with the 
epidermal growth factor receptor (EGFR) and with β1-integrin through its disintegrin-
like domains leads to the internalisation of the cytomegalovirus (Feire et al., 2010). 
The UL74 gene encodes for the membrane bound glycoprotein O and it interacts with 
glycoproteins L/H to form a trimeric complex, which attains the fusion of the virus 
into the host cell (Huber and Compton, 1998). Viral nucleocapsid is carried next to the 
nuclear pore via microtubules, where it can release the viral genomic DNA. Early gene 
expression, viral genome replication, virus assembly and release follow the immediate 
early gene expression. Viral tegument proteins such as pUL86 (major capsid protein), 
pUL46 (minor capsid protein), pUL85 (minor capsid protein) are the viral capsid 
proteins (Chen et al., 1999). pUL80 functions during the nucleosomal translocation of 
the capsid proteins and cleavage of the viral capsid. pUL104, pUL77 and pUL93 is 
another set of viral proteins that are essential for the viral genome packing (Toropova 
et al., 2011). The HCMV genome cleavage starts with the pac1 and pac 2 signals, 
which are located in the viral genome (Wang and McVoy, 2011). Genome cleavage is 
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followed by the DNA encapsidation and nuclear egress. Primary envelopment of the 
virion capsid takes place in the perinuclear compartment of the cell. The egress occurs 
with the nuclear egress complex components, in the case of HCMV, pUL50 associates 
with pUL53 forming a heterodimer, pUL97 and RASCAL also function within the 
nucleus, to initiate the translocation of the nucleocapsid (Milbradt et al., 2007;Miller et 
al., 2010;Sam et al., 2009). Viral protein kinase (pUL97) controls the host cell kinases 
and DNA synthesis of the virus (Prichard, 2009). Assembly compartment is formed 
for the tegumentation of the nucleocapsid, envelopment and release of the mature 
virions from the host cell. It was observed that tegument proteins pUL32, pUL99, 
pUL83 and envelope glycoproteins gB and gL was located in this assembly 
compartment of the infected host cell during the late infection (Sanchez et al., 2000). 
After formation of the mature virus, they are released from the host cell. During the 
viral replication infectious and non-infectious viral particles are produced. The 
functions of these non-infectious viral particles are not well understood. Non-
infectious enveloped particles (NIEPS) do not have the viral genome only, whereas 
dense bodies do not have the viral nucleocapsid and only possess the tegument part 
with the lipid bilayer (Irmiere and Gibson, 1983).   
1.7 Receptors Involved in Generation of an Innate Immune 
Response to Herpesvirus Infection 
 The entry of the herpesviruses can be achieved through two pathways, which are 
either the endocytic or non-endocytic pathway (Akhtar and Shukla, 2009). The 
endocytic pathway causes the exposure of viral DNA in the endosomes where TLR9 is 
present. This can trigger the MyD88 dependent downstream signalling pathway 
causing the interferon and pro-inflammatory gene transcription in the nucleus (See Sec 
1.3.2). On the non-endocytic entry, the direct interaction of the virus with the cell 
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surface receptors is followed by the release of the virial capsid into the cytoplasm. The 
first interaction with the cell surface PRRs does initiate a downstream signalling 
cascade through the MyD88-dependent signalling pathway (See Sec. 1.3.2). The viral 
capsid can be sensed, which results in the ubiquitylation of the capsid, this leads to the 
proteasomal activity and exposure of the viral genome to the intracellular DNA 
sensors. Once the DNA is exposed IFI-16 and DAI work with the signalling adaptor 
molecule STING for further activation of the interferons and pro-inflammatory 
cytokines. Unstimulated STING sits on the endoplasmic reticulum and viral sensing 
leads to the TANK-binding kinase 1 binding at the globular C-terminal of STING. The 
complex then colocalizes at the perinuclear compartments, IRF3 is phosphorylated by 
the STING/TBK-1 complex while phosphorylated IRF3 moves into the nucleus. 
Moreover the viral DNA is detected by the novel receptors, known as DExD/H box 
helicases, initiating either the MyD88 dependent signalling pathway or the 
STING/TBK1 signalling pathway. Therefore HSV recognition is through a plethora of 
PRRs. 
TLR2-dependent recognition.  Cell surface pattern recognition receptor TLR2 can 
form a heterodimeric structure with TLR1 to detect herpesviruses like HCMV 
(Boehme et al., 2006). TLR2 detects the hydrophobic bonds in the viral glycoproteins, 
which are exposed due to the conformational changes during the viral entry and fusion 
(Triantafilou et al., 2006). Followed by signalling via MyD88, which initiates the NF-
κβ and proinflammatory cytokine secretion (Gaudreault et al., 2007;Kurt-Jones et al., 
2004;Wang et al., 2005). Studies have shown that TLR2 deficient mice were more 
susceptible to HSV-2 infection and they had disrupted cytokine and natural killer cell 
activation (Sørensen et al., 2008) (Szomolanyi-Tsuda et al., 2006). Studies have shown 
a relation between the TLR2 polymorphism and increased number of vaginal lesions 
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as a result of HSV-2 infection, as well as increase in the viral replication during the 
HCMV infection (Bochud et al., 2007;Kijpittayarit et al., 2007).    
TLR9-dependent recognition. The recognition of the intracellular viral or bacterial 
DNA is attained by the TLR9 in the endosomes (Ahmad-Nejad et al., 2002). UNC93B 
is a membrane spanning protein that is located on the endoplasmic reticulum, 
responsible for the endosomal TLR trafficking from endoplasmic reticulum to the 
endosome. Mutation in the gene Unc93b1 that encodes for UNC93B protein and a 
single point mutation at H412R, leads to impaired major histocompatibility complex 
(MHC) class 1 and class 2 presentation by disrupting the TLR3, TLR7 and TLR9 
signalling pathway, H412 R mutation causes the disruption of the direct UNC93B 
binding within the transmembrane domains of TLR3 and TLR9 (Brinkmann et al., 
2007;Tabeta et al., 2006). TLR9 can recognize all herpesviruses and IRF7 activation 
by TLR9 leads to type I interferon activation in plasmacytoid dentritic cells (Delale et 
al., 2005;Honda et al., 2005b;Lim et al., 2007;Lund et al., 2003;Varani et al., 2007).  
TLR7-dependent recognition. This single stranded RNA sensor can IFN α response 
as a result of murine cytomegalovirus infection, TLR7 and TLR9 deficient mice had 
high susceptibility to the MCMV infection (Zucchini et al., 2008).  
MDA5-dependent recognition. It was reported that HSV-1 infection could lead to 
MDA5 and MAVS dependent interferon production in macrophages (Melchjorsen et 
al., 2010;Melchjorsen et al., 2006). The expression of the HSV-1 viral RNA structure 
is detected by MDA5 n in human macrophages. 
DAI-dependent recognition. This cytoplasmic DNA sensor can initiate type I 
interferon production via IRF3 (Takaoka et al., 2007). In addition to HSV, it can 
recognize HCMV and trigger type I interferon secretion (DeFilippis et al., 
2010a;DeFilippis et al., 2010b). 
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AIM2-dependent recognition. Absent in Melanoma 2 is an inflammasome that can 
activate caspase-1 and trigger IL1β and IL18 production (Bürckstümmer et al., 
2009;Fernandes-Alnemri et al., 2009;Hornung et al., 2009;Roberts et al., 2009b). This 
cytosolic DNA sensor has HIN domains where it interacts with the viral DNA. AIM2 
and DNA interactions cause formation of the inflammasome complex that leads to the 
secretion of the IL-1β and IL-18 from the cell. Murine CMV infection can trigger the 
activation of the AIM2 inflammasome and its deficiency lowers the IL-18 and 
interferon-γ levels. HSV-1 dependent inflammasome activation is not dependent on 
AIM2 but on NLRP3 (Rathinam et al., 2010). 
IFI-16-dependent recognition. This intracellular receptor is also a DNA sensor that 
triggers the IFN-β and pro-inflammatory cytokines due to the HSV-1 DNA detection. 
It localizes to the cytoplasm where it detects the viral genome. Low levels of IRF3 and 
NF-κβ were observed due to the reduction in IFI-16 expression (Unterholzner et al., 
2010). 
DHX41, DHX9 and DHX36-dependent recognition. These novel receptors are 
known as DExD/H box helicases, they are located in the cell where they detect CpG 
DNA and stimulate the IRF7 and NF-κβ activation through the adaptor molecule 
MyD88. HSV-1 infection of plasmacytoid DC results in the activation of IFNα and 
proinflammatory cytokine expression (Kim et al., 2010). DHX41 DEAD domain 
interacts with synthetic dsDNA and initiate the type I interferon production through 
the STING/TBK1 complex (Zhang et al., 2011).   
1.8 Project Hypothesis, Aims and Objectives 
The innate immune system has evolved many molecular sensors and signalling 
pathways to activate host-defence mechanisms that counteract viral infection. The 
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host’s immune response senses viral infection largely through germline-encoded PRRs  
that recognize evolutionarily conserved structures known as PAMPs. 
Herpesviruses are a large family of DNA viruses that establish chronic infections in 
the host. The purpose of this study was to shed light on how herpesviruses, are initially 
recognized during cellular infection by PRRs. Surprisingly, this involves multiple 
PRRs both on the cell surface and within endosomes and the cytosol.  
The aims of this project: 
• To distinguish the specific PRRs involved in herpesviruses recognition (HSV2 
and HCMV) in HeLa and primary vaginal epithelial cells.  
• To identify the downstream signalling cascades and cytokine responses that 
have been activated due to viral infection in HeLa cells and in primary vaginal 
epithelial cells.  
• To determine the virus internalization process and how viral entry activates 
signalling pathways and PRRs detection. 
• To test the effect and efficacy of PRR agonists on viral replication.  
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2.1 Antibodies: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: This table lists the primary and secondary antibodies used during this project and their sources. 
Receptor Species Company 
TLR 2 Goat  Santa Cruz Biotechnology 
sc-8690 
TLR 3 Rabbit  Santa Cruz Biotechnology 
sc-10740 
TLR 4 Goat  Santa Cruz Biotechnology 
 sc-8694 
TLR 9 Goat  Santa Cruz Biotechnology 
sc-13218 
DAI/ ZBP-1 Goat Santa Cruz Biotechnology 
sc-50686 
AIM-2 Rabbit Santa Cruz Biotechnology 
sc-137970 
IFI-16 Rabbit Santa Cruz Biotechnology 
sc-6050 
   
Phospho-IKappaB Rabbit Cell Signaling Technology 
#2859L 
STING Rabbit Abcam 
Secondary Antibody Label Company 
Rabbit anti goat FITC DAKO (Code Nr. F0250) 
Swine anti rabbit FITC DAKO (Code Nr. F0205) 
Rabbit anti goat IgG FITC DAKO (Code Nr. F0250) 
Rabbit anti goat  IgG FITC DAKO (Code Nr. F0250) 
Rabbit anti goat  IgG FITC DAKO (Code Nr. F0250) 
Swine anti rabbit  IgG FITC DAKO (Code Nr. F0205) 
Swine anti rabbit  IgG FITC DAKO (Code Nr. F0205) 
Goat anti rabbit  IgG HRP Jackson-Immunoresearch 
(Cat 111-035-045-JIR) 
Rabbit anti goat  IgG HRP DAKO (Code Nr. P0449) 
Goat anti rabbit IgG Alexa 647 Molecular probes (Code Nr-
A21071) 
 
Donkey anti rabbit  
IgG 
Alexa 546 Molecular probes (Code Nr-
A10040) 
 
Isotype control IgG Alexa 647 BD (code Nr 558053 ) 
 Isotype control IgG Alexa 488 BD (code Nr - 558055) 
Mouse IgG isotype 
control 
Alexa 
546/TRITC 
BD (code Nr 558595) 
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2.1.1 Chemicals: 
All fine chemicals were purchased from Sigma (UK). TLR2, TLR4, TLR9, IFI16 and 
DAI specific polyclonal antibodies were obtained from Santa Cruz Biotechnology Inc. 
(Germany).  
The anti-HSV2 ICP5 antibodies, as well as the rabbit anti STING antibody, were 
purchased from Abcam. Secondary antibodies Ig Alexa -546 and Ig-Alexa 633, Ig 
Alexa -488  were obtained from Molecular Probes, Netherlands. Manufacturer’s 
instructions were taken into account during the viral DNA labelling with the Alexa-
Fluor-488-Ulysis reagent (MolecularProbes Inc.; Cambridge Biosciences, Cambridge, 
UK).  
Pam2CSK4, Pam3CSK4, FSL-1, CpG DNA, c-di-GMP and c-di-AMP were obtained 
from Invivogen USA.  
2.2 Tissue Culture:  
Tissue culture (TC) was performed in Microflow Advanced Biosafety Class 2 laminar 
flow cabinet under sterile working area. All the cell lines that were used in this project 
were cultivated under the same conditions and were kept in a 37°C 5% CO2 incubator 
(Sanyo Biomedical). Sanyo Biomedical incubator has a distilled water open container 
at the bottom, which is essential for creating the humidified air in the incubator. 
Distilled water quality was achieved by adding 2-3 ml of an aqueous prothermal 
solution from Lucerna-Chem AG (Switzerland). The sterility of the cabinet and the 
equipment was attained, by using aqueous ultimate disinfectant Virkon (Du PontTM 
Company). Before entering the tissue culture room, fundamentals like lab coats and 
overshoes were worn to keep the sterile environment to the maximum, and during the 
tissue culture procedure disposable gloves were used. Gilson pipettes were sterilised 
 51 
by using industrially methylated spirit before and after the tissue culture process. 
Autoclaved pipette tip boxes and disposable plastic serological pipettes were kept 
separately in a sterile environment; used plastic pipettes and pipette tips were 
discarded by a technician. 25 cm2 NunclonTMΔ Surface and 175 cm2 BD FulconTM cell 
culture surfaces, Fisher Brand sterile centrifuge conical tubes, were utilised for the 
cultivation of the cells. 
2.2.1 Cell Lines: 
2.2.1.1 HeLa – Human Cervical Cell Line:  
The human cervical cell line was obtained from ATCC (American Tissue Culture 
Collection); they were derived from cervical cancer cells of a 31 year-old black 
female patient in February 1951. The cell line is an adherent epithelial first 
immortalised cell. The cells were maintained in 25 cm2 flasks with a medium 
consisting of DMEM-Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich) + 10% 
of FCS (foetal bovine/calf serum) + 1% N.A. (non-essential amino acids). A volume 
of 2.0 - 3.0 ml of proteolytic enzyme trypsin (Sigma) was applied to the confluent 
cells for the sub culturing and 1:2 to 1:6 sub cultivation ratios were used as 
recommended by the supplier.  
2.2.1.2 GMK-African Green Monkey Kidney Cell Line:  
African Green Monkey (Chlorocebus sabaeus) Kidney cell line (ATCC-American 
Tissue Culture Collection) is an adherent epithelial cell line, which was kept in the 
liquid nitrogen in 10% (v/v) dimethyl sulfoxide (DMSO) and FCS growth medium. 
The cells were generated in 175 cm2 BD FalconTM cell culture flasks with DMEM-
Dulbecco’s Modified Eagle’s Medium (Life TechnologiesTM) + 10% of FCS (foetal 
bovine/calf serum) + 1% N.A. (non-essential amino acids). Sub culturing of the cell 
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line was accomplished by the use of proteolytic enzyme trypsin (Sigma). Green 
monkey kidney cells used to propagate viruses. 
2.2.1.3 Human Embryonic Kidney (HEK) 293 Cell Line:  
HEK-Blue IFN-α/β Cells  
HEK-Blue IFN-α/β cells and HEK-Blue-IL-1β as well as HEK-IL6 reporter cell lines 
were purchased from Invivogen USA DMEM, 4.5 g/l glucose, 2-4 mM L-glutamine, 
10% (v/v) fetal bovine serum, 50 U/ml penicillin, 50 µg/ml Blasticidin, 10 µg/ml 
Zeocin were used to maintain these cells. 
ISGF3 pathway activation can be analysed via HEK-Blue IFN-α/β cells, which makes 
it possible to observe human type I Interferon production (Alain et al., 2010;Bego et 
al., 2012). After steady transfection of HEK293 cells with the human STAT2 and 
IRF9 genes, HEK blue cells were produced. IFN-α/β inducible IFN-stimulated gene 
(ISG54) promoter is activated by ISGF3, phosphorylated STAT1 and STAT2 and 
IRF9 complex. This complex triggers ISRE (IFN-stimulated response elements) on the 
promoters to initiate the SEAP (secreted embryonic alkaline phosphatase) production. 
Interaction of Janus kinases; JAK1 and TyK2 with the complex is JAK/STAT/ISGF3 
pathway (Figure 2.1). 
 
 
 
Figure 2.1: The mechanism behind HEK-Blue IFN-α/β cells. 
Once the HEK293 cells are stimulated with type I IFN-α and 
IFN-β, this leads to ISGF3 pathway activation, which ends up 
in ISG54 promoter activation and SEAP production. Adapted 
from: www.invivogen.com (03/05/14). 
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HEK-Blue™ IL-1β cells can only respond to IL-1β secretion. They consist of an NF-
κB/AP-1-inducible SEAP reporter gene, which gets activated once IL-1β binds to the 
IL-1R receptor that is located on the surface of HEK-Blue™. Once the receptor 
initiates the signalling cascade because of the IL-1β binding, this interaction leads to 
the activation NF-κB through MyD88/MAPK/TRAF6 pathway (Neerincx et al., 2010).  
HEK-Blue IL-6 cells allow the detection of bioactive IL-6 by monitoring the 
activation of the STAT-3pathway. These cells were generated by stable transfection of 
HEK293 cells with the human IL-6R gene and a STAT3-inducible SEAP reporter 
gene. Upon IL-6 stimulation, HEK-Blue IL-6 cells trigger the activation of STAT3 
and the subsequent secretion of SEAP. SEAP can be readily monitored using 
QUANTI-Blue. 
QUANTI-Blue is a colorimetric enzyme detection medium developed to determine the 
quantity of the secreted embryonic alkaline phosphatase (SEAP). This assay has been 
widely used in many inflammasome studies. The colour of the assay transforms from 
pink to purple/ dark blue, the concentration of the blue colour represents the AP 
promoter activity. The quantitative analysis of levels of AP promoter activity can be 
achieved by using a spectrophotometer at 620-655 nm. 
2.2.1.4 Human Vaginal Epithelial Primary Cells: 
Primary vaginal epithelial cells were purchased from Celprogen, CA, USA. Human 
Vaginal Epithelial Primary Cell Culture medium was used as recommended by the 
supplier. The cells were positive for ESA, cytokeratin-4, 8, & 18 and grown at 37C in 
5% CO2 humidified incubator. The cells were used up to eight passages. 
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2.2.2 Thawing Cells:  
A small tube of cells was taken out of the liquid nitrogen, and when they were fully 
defrosted, cells were transferred into 15 ml centrifuge tubes with 5 ml of DMEM 
growth medium. Cells were centrifuged at 626,258 g for five minutes, and then the 
pellet was re-suspended with a new 5ml of fresh DMEM Dulbecco’s Modified Eagle’s 
Medium (Life TechnologiesTM) and transferred into a 25 cm2 NunclonTM Δ surface 
flask. Flasks were placed in a 37°C 5% CO2 incubator (Sanyo Biomedical). 
2.2.3.1 Propagating Adherent Cell Lines:  
The supernatant was removed from the flask and the adherent cells were washed with 
2ml of 1X PBS to remove dead cells or cell debris. The cells were then incubated with 
2ml of trypsin, followed by the addition of 2ml of the appropriate growth medium to 
neutralise the trypsin. Equal amounts of cells were distributed into the flasks and fresh 
medium was added (to a total of 4ml). The flasks were placed back into 37oC 5% CO2 
incubator.  
2.3 Viruses: 
Towner strain of cytomegalovirus (CMV) and Herpes simplex virus 2 (strain G) were 
originally obtained from the American Type culture collection (ATCC). HSV2 and 
HCMV were propagated either at GMK or Hela cells. Virus stocks were kept frozen at 
-80oC.  
2.3.1 Virus Purification: 
HSV2 was purified as described by A. G. Vahlne and J. Blomberg in 1974. Cell 
monolayers were infected at a multiplicity of 5 PFU/cell and incubated at 37oC and 
5% CO2 for approximately 72 hours. The virus was harvested once the cells had been 
killed. The flasks were freeze-thawed three times, to break open the cells and release 
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the virus. The supernatant fluid containing free virus particles was loaded to a sucrose 
gradient and purified by sedimentation through a 10% to 60% sucrose gradient using a 
Beckmann SW28 ultra-centrifuge for 90 min, followed by a brief centrifugation 
through a preformed gradient of cesium chloride (density, 1.16 to 1.37 g/cm3).  
2.3.2 Double-Stranded DNA (dsDNA) from Purified HSV2 and 
HCMV  
Viral genomic DNA was isolated from purified virus (HSV2 or HCMV) according to 
the protocol described by Ling et. al in 1996.  
Viral purified DNA was used to stimulate cells at 20 µg/ ml.  All procedures, for DNA 
extraction, were performed in a class I cabinet, using sterile endotoxin free plasticware 
and endotoxin free water. Endotoxin content using LAL assay was also performed. 
The test showed low levels of endotoxin <0.1 EU/ug DNA (considered endotoxin 
free). 
2.4 Immunofluorescence: 
 Immunofluorescence is a method that works with fluorescence antibody tags to be 
able to observe the protein molecule of interest. The light emitted by fluorescence 
microscope and light microscope cause and excitation of the fluorophore on the cell. 
These fluorescent tags go through excitation and emission stage where their excited 
electrons emit light until they reach the ground state.  There are different kinds of 
fluorescent tags that are used during immunofluorescence. During this research, FITC 
(Fluorescein Isothiocyanate), Alexa 546 and Alexa 633, Alexa 488, TOPRO were used 
for quantifying or for visualizing the pattern recognition receptors (PRRs). FITC has 
maximal absorbance (excitation) wavelength at 490 nm and maximal emission at 525 
nm, which is in the green spectrum. Alexa 546 has 561nm excitation and 572 emission 
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wavelengths, for Alexa 633 this is 632nm and 648nm, for Alexa 488 this is 499 and 
519. Except from fluorescein isothiocyanate, there are more fluorescent tags that are 
used with different absorbance and emission levels. This large scale makes it easier for 
the scientists to examine different molecules at the same time. There are two types of 
immunofluorescence techniques, which are direct and indirect immunofluorescence. 
During direct immunofluorescence technique it is the primary antibody that has the 
fluorescent label, whereas in indirect immunofluorescence fluorescent tag is on the 
secondary antibody (USBiological, URL). 
2.4.1 Indirect Immunofluorescence: 
Throughout both of the direct and indirect techniques, antibody-antigen specificity 
plays the main role.  These tags attach to the functional groups of the protein; 
antibodies used in the immunofluorescence are specific for the favourite protein. In 
direct immunofluorescence the 
primary antibody has a fluorescent 
tag attached to it and when the 
primary antibody binds to the 
specific molecule, that molecule 
can be visualized with microscopy 
or flow cytometry (Figure 2.2 A). 
That is why; antibody-antigen 
specificity plays an important role. 
Indirect immunofluorescence 
includes a primary and a 
secondary antibody with a 
conjugated fluorophore tag. While 
A) 
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in indirect immunofluorescence the secondary antibody has the fluorescent tag 
covalently attached to it. In order to visualise the fluorophore, the laser light will hit 
the tag and which will emit coloured light, (Figure 2.2 B). 
                                                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Direct Immunofluorescence is depicted. The primary antibody has a fluorescence-
conjugated tag. When the UV light hits the fluorophore, it emits a fluorescence light. On the right side 
of the diagram the antigen is absent thus there is no antibody antigen binding and no fluorescence light 
is observed. Adapted from: http://www.di.uq.edu.au/directif (A). Indirect Immunofluorescence is 
depicted. s. In both of the diagrams unbound antibodies were washed away with PBS Tween. Adapted 
from: http://www.di.uq.edu.au/indirectif (28/1/13) (B) 
   
 
B) 
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2.5 Flow Cytometry: 
Flow cytometry is a technique used for assessing single cell characteristics. The 
method is used in immunophenotyping, ploidy analysis, cell counting and GFP 
expression analysis. The ability of the machine, to move thousand cells in a second 
through a laser light, provides information about the structural properties of the cell 
like the dimension, the composition, the phenotype and the health. Cells go through a 
stream by hydrodynamic focusing, passing through the laser beam one by one. In this 
project, cells were assessed by the flow cytometer called the Becton Dickinson (BD) 
Fluorescence-Activated Cell Sorting (FCASCaliburTM) System (Figure 2.3). 
 
 
Figure 2.3: Becton Dickson (BD) Fluorescence-Activated Cell Sorting System (FACSCalibur). 
Adapted from: http://www.bdbiosciences.com/instruments/facscalibur/index.jsp (25/1/13) 
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2.5.1 Principles of Flow Cytometry:  
This method is a complex of fluidics system, laser, a lens, the optics, the filters and 
the detectors, which transmits the data onto the computer screen (Figure 2.4). Fluidics 
system operates with the hydrodynamic focusing leading to a stream of cells in front 
of the laser; cells have to pass through the laser one at a time. Sheat fluid reservoir 
passing through the central core, forces the cells to be in a line. The central core is 
quite narrow to make sure that cells moves through the laser beam uniformly. The 
laser light is needed for the illumination of the cells during their movement through 
the fluidics system. The light travels through the lens and hits every single cell 
reflecting a scattered light on to the detectors. Excitated electrons in the laser hits the 
fluorescence conjugated tagged antibody on the cells and produces scattered light that 
has fluorescence light coming from our fluorophore of interest. The light scattered 
forward provides information about the size of the cell. When the dimension of the 
particle or the cell is small, then the scattered light is less, as the size gets bigger the 
light scattered on the detector gets bigger as well. The side scatter provides 
information about the structural complexity granularity of the cell (Rahman, 2006). A 
different detector detects light that is scattered to the sides. The fluorescence light is 
directed to the detectors by optics, where intensity of the light is converted into a 
voltage pulse. Every optic reflects individual fluorescence at the right wavelength and 
the intensity. When the fluorophore-labelled antibody hits the laser beam, the 
fluorescence intensity and the wavelength will be detected by a detector, which only 
detects that particular range of wavelength. The filter in front of a particular detector 
catches the precise light wavelength range. The detectors are photomultiplier tubes 
(PMT), which convert the light intensity into voltage. Photomultipliers are forward 
scattered detector, side scattered detector, FL-1, FL-2, FL-3, FL-4. All the detectors 
convert the light into a voltage pulse; the scattered data is plotted on a one-
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dimensional histogram graph. However the scattered data only includes the results 
from cells or particles of interest, this is achieved by setting a threshold on the 
scattered histogram, so that the samples scatter light above a certain voltage will 
dictate on the plotted histogram. Thus the particles that are smaller in size will not be 
taken into account in the scattered histogram.   
 
 
Figure 2.4: The diagram shows the flow cytometer mechanism. Fluidics system forces the cells to pass 
through the laser beam one at a time. The scattered light splits apart and depending on the wavelength 
of the scattered light they pass through the filters to a specific detector. FSC detector detects forward 
scattered light; SSC detector detects side-scattered light, as it is shown on the diagram. The other tubes 
detect certain wavelengths of the fluorescence. Adapted from: 
http://static.abdserotec.com/uploads/Flow-Cytometry.pdf (25/01/13) 
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2.6 SDS-PAGE: 
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis known as SDS-PAGE 
separates macromolecules in an electric field depending on their Molecular Weight 
(MW) (Carpette, 2011). There are two types of SDS-PAGE; continuous and 
discontinuous (Figure 2.5). 
2.6.1 Continuous SDS- PAGE: 
Continuous SDS-PAGE includes identical gel and running buffer concentrations, 
which is easy to prepare. This protocol is adequate for small molecules but not for the 
big molecules.  
2.6.2 Discontinuous SDS-PAGE:  
Discontinuous SDS-PAGE uses different solution for the tank and for the gels. The gel 
made of two different gels. The upper stacking gel with a larger pore dimensions with 
a pH of 6.8 and the lower resolving gel with a smaller pore dimensions with a pH of 
8.8. The protein samples are stacked into very thin, sharp zones at the interface 
between the stacking gel and resolving gel, and are then separated according to their 
MW as they pass through the resolving gel (Aldroubi et al., 1995).  
During this procedure samples were placed on a discontinuous gel and were run in an 
electric field. Sodium dodecyl sulphate solution is an anionic detergent, denaturing 
protein molecules without affecting the peptide bonds (Schmieg, 2011). Thus the 
protein samples are in their primary linear structure. SDS adds negative charges to the 
amino acids leading to the disruption, whereas β-mercaptoethanol breaks the 
disulphate bonds. Denaturation of the proteins can be speeded up by boiling the 
sample at 90°C-100°C.  Proteins that are now negatively charged will be attracted to 
the anode, passing through stacking into resolving part of the gel. When the proteins 
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are moving on this polyacrylamide gel under the effect of an electric field, the larger 
molecules will migrate slower than the smaller molecules. The stacking gel has a 
lower concentration compared to the resolving gel, thus until the end of the stacking 
gel the samples move at the same rate. When they reach the point where the resolving 
gel starts, the molecules start to move to the positive pole according to their molecular 
mass creating different levels of banding patterns. 
 
Figure 2.5: The diagram shows sodium dodecyl sulphate (SDS)-Polyacrylamide Gel Electrophoresis. 
The gel stands in a gasket electrode assembly. Samples are loaded onto the stacking gel and then when 
they reach to the resolving gel level, proteins start to separate according to their molecular weight. 
Negatively charged samples move from cathode end to the anode end. Adapted from: 
http://www.imbjena.de/~rake/Bioinformatics_WEB/proteins_purification.html (28/1/13) 
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2.6.2.1 Discontinuous SDS-PAGE Preparation:  
10% of resolving and 4% of stacking gel were prepared (see Appendix).  
After the preparation of the resolving gel solution, the solution was poured through the 
glass plates. Few drops of isopropanol were added in order to get rid of any bubbles on 
top and to make the gel even. After approximately 45-60 minutes when the resolving 
gel was polymerised, the isopropanol was washed away with dH2O and the stacking 
gel was poured on top. The well combs (1.00mm) were added on top of the stacking 
gel and were left to set for approximately 30 minutes. Once polymerized, the gel was 
placed into a tank. The tank was filled up with approximately 200 ml of running buffer.  
The samples were re-suspended in x2 SDS-PAGE Reducing Sample Buffer (See 
Appendix) and were boiled in a water bath for 10 minutes. 40µl of each sample was 
loaded in each well as well as a molecular weight marker. The gels were run for 45 
minutes at a constant voltage of 200V. 
2.7 Western Blot:  
The proteins that were separated by SDS-Page gel electrophoresis were transferred 
onto the membrane via western blotting. The membrane that was used was 
nitrocellulose membrane (Whatman®). During this process a sandwich of the gel was 
made by packing the gel with the nitrocellulose membrane in a cassette between two 
layers of blotting paper and pads. Pads, blotting paper and nitrocellulose membrane 
were pre-soaked in a transfer buffer before preparing the sandwich. In the following 
step, the cassette was placed into a tank transfer system. A block of ice was placed into 
the tank to keep the system cool enough and the tank was filled up with transfer buffer.  
Electroblotting procedure lasted for 60 minutes at a constant current of 210mA. 
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2.7.1 Blocking and Primary Antibody Incubation:  
Blocking the membrane prevents any other proteins from binding onto the surface as 
well as preventing any background signal coming from the unspecific antibody 
binding. This was achieved by 5% blocking reagent (milk powder) in 0.1% of PBS-
Tween. The membranes were left on a rocking table for 60 minutes with the blocking 
reagent. Approximately 5-6ml of blocking reagent was used for each membrane, to 
make sure that the surface of the membrane is completely covered. This was followed 
by the washing of the membranes with a 0.1% PBS-Tween for 30 minutes. 
Appropriate primary antibody was added on to the membranes with a dilution of 
1:1000 in 0.1% PBS-Tween. The membrane can be incubated in the primary antibody 
for 60 minutes or overnight in 4°C. 
2.7.2 Secondary Antibody Incubation:  
After the incubation with the primary antibody, three washes were performed with 
x0.1% PBS-Tween to remove any excess primary binding. The appropriate secondary 
antibody and a streptavidin-HRP conjugate were added with a dilution of 1:6000. The 
membranes were incubated with the secondary antibody for 45-60 minutes on a 
rocking table and washed with 0.1% PBS-Tween for 2-3 hours to make sure that 
excess antibody had been removed (changes every 15 minutes), before enhanced 
chemiluminescence detection.  
2.7.3 Enhanced Chemiluminescence: 
The termed chemiluminescence is a chemical reaction that occurs when an excited 
substance emits light. During this procedure phenols are used to increase the light 
output and extend the light emission duration. Detection of the bands was performed 
in a dark room, to avoid exposure of the autoradiography film to light (Quan et al., 
2006).  During this process, the nitrocellulose membranes were probed with ECL 
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detection reagents (GE Healthcare, AmershamTM). Equal amounts of ECL solutions 
were added for each membrane (2ml), which is an excited state of this reaction, in the 
dark room (Figure 2.6). After the incubation of the membrane with the ECL reagent, 
the membrane was wrapped in a cling film, and put in a cassette. A sheet of 
autoradiography film was put on top of the membrane and then left in a cassette for 2-
5 minutes. The film was then developed immediately, and depending on the intensity 
of the bands seen, a new exposure time could be tried. 
 
Figure 2.6: The diagram shows different western blot detection mechanisms. The diagram B represents 
the mechanism of how chemiluminescent signals are created with the use of streptavidin-biotinylated 
horseradish peroxidase complex.        Adapted from: http://www.bio-
rad.com/evportal/en/UK/evolutionPortal.portal?_nfpb=true&_pageLabel=SolutionsLandingPage&catID
=LUSQ6KKG4 (27/1/13) 
 
2.8 Confocal Microscopy: 
This study enables the visualisation of the specific molecules in the cell to identify the 
location, and the interaction with the other molecules. The images obtained with the 
confocal microscopy have a better contrast and are three-dimensional, which is 
attained by excluding any light except from the microscope’s focal plane (Triantafilou 
et al., 2012). This is achieved by using a spatial pinhole. Laser excitation source 
creates a beam of light through the pinhole aperture, which will hit the dichromatic 
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mirror and direct to the objective. Illumination is focussed on the objective lens, 
which is then reflected onto the detector pinhole aperture. Detector is connected to a 
photomultiplier where the data is shown as an image and can be displayed on the 
computer screen (Figure 2.7). 
 
Figure 2.7: The diagram represents the principal light pathways in confocal microscopy. Laser source 
creates the light that is directed onto the objective for focusing. When the focussed light hits the cells 
emission light ray is created that hits the detector which creates an image on the computer system. 
Adapted from: http://www.microscopyu.com/articles/confocal/confocalintrobasics.htm (27/1/13) 
 
2.8.1 Slide Preparation: 
Human primary vaginal epithelial cells were stimulated with HSV-2 virus. The 
colocalization of TLR2, DAI, STING, TLR9 and IFI16 was investigated. HSV2 
internalisation and the intracellular trafficking of DAI and IFI16 were also studied. 
Lab-Tek microchamber culture slides were used and all of the samples were examined 
at certain time points, three wells were used per time point. Cells were incubated 
overnight at 37°C 5% CO2 incubator overnight until they are 80%-90% confluent, 
followed by the viral stimulations either with HSV2 (50 PFU) or with purified HSV2 
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DNA (20µg). Incubation times with virus were 1h, 4h and 6h. The cells were fixed 
with 4% PFA for 15 minutes, washed twice with 300µl of PBS and then treated with 
150µl PBS/BSA/Saponin/NaN3. Samples were incubated with primary antibody 
followed by the appropriate secondary antibody conjugated to Alexa 488 and Alexa 
546. To preserve the fluorescence intensity of the secondary antibody, SlowFade Gold 
Antifade Reagent was used before placing the cover slip on top of the slide. The air 
bubbles were removed and the slides were sealed with a nail varnish. The samples 
were visualised under LSM510 confocal microscope.  
2.8.2 Confocal Image Analysis: 
During this procedure it is important to get accurate quantitative data thus the user bias 
was eliminated, then by automatically creating a threshold the interdependence of the 
red and green channels were calculated with the use of the correlation coefficient. 
2.8.2.1 LSM Image Browser and AxioVision LE: 
There are three software systems in confocal microscopy that enables the user to 
adjust the brightness and the contrast of the images and it saves the images as a LSM 
file. AxioVision LE software (Carl Zeiss, Inc.) is used to convert the image data to TIF 
files. Otherwise the images cannot be analysed with the next software system ImageJ 
and JACoP. 
2.8.2.2 ImageJ and JACoP: 
This software is used to analyse the TIF files that are converted by AxioVision LE 
software (Carl Zeiss, Inc.). This program is capable of analysing the confocal images 
in Java software. It automatically thresholds the images and removes the user bias. 
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2.9 Plasmid DNA: 
2.9.1 Plasmid DNA Preparation: 
2.9.1.1 Transformation: 
Several agar plates were prepared with a selection antibiotic (1 µg/ml), either Zeocin, 
puromycin or ampicillin. pshRNA-TLR2, pshRNA-TLR4, pshRNA-TLR9, pshRNA-
DAI, pshRNA-STING and pshRNA-RIG-I were transformed into a competent E.coli 
strain (E.coli GT116). Zeocin is a selection antibiotic for pshRNA TLR2, STING and 
TLR9 (Invivogen). Puromycin is the selection antibiotic for ZBP1 pshRNA plasmid. 
Ampicillin is for pshRNA RIG-I and was used as a negative control. The lyophilized 
pshRNA plasmid DNA (in powder form) was diluted in 200µl of sterile endotoxin free 
deionized water. The liquid solution was vortexed and 5µl of plasmid was introduced 
into tubes with 100µl of E.coli competent cells. The tubes were placed on ice for 30 
minutes. The E.coli and pshRNA plasmid complex was placed on a hot plate for 1 
minute at 42°C, which causes a heat shock to the bacteria to initiate the intake of the 
plasmid DNA. The tubes were then placed back on ice for 2 minutes and 0.5ml of 
Luria Broth was added in the eppendorf tubes, followed by incubation in a shaking 
incubator at 37°C for 2 hours.  
All procedures for DNA extraction were performed in a class I cabinet. 100µl of 
transformed E.coli was added onto the agar plates containing the selection antibiotic 
and evenly distributed onto the agar surfaces using a glass spreader. The agar plates 
were incubated in an incubator at 37°C overnight. The plasmids contain the antibiotic 
resistance gene, so only the E.coli that have taken up the plasmid will survive on the 
agar plates containing the specific antibiotic.  
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After growing up the E.coli colonies, the transformed E.coli and plasmids were 
expanded. 25µl Zeocin, or Puromycin or Ampicillin depending on the plasmid used 
was added to 25ml LB in bottles, and individual colonies were added to the broths, as 
well as being added to the reference plate, and incubated overnight in a shaker 
incubator at 225 rpm at 37oC. 
2.9.1.2 DNA Isolation: 
Luria Broth solutions were spun at 3000rpm for 30 minutes; the pellets were treated 
with 400µl of STET Buffer (see Appendix). The samples were vortexed and 
transferred into autoclaved tubes. The pellets were placed on ice and 10µl of lysozyme 
was added. The tubes were boiled for a minute and placed back on ice bucket for 
another 5 minutes. The tubes were centrifuged at 13000 rpm for 30 minutes; the 
pellets were removed with autoclaved toothpick. 5µl of 20mg/ml RNAse A was added 
and incubated at a temperature between 37°C-42°C for 30 minutes. An equal amount 
of phenol/chloroform/isoamyl alcohol was added into the solution and vortexed. The 
tubes were centrifuged again for 20 minutes and the supernatant of the solution was 
kept. 400µl of chloroform/isoamyl alcohol was added in each tube. The tubes were 
centrifuged again for 20 minutes and the supernatant was kept and was placed in new 
tubes. The nucleic acids were precipitated by the addition of 1/20th of the original 
volume of sodium acetate 2M (pH 6.5) and 2.5 of the original volume of absolute 
ethanol in each tube. The components were mixed and the eppendorfs were placed into 
-80°C for at least 60 minutes. Afterwards, the eppendorfs were quickly removed from 
the -80°C to be centrifuged at 13,000 rpm for 20 minutes at room temperature. The 
excess supernatant was removed, and the eppendorfs were centrifuged at 13,000 rpm 
for a further minute, and the remaining supernatant was removed. 80µl sterile water 
(ddH2O), or LAL water, was added to each eppendorf, and the samples frozen at -20oC. 
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2.9.1.3 Agarose Gel Electrophoresis: 
Agarose gel electrophoresis was applied after the DNA isolation. The purpose of this 
electrophoresis technique was to examine the purity of the samples for the plasmid 
preparation procedure. An agarose gel was prepared with a concentration of 1g in 
100ml of x1 ELFO buffer (see Appendix). 15µl of the samples were mixed with 7µl of 
ELFO Loading Buffer (see Appendix) were added in each well. The tank was filled up 
with ELFO running buffer. 5µl of 1kb DNA ladder with 10µl of ELFO Loading 
Buffer were added into the well of the gel, to examine the banding patterns of the 
samples. The system was set to run for 45 minutes at a constant voltage of 100V. 
2.9.1.4 RNA Interference:  
The silencing of a particular gene includes the inhibition or suppression of the 
expression of that molecule that the gene is coding for in the cell mechanism 
(Czauderna et al., 2003;Koper-Emde et al., 2004). Thus affecting the downstream 
signalling cascades that are related to that particular molecule.  This is achieved by 
introducing a plasmid plus hairpin RNA to knock down the gene expression (ter Brake 
et al., 2008;Triantafilou et al., 2005). Short hairpin RNA interacts with a 
Dicer/Argonaute 2 complex, where dicer cleaves it. Passenger strand is cleaved by 
Argonaute 2 and is realeased, whereas RNA Interference Specificity Complex (RISC) 
uses guide strand for targeting our mRNA of interest. RISC translocates mRNA into 
processing bodies. Processing bodies contain proteins, which degrade the mRNA. In 
this project transfections of shRNAs were carried out using Lipofectamine. The target 
sequence of shRNA used were:  
for TLR2 5’GTCAATTCAGAACGTAAGTCA3’,  
for TLR4 5’GCUUAUAUCCUUAAAGAAATT3’ 
for ZBP1, 5’GGCCACCUUGAACAAAGAAtt-3’,  
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for STING, 5’GCAUCAAGGAUCGGGUUU3’ 
for TLR9 5’CCGCATCGTCAAACTGGCG3’. 
Transfections with the specific shRNAs resulted in an approximately 90% decrease in 
receptor expression as determined by western blotting whereas transfection of cells 
with the scrambled shRNA did not show any decrease in TLR or STING and DAI 
expression. 
 
2.10 Cytometric Bead Array:  
The Human inflammation BDTM Cytometric Bead Array (CBA (BD Biosciences)) kit 
was used for determining the cytokine concentrations in the sample. Interleukin-8 (IL-
8), Interleukin-1β (IL-1β), Interleukin-6 (IL-6), Interferon-β (IFN-β), Tumour 
Necrosis Factor (TNF) and Interleukin-12p70 (IL-12p70) are the cytokines that the 
cytometric bead array can detect. These cytokines function during the human 
inflammatory response. The beads are coated with antibodies specific for each 
cytokine, thus they are capable of capturing the cytokines in a solution. This method is 
very specific to quantify the amount of the cytokines. Each of them has different 
fluorescent intensities. Detection antibody, which is phycoerythrin (PE) conjugated, is 
added to the cell samples. Each bead will give out different intensity of a signal; this 
makes it easier to identify the cytokines in the samples. 
2.10.1 Assay Procedure:   
This procedure was achieved by adding 50µl of the tissue culture supernatant into the 
flow tubes, followed by the addition of the cytokine beads (50µl) into the solution, 
mixed thoroughly. The complex was incubated for 60 minutes at room temperature. 
PE detection reagent (50µl) was injected into the tube, mixed and incubated in the 
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dark for two hours at room temperature. The pellets were washed with PBS-Tween 
and then centrifuged for five minutes. The supernatants were removed, and the pellets 
were re-suspended in a 300µl PBS-Tween. They were examined by using flow 
cytometry. 
2.11 TLR Agonists:  
Tests were carried out on primary human vaginal epithelial cells, which were obtained 
from healthy donors (Celprogen, Torrance, CA). They were cultured in human vaginal 
epithelial primary cell culture complete growth medium, which was obtained from 
Celprogen; the culture media were replaced with a fresh media every 24-48 hours. 
During this procedure the primary cells were cultured in a six well plate with the 
density of 1.5×106, cells were used up to 8 passages only. Subculturing was performed 
every 24-48 hours in a microflow cabinet and then placed back to 37°C in 5% CO2 
humidified incubator. Pam2CSK4, Pam3CSK4, FSL-1, CpG DNA (type C), cyclic 
diguanylate monophosphate (c-di-GMP), and cyclic diadenylate monophosphate (c-di-
AMP) were obtained from Invivogen (San Diego, CA). Pam2CSK4, Pam3CSK4, FSL-1 
were used as TLR2 agonists. CpG DNA was used as a TLR9 agonist and c-di-GMP 
and c-di-AMP for STING. Cells were stimulated with different concentrations of 
agonists and incubated for 60 minutes in 37°C in 5% CO2 humidified incubator. 
50ng/ml, 100 ng/ml and 150 ng/ml of Pam2CSK4, 100 ng/ml, 200ng/ml, 300ng/ml of 
Pam3CSK4, 50ng/ml, 100ng/ml, 150ng/ml of FSL-1 agonists were used for receptor 
TLR2. 100nM, 200nM and 300nm of CpG DNA (type C) were used for TLR9. 2µg/ml, 
4µg/ml, 6µg/ml of c-di-GMP and c-di-AMP were used to test on STING (Triantafilou 
et al., 2014). 5MOI of HSV2 was introduced into the cells and they were left for 18 
hours incubation in 37°C in 5% CO2 humidified incubator. Indirect 
immunofluorescence technique was applied onto the cells to be able to examine the 
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HSV2 replication levels before and after the agonists, specific antibody known as anti-
HSV2 ICP5 antibody from Abcam (Cambridge, UK) was used against ICP5 major 
capsid protein of HSV2 (Part 2.4.1). This was followed by indirect 
immunofluorescence using a FACSCalibur to determine the PRR expression levels.  
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CHAPTER 3: A SYNERGIC INVOLVEMENT OF 
DIFFERENT PRRs IN HERPESVIRUS INNATE IMMUNE 
RESPONSE 
3.1 Introduction 
Herpesviruses are a large family of dsDNA viruses. Alphaherpesviruses include two 
subtypes, which are HSV 1 and HSV 2. HSV-2 is the most common subtype seen in 
genital infections (Cunningham et al., 2006;Molina et al., 2011;Wald and Link, 2002).  
Immunological control of herpesviruses by the infected host is achieved by both the 
innate and the adaptive immune systems. In the innate antiviral immune response, type 
I interferons (IFNs) and cytokines have key roles in the containment of herpesvirus 
infections. This response is governed by a variety of PRRs that recognize PAMPS and 
DAMPS and activate downstream signaling molecules. Cytokines and chemokines aid 
in mediating this response. Nucleic acids that are released into the cytosol during HSV 
infection are recognized by a range of intracellular DNA sensors that activate the type 
I interferon response. 
To date, many TLRs and cytosolic DNA sensors have been described, however it is 
unclear how these receptors work in concert to mediate HSV clearance Previous 
studies show that TLRs can recognize herpesvirus glycoproteins. This recognition 
controls cytokine and IFN expression in various cell types (Kurt-Jones et al., 
2004;Sato et al., 2006). Furthermore DAI recognizes HSV DNA (Takaoka et al., 
2007). Herpesviruses are also detected by IFI16, which stimulates the expression of 
IFN-β (Unterholzner et al., 2010). Our understanding of how herpesviruses are 
detected by PRRs and the innate immune system and stimulate antiviral activities has 
grown tremendously over the past decade however it is essential to establish their roles 
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and mechanisms of action in different tissue types and cells. This part of the study 
aims to investigate the role of different PRRs in HSV2 infection, which is one of the 
most common pathogens in genital infections and how the innate immune system 
recognizes this virus in HeLa cells. Utilising siRNA knockdown of different PRRs as 
well as bead array assays to determine cytokine secretion our results have shown that 
TLR2 and TLR9 recognize HSV2 and trigger IL-6 secretion. While the DNA sensors 
DAI, IFI16 recognize the viral DNA and trigger type I IFN production through STING. 
Inflammasome activation and IL-1β secretion occurs through AIM2 in HSV2 infection. 
 
3.2 Results 
3.2.1 PRR Expression Levels in Response to HSV2 and HSV2 
DNA 
To determine the expression levels of PRRs, during the initial HSV2 infection in HeLa 
cells, we used indirect immunofluorescence and determined the fluorescence intensity 
by flow cytometry. HeLa cells were stimulated with HSV2 and also exposed to 
purified viral DNA at specific time points (Fig. 3.1 and Fig. 3.2 respectively). During 
the first hours of the viral entry there is an increase in the expression levels of TLR2, 
TLR9, DAI and a slight increase in the TLR4 (Fig. 3.1). TLR2 the cell surface 
receptor upregulation is probably due to detection of the glycoproteins on the envelope, 
which is consistent with the other studies (Compton et al., 2003;Kurt-Jones et al., 
2004). TLR9 and DAI are intracellular receptors which recognize viral genomic 
dsDNA thus the upregulation of these receptors observed in the first few hours is due 
to the presence of HSV2 DNA after cell entry, these receptors seem to increase 
significantly again from 10hr onwards when the virus begins to replicate and the new 
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2007).  
 
Figure 3.1: PRR responses to HSV2 infection. HeLa cells were stimulated with 5 MOI HSV2 at 
different time points and then PRR expression was determined by using a specific primary antibody for 
each receptor of interest followed by the appropriate secondary conjugated to FITC. The expression 
levels were represented by the mean fluorescence intensity determined by flow cytometry. The data 
represents the mean ± SD of three independent experiments. 
 
 
HeLa cells were also stimulated with HSV2 DNA (Fig. 3.2). 
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Figure 3.2: PRR responses to HSV2 DNA infection. HeLa cells were stimulated with 20 µg/ml of 
purified DNA at different time points and then PRR expression was determined by using a specific 
primary antibody for each receptor of interest followed by the appropriate secondary conjugated to 
FITC. The expression levels were represented by the mean fluorescence intensity determined by flow 
cytometry. The data represents the mean ± SD of three independent experiments. 
 
 
HSV2 dsDNA seems to be recognized by a plethora of DNA sensors (Fig. 3.2). At 
first there is an upregulation of TLR9 which is logical since it is known that TLR9 
recognizes viral DNA in the endosomal compartments during viral entry and DAI is 
abundant in the cytoplasm so they are the first DNA sensors picking up the HSV2 
dsDNA inside the cell. Initially AIM-2 and IFI-16 expression levels do not change in 
the cell. However when TLR9 and DAI expression in the cell decrease there is an 
increase in the expression levels of AIM-2 and IFI-16 compensating for the loss of 
DAI. This possibly signifies that these receptors are triggered later on in the virus 
replication cycle when the virus replicates and there is an increase of viral DNA. In the 
4th hour AIM-2 inflammasome and IFI-16 expression reaches to the maximum. IFI-16 
is localized in the cytoplasm and in the nucleus (Unterholzner et al., 2010) and my 
data suggests that the viral genome accumulation in those compartments leads to the 
detection by IFI-16. During the 12th hour the expression levels of these sensors are 
diminished massively, which can be either linked to the lytic phase of the viral cycle 
or the inhibition of the detection mechanism by the viral components.  
3.2.2 Host response and Signalling upon Infection with HSV2 
and viral DNA 
After the detection of the PRRs that were involved in HSV2 detection in HeLa cells, 
the downstream signalling cascades of those receptors were examined to verify their 
involvement in HSV2 and HSV2 dsDNA recognition. 
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TLRs when activated by their ligand induce the recruitment of downstream signalling 
molecules. This results in IκB being released from the NF-κB complex and getting 
phosphorylated, marking it for ubiquitination and degradation by proteosomes. The 
transcription factors NF-κB and IRF3 transcriptionally upregulate type I IFNs to 
mediate induction of the innate immune response. The detection of phospho-IκB 
therefore corresponds to NF-κB activation.   
HeLa cells were infected with HSV2 and the cell lysate was used to detect phospho-
IkkB via western blotting (Fig. 3.3). 
 
Figure 3.3: Immunostimulatory effect of HSV2 on HeLa cells. HeLa cells were stimulated with 5 
MOI of HSV2 at different time points. The cell lysate obtained from each stimulation was used for 
SDS-PAGE gel electrophoresis and western blot analysis using primary antibodies for phospho-IkkB 
followed by the appropriate secondary antibodies conjugated to HRP. The data represents one set from 
three independent experiments.  
 
As expected after the HSV2 infections as a result of immunostumulatory effect TLRs 
trigger signalling cascades leading to the activation of the transcription factor NF-κβ 
in HeLa cells. As a result of the viral stimulation the transcription factor production is 
quite high during the virus infectious cycle thus leading us to hypothesize that 
elevation in the PRR expression levels, which recognize the virus, causes activation of 
NF-κβ and their downstream signalling cascades.  
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To verify the PRR involved in HSV2 host immune response, DAI was also examined 
(Fig. 3.4). 
 
 
Figure 3.4: DAI synthesis after HSV2 stimulation. HeLa cells were stimulated with 5 MOI of HSV2 
at different time points. The cell lysate obtained from each stimulation was used for SDS-PAGE gel 
electrophoresis and western blot analysis using primary antibodies for DAI, followed by the appropriate 
secondary antibodies conjugated to HRP. The data is a representative gel of three independent 
experiments.  
 
The western blot analysis of the HeLa cell lysates shows DAI production in the 
presence of HSV2. DAI expression seems to increase up to the first 6hrs as the band 
becomes denser as time progresses. After 6hrs there is a decrease in DAI production.  
 
HSV2 is a DNA virus so the presence of the adaptor STING that is crucial in DNA 
sensor signalling was also investigated (Fig. 3.5). 
 
 
Figure 3.5: The presence of the adaptor STING in HeLa cells. HeLa cells were stimulated with 5 
MOI of HSV2 at different time points. The cell lysate obtained from each stimulation was used for 
SDS-PAGE gel electrophoresis and western blot analysis using primary antibodies for STING, followed 
by the appropriate secondary antibodies conjugated to HRP. The data is a representative gel of three 
independent experiments. 
 81 
 
Stimulator of IFN genes-STING (also known as MITA, MPYS, ERIS), is also 
activated in response to the cytosolic viral DNA and acts as an adaptor for DNA 
sensors DAI, AIM2 and IFI16 (Hornung and Latz, 2010). The amount of STING in 
the cell lysates was quite high during the first four hours of the infection since STING 
acts as an adaptor molecule in the downstream signalling cascades of DAI, AIM2 and 
IFI16 during the HSV2 infection.   
In addition to the live virus infection cells were stimulated with HSV2 DNA as well 
and NF-κβ production was investigated by phospho-IkkB detection via western 
blotting (Fig. 3.6). 
      
Figure 3.6: Immunostimulatory effect of HSV2 DNA on HeLa cells. HeLa cells were stimulated 
with 20µg/ml of HSV2 dsDNA at different time points. The cell lysate obtained from each stimulation 
was used for SDS-PAGE gel electrophoresis and western blot analysis using primary antibodies for 
phospho-IkkB followed by the appropriate secondary antibodies conjugated to HRP (A). Loading 
control for β-actin is also displayed (B). The data is a representative gel of three independent 
experiments. 
 
NF-κβ production after HSV2 DNA stimulation was not as strong as the stimulation 
with the whole viral structure. The viral DNA is being recognized by the DNA sensors 
during the first few hours of cell entry, as time progresses there will be some 
degradation of the inserted DNA which could lead to diminished host response and 
recognition especially since there is no live virus present to replicate and produce 
more viral DNA. 
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 DAI synthesis after HSV2 DNA stimulation was also examined (Fig. 3.7).             
     
 
 
 
Figure 3.7: DAI involvement in HSV2 DNA detection. HeLa cells were stimulated with 20µg/ml of 
HSV2 dsDNA at different time points. The cell lysate obtained from each stimulation was used for 
SDS-PAGE gel electrophoresis and western blot analysis using primary antibodies for DAI, followed 
by the appropriate secondary antibodies conjugated to HRP. Loading controls for β actin are also 
depicted T he data is a representative gel of three independent experiments. 
 
As seen with NF-κB activation DAI synthesis after the viral DNA entry increases for 
the first few hours but decreases gradually as the viral DNA begins to degrade. Finally 
STING expression after HSV2 DNA stimulation was also investigated (Fig. 3.8). 
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Figure 3.8: STING involvement in HSV2 DNA detection. HeLa cells were stimulated with 20µg/ml 
of HSV2 dsDNA at different time points. The cell lysate obtained from each stimulation was used for 
SDS-PAGE gel electrophoresis and western blot analysis using primary antibodies for STING, followed 
by the appropriate secondary antibodies conjugated to HRP. Loading controls for β actin are also 
depicted. The data represents the mean of three independent experiments. 
 
The activation of STING is the highest during the first hours of entry. From the 8th 
hour there is decreased activation of STING, perhaps due to DNA degradation.   
 
3.2.3 IFN-β, IL-6 and IL-1β Production 
HEK IFN-β, HEK-IL-6 and HEK-IL-1β reporter cell lines were used to determine 
cytokine production in the cells during HSV2 infection. Supernatants of cell cultures, 
which had been infected with HSV2 or stimulated with HSV2 DNA at different times 
points, were incubated with the HEK-Blue cells between 18-24 hrs. After the addition 
of Quanti-Blue and incubation period between 30min-6hrs, samples were tested with 
the spectrophotometer and the SEAP production levels were determined (Fig. 3.9, Fig. 
3.10, Fig. 3.11).  
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HEK IFN-β cells incubated with HSV2 stimulated HeLa cell supernatants (Figure 3.9). 
 
Figure 3.9: Levels of IFN-β  secretion in HeLa cells. HeLa cells were stimulated with 5 MOI of HSV2, 
at different time points. The supernatants were harvested, incubated with HEK IFN-β cells between 18-
24hr and assayed for IFN-β secretion by measuring the levels of SEAP in the supernatant using the 
Quanti-Blue assay.  The SEAP levels were determined via spectrophotometer at 655nm. The data 
represents the mean ± SD of three independent experiments. 
 
 
The specific times points were compared with the unstimulated cell sample and it was 
observed that there was a high IFN-β production in the cells due to the HSV2 
stimulation. This is due to the recognition of the virus by TLR9 and DAI triggering 
their downstream signalling cascades to initiate the type I IFN secretion in the cell. In 
support of these findings another study using human cervical epithelial cells (HCE) 
infected with HSV2, observed an increase in TLR4 and TLR9 expression which lead 
to an increase in the IFN-β production (Li et al., 2009). The cytokine production 
increases for the first hours of the virus replication cycle then once a new replication 
cycle begins at the 12th hour there is an upregulation again.  
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HEK IL-6 cells incubated with HSV2 stimulated HeLa cell supernatants (Figure 3.10). 
 
 
Figure 3.10: Levels of IL-6 secretion in HeLa cells. HeLa cells were stimulated with 5 MOI of HSV2, 
at different time points. The supernatants were harvested, incubated with HEK IL-6 cells between 18-
24hr and assayed for IL-6 secretion by measuring the levels of SEAP in the supernatant using the 
Quanti-Blue assay.  The SEAP levels were determined via spectrophotometer at 655nm. The data 
represents the mean ± SD of three independent experiments. 
 
  
 
Once cells become infected with HSV2 there was an increase in IL-6 production. TLR 
upregulation leads to IL-6 expression in the cell (Li et al., 2009;Sato et al., 2006). 
These results show a marked increase in IL-6 production thus verifying PRR 
activation by HSV2.  
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HEK IL-1β cells incubated with HSV2 stimulated HeLa cell supernatants (Figure 
3.11). 
 
 
Figure 3.11: Levels of IL-1β  secretion in HeLa cells. HeLa cells were stimulated with 5 MOI of 
HSV2, at different time points. The supernatants were harvested, incubated with HEK IL-1β cells 
between 18-24hr and assayed for IL-1β secretion by measuring the levels of SEAP in the supernatant 
using the Quanti-Blue assay.  The SEAP levels were determined via spectrophotometer at 655nm. The 
data represents the mean ± SD of three independent experiments. 
 
  
From the data obtained there was an increase in the IL-1β beginning at the 2nd hour, 
reaching a plateau at the 6th hour. 
 
To determine the immunostimulatory effect and cytokine production of viral DNA, 
cells were stimulated with HSV2 DNA and cytokine secretion was determined (Fig. 
3.12, Fig. 3.13, Fig. 3.14).  
HEK IFN-β cells incubated with purified HSV2 DNA stimulated HeLa cell 
supernatants (Figure 3.12). 
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Figure 3.12: Levels of IFN-β  secretion in HeLa cells in response to HSV2 DNA. HeLa cells were 
stimulated with 20µg/ml HSV2 DNA, at different time points. The supernatants were harvested with 
HEK IFN-β cells incubated between 18-24hr and assayed for IFN-β secretion by measuring the levels 
of SEAP in the supernatant using the Quanti-Blue assay.  The SEAP levels were determined via 
spectrophotometer at 655nm. The data represents the mean ± SD of three independent experiments. 
 
There is a gradual increase in the IFN-β secretion as a result of HSV2 genomic DNA 
between the 1st hour and 6th hour, following a drop in IFN-β production later on.  
HEK IL-6 cells incubated with purified HSV2 DNA stimulated HeLa cell supernatants 
(Figure 3.13). 
 
Figure 3.13: Levels of IL-6 secretion in HeLa cells in response to HSV2 DNA. HeLa cells were 
stimulated with 20µg/ml HSV2 DNA, at different time points. The supernatants were harvested with 
HEK IL-6 cells incubated between 18-24hr and assayed for IL-6 secretion by measuring the levels of 
SEAP in the supernatant using the Quanti-Blue assay.  The SEAP levels were determined via 
spectrophotometer at 655nm. The data represents the mean ± SD of three independent experiments. 
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IL-6 production, due to HSV2 DNA stimulation, is quite high and it shows an increase 
between the 1st hour and the 6th hr, which can be dependent on the rise of TLR9 
expression levels.  
HEK IL-1β cells incubated with purified HSV2 DNA stimulated HeLa cell 
supernatants (Figure 3.14). 
 
 
Figure 3.14: Levels of IL-1β  secretion in HeLa cells in response to HSV2 DNA. HeLa cells were 
stimulated with 20µg/ml HSV2 DNA, at different time points. The supernatants were harvested with 
HEK IL-1β cells incubated between 18-24hr and assayed for IL-1β secretion by measuring the levels of 
SEAP in the supernatant using the Quanti-Blue assay.  The SEAP levels were determined via 
spectrophotometer at 655nm. The data represents the mean ± SD of three independent experiments. 
 
 
As expected HSV2 DNA entry has an effect on the IL-1β synthesis probably via 
AIM2, which triggers IL-1β secretion. 
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3.3 Silencing of TLRs, DAI and RIG-I 
3.3.1 The effect of TLRs and DNA sensors in HSV2 and HSV2 
DNA detection 
To determine the importance of innate immunity in HSV2 infectious cycle, TLR2, 
TLR9, DAI, AIM2 as well as an independent irrelevant PRR, RIG-I that recognizes 
RNA instead of DNA, were silenced. The knockdown efficiency was at 80% and was 
determined by western blotting (Fig. 3.15). The pro-inflammatory response was 
examined to see the knockdown effect.  
 
 
Fig 3.15: PRRs knockdown. TLR9, TLR2, DAI AIM2 as well as RIG-I expression was knocked down 
by shRNA and the expression levels were determined by western blotting using primary antibodies for 
TLR2, TLR9, DAI, AIM2 or RIG-I, followed by the appropriate secondary antibodies conjugated to 
HRP. Loading controls with β-actin are also depicted (A) pshRNA-h7SKGFPzeo-derived plasmid with 
scrambled sequence was used as a control. It had no effect on TLR9, TLR2, DAI, AIM2 or RIG-I 
expression (B). These gels are representatives of three independent experiments. 
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PRR involvement in HSV2 sensing 
 
 
Figure 3.16: HeLa cells were either infected with 5moi of HSV2 or TLR2, TLR9, DAI, RIG-I or AIM2 
expression was knocked down by shRNA and the silenced cells were infected with 5moi of HSV2. 
Supernatant was collected at 12hr post infection and analysed for IL-1β (A), IL-6 (B) and IFN-β (C). 
The data represent the mean of three independent experiments. 
 
From the results we can see that by knocking down TLR2 and TLR9 there is a 
significant decrease in IL-1β production (Figure 3.16). The inflammasome is activated 
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via a two signal mechanism which leads to IL-1β secretion (Latz, 2010) thus leading 
us to the conclusion that TLR2 and TLR9 must provide signal 1 for caspase 1 
activation and subsequent IL-1β production, thus by eliminating signal 1 we have a 
reduction in IL-1β. ΑΙΜ2 is part of the DNA sensing inflammasome (Rathinam et al., 
2010) thus by knocking down AIM2 we are now knocking down signal 2 even though 
signal 1 is triggered from the TLRs without AIM2 for the second signal we have no 
IL-1β secretion. As expected knocking down RIG-I or DAI has no effect in IL-1β 
secretion. 
IL-6 is triggered by the TLRs, (Kawai and Akira, 2010) so we can see a considerable 
reduction in IL-6 secretion when TLR2, which recognizes the virus glycoproteins, is 
knocked down as well as a reduction when TLR9 is knocked down, since TLR9 
recognized the HSV2 DNA (Figure 3.16). DAI as well as AIM2 silencing have no 
effect in IL-6 secretion since although they can recognize DNA they do not play a role 
in IL-6 activation and secretion. RIG-I silencing as expected has no effect (Figure 
3.16). 
Finally in respect to IFN-β production, the knockdown of DAI and TLR9 reduced 
IFN-β production (Figure 3.16). Knockdown of TLR2 had an effect as well by 
reducing IFN-β production albeit much less than the effect that DAI and TLR9 had on 
HSV2 infected HeLa cells. AIM2 and RIG-I had no role in IFN-β secretion. 
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Identifying the importance of PRRs in HSV2 DNA sensing 
AIM2, DAI, TLR2, TLR9 and RIG-I were knocked down by shRNA. Cells were then 
stimulated with HSV2 DNA (Fig. 3.17) and cytokine secretion was measured.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: HeLa cells were stimulated with 20µg/ml of HSV2 DNA also TLR2, TLR9, DAI, RIG-I 
or AIM2 expression was knocked down by shRNA and the silenced cells were stimulated with 20µg/ml 
of HSV2 DNA. Supernatant was collected at 12hr post infection and analysed for IL-1β (A), IFN-β (B) 
and IL-6 (C). The data represent the mean of three independent experiments. 
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The data show that IL-1β secretion was reduced only when AIM2 was knocked down, 
thus confirming that AIM2 inflammasome recognizes HSV2 DNA and triggers IL-1β 
production (Figure 3.17). IFN-β was reduced when DAI, and to a lesser extent TLR9, 
were knocked down verifying their role in type I IFN production. Finally, IL-6 was 
only reduced when TLR9 was knocked down, which is expected since TLRs have 
been shown to trigger IL-6 secretion and TLR9 recognizes viral DNA. 
3.4 Conclusion 
From this data we can see that HSV2 is recognized by different PRRs such as TLR2 
and TLR9 initially which trigger IL-6 secretion followed by the DNA sensors in the 
cytoplasm DAI, IFI16 and AIM2 where cytosolic STING‑dependent DNA signalling 
occurs which leads to type I IFN production through STING, while AIM2 triggers 
inflammasome activation and IL-1β secretion. We have seen that these receptors are 
upregulated and trigger a strong pro-inflammatory host response during the viral and 
DNA stimulations. Since the discovery that intracellular DNA could elicit a TLR 
independent IFN response in a variety of mammalian cells (Ishii et al., 2006;Okabe et 
al., 2005;Stetson and Medzhitov, 2006) much work has focused on finding the DNA 
receptors that initiate this response.  The involvement of more than one PRR shows a 
complexity in HSV2 recognition, this is possibly a defense mechanism of the host, due 
to redundancy at the receptor level, co-operation of several DNA binding receptors 
upstream of STING activation, or access to different DNA receptors in different 
compartments, as has been proposed for the inflammasome activation by AIM2 in the 
cytosol and IFI16 in the cytosol and the nucleus (Kerur et al., 2011;Singh et al., 2013) 
gives the host a better chance to combat and control viral infections such as HSV2 
which if not controlled by the immune system could become life threatening.  
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As a result of these findings we can conclude that virus uses cell surface receptor 
TLR2 while entering the cell, followed by interaction with TLR9 and with other DNA 
sensors. Infections with purified HSV2 DNA have shown that viral DNA does not 
interact with TLR2 on the cell surface. Internalisation of the virus is achieved by 
endocytic pathway that mainly leads to TLR9 and DAI activation straightaway. These 
interactions lead to MyD88 pathway, adaptor molecule STING activation, followed by 
activation of type I interferon and pro-inflammatory cytokine production.  
Thus these findings identify TLRs and DNA sensors as PRRs that recognize HSV-2 
infection, and also show that cytosolic receptors act in concert with TLR9 to induce 
cytokine expression. 
Two previous studies have shown that two different PRRs RIG-I and TLR3 
coordinately activate the host response against influenza A virus and respiratory 
syncytial virus infections (Liu et al., 2007), and our work further supports the idea that 
a full innate antiviral response is induced through activation of several PRRs that act 
in concert to mediate host defense. 
Collectively, our work has identified PRRs recognizing HSV2 infection, and shown 
that simultaneous stimulation through two or more PRRs impacts on the nature of the 
antiviral response. 
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CHAPTER 4: HERPES SIMPLEX VIRUS 2-INDUCED 
ACTIVATION IN VAGINAL CELLS INVOLVES TOLL-
LIKE RECEPTORS 2 & 9 AND DNA-SENSORS DAI & IFI16 
4. 1 Introduction  
Genital infections caused by HSV2 are the most frequent cause of genital ulcerations 
(Beauman, 2005;Steben M, 1997). HSV infection has a high prevalence and represents 
a large economic burden. In industrialized countries, the prevalence rate for HSV-2 
infection in adults is up to 20% (Benedetti et al., 1994). In a subset of people with 
more than 10 lifetime partners, the rate of genital herpes was 50% (Malkin et al., 
2002). Although some infections are self-limiting, HSV2 genital infection has a 
relapsing pattern of illness (staying latently in sensory ganglia before reactivation) 
which impacts of patients’ quality of life both psychologically and socially, as well as 
increasing susceptibility to other infections such as Human Immunodeficiency Virus 
(HIV) (Molina et al., 2011). 
There is currently no vaccine available, and although many antivirals such as acyclovir 
have been developed to reduce duration and severity of infection, there are no 
therapies, which prevent initial infection. Innate immune responses are crucial during 
the period of acute infection to limit early virus replication and to facilitate the 
development of an appropriate specific acquired immunity. Knowledge of these innate 
immune mechanisms is therefore vital if a new therapeutic approach is to be 
developed. Thus experiments on primary cells with TLR agonists can provide us an 
important data about the effect of these novel therapies on viral replication cycle. 
These data can be used during the animal studies and pre-clinical studies for 
development of a vaccine against herpesvirus initial infections. 
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The pathway by which HSV2 triggers the innate immune system in the urogenital 
system has not as yet been fully elucidated. We have already seen that HSV2 is 
detected by a plethora of pattern recognition receptors (PRRs) in Hela cells in order to 
limit host infection. TLR2 recognizes virus lipoproteins and TLR9 as well as DAI and 
to a lesser extent IFI16 recognize the viral DNA and mount a strong inflammatory 
response.  
4.2 Results 
In this study I have utilized primary vaginal cells and TLR2 and TLR9 agonists as 
well as agonists for STING which is a crucial signaling adaptor for DAI and IFI16, in 
order to limit HSV2 infection in vaginal cells. The aim of this study was to identify 
whether these compounds could have therapeutic utility for urogenital HSV2 
infection, also to spot out the cell compartments HSV2 is interacting with. The 
invasion pathway of HSV2 should be the same as in HeLa cervical cells, thus an 
increase in the synthesis of TLR2, TLR9, IFI16 and DAI is expected, furthermore the 
production of adaptor molecules and cytokines that are related to these immune 
receptors should increase. If TLR agonists are successful then there should be a 
decrease in the viral replication. Receptors that function in the recognition of HSV2 
are located on the cell surface, in the endosomes, endoplasmic reticulum, cytoplasm 
and in the nucleus. For this reason localization of HSV2 or purified HSV2 DNA in 
these parts of the cell is expected. 
4.2.1 PRRS Involved in HSV2 Recognition 
Herpes simplex viruses can trigger a strong innate response that involves a synergy of 
several pattern recognition receptors. Studies have shown that TLR2 recognises HSV 
glycoproteins and initiates a signalling cascade which leads to NF-κB activation and 
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cytokine secretion (Leoni et al., 2012). In addition DNA sensors TLR9 as well as DAI 
and IFI16 have been shown to play a key role in recognizing genomic DNA from 
herpesviruses and trigger IFN type I production (Fortin et al., 1999;Krug et al., 
2004b;Lund et al., 2003;Unterholzner et al., 2010). However it has been shown that 
innate immune responses to viral infections can be tailor made depending on specific 
tissues or subsets of cells where TLR9 can be redundant as well as DAI (Ishii et al., 
2008). 
To determine which PRRs contribute to HSV2 recognition in vaginal cells, HSV2 as 
well as purified DNA from HSV2 (20 mg) was used to stimulate vaginal cells at 
different time points and the PRR expersion levels were investigated by indirect 
immunofluorscence and flow cytometry (Figure 4.1A). Isotype controls were also 
performed, which showed values similar to unstimulated samples (Figure 4.1B). 
From the data obtained there was TLR2 upregulation when cells were infected with 
HSV2. There was also an upregulation in DAI and TLR9 in both HSV2 and HSV2 
DNA stimulation suggesting that DAI and TLR9 play a role in HSV2 DNA 
recognition in the first hours of the infection probably when the DNA is released from 
the endosomes in the cytoplasm. A small upregulation in IFI16 DNA sensor is also 
detected in both HSV2 and DNA stimulation (Figure 4.1). 
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Figure 4.1: PRRs expression levels in vaginal cells during HSV2 infection 
Vaginal cells were infected with 5 MOI of HSV2 or transfected with 20 mg HSV2 DNA for different 
time points. The 2 hr time point is depicted in this graph. The cells were stimulated, harvested, fixed 
and permeabilised, followed by incubation with TLR2, TLR4, TLR3, TLR7, TLR8, TLR9, DAI and 
IFI16 primary antibody and the appropriate secondary antibody conjugated to FITC. PRR expression 
levels are depicted as bar charts (A). Flow cytometric diagrams of individual PRR are also depicted (B). 
Fluorescence intensity was detected using a FACSCalibur (Becton Dickinson) counting 10,000 cells not 
gated. Isotype controls were performed, with values similar to unstimulated samples. The data 
represents the mean ± SD of three independent experiments. 
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4.2.2 TLR2, TLR9 and DAI Play a Role in The Innate Immune 
Response of Vaginal Cells 
In order to determine the significance of TLR2 and DNA sensors in the host response 
to HSV2, we silenced TLR2, TLR9, DAI and IFI16 and then we stimulated with either 
HSV2 or HSV2 DNA (Figure 4.2A) and cytokine production was measured. TLR4 
was silenced as a control since it  is not involved in HSV2 recognition. Our data 
showed that IL-6 secretion was severely impaired when TLR2 was knocked down and 
cells were stimulated with HSV2. TLR9 silencing also affected IL-6 secretion when 
cells were stimulated with HSV2 or viral DNA. Furthermore when both TLR9 and 
TLR2 were silenced there was a significant inhibition in IL-6 secretion when cells 
were stimulated either with HSV2 or DNA (Figure 4.2A). As expected, DAI and 
IFI16 silencing had no effect on IL-6 secretion since they trigger IFNα/β production.  
Knocking down DAI and TLR9 reduced IFN-β secretion, however it was only 
minimally affected when IFI16 was knocked down. TLR2 silencing had no effect on 
IFN-β secretion. When TLR9 and DAI were simultaneously silenced there was a 
significant reduction indicating that they are the main sensors, which activate IFN-β 
production (Figure 4.2B).  
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Figure 4.2: TLR2, TLR9 and DAI trigger HSV2 recognition 
Vaginal cells were infected with 5 MOI of HSV2 or transfected with 20 mg HSV2 DNA. Supernatants 
were collected at 12 hr post infection and analysed for IL-6 (A) and IFN-β production (B) using the 
CBA bead array system on a FACSCalibur (Becton Dickinson). TLR2, TLR4, TLR9, DAI and IFI16 
expression was knocked down by shRNA (the expression levels of these receptors as well as b-actin 
before and after pshRNA are depicted) (C) and the cells were again infected with 5 MOI of HSV2 or 
transfected with 20mg HSV2 DNA. Supernatant was collected at 12 hr post infection and analysed for 
IL-6 or IFN-β using the CBA system. The data represents the mean ± SD of three independent 
experiments. 
 
4.2.3 Activation of Signal Transduction in Response to 
Intracellular DNA Sensing  
Cytosolic DNA recognition leads to the activation of TANK-binding kinase 1 (TBK1) 
and IRF3, and the production of type I IFNs and proinflammatory cytokines 
(DeFilippis et al., 2010a;Schröder et al., 2008). TBK1 interacts with the endoplasmic 
reticulum (ER) adaptor molecule STING (also known as TMEM173) (Ishikawa and 
Barber, 2008). STING is essential for activation of the signalling pathway upstream of 
TBK1 following HSV1 infection and has been shown to associate with IFI16 and to 
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relay signals downstream of DAI (DeFilippis et al., 2010a;Ishikawa et al., 
2009;Unterholzner et al., 2010). 
In order to determine the activation of signal transduction in response to intracellular 
HSV2 DNA sensing, vaginal cells were infected with HSV2 and the presence of 
STING as well as IRF3 was determined via western blotting (Figure 4.3A). The data 
showed an increased expression of STING and IRF3 in vaginal infected cells. To 
demonstrate the importance of STING in HSV2 innate immune responses, STING 
expression was knocked down by pshRNA in vaginal cells and then cells were 
infected with HSV2, HSV2 DNA as well as Cyclic diadenylate monophosphate (c-di-
AMP), which is a second messenger molecule produced in bacteria but not in 
mammals. STING has been shown to directly sense this cyclic dinucleotide and induce 
type I interferon production, therefore cyclic dinucleotides were used as a positive 
control (Burdette et al., 2011). The data showed a significant decrease in IFN-β 
production in the absence of STING, confirming the importance of STING mediation 
in HSV2 DNA detection and host response. Overall these data verify that STING is 
essential for activation of the signalling pathway in response to HSV2 DNA and IFN-
β production (Figure 4.3B).  
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Figure 4.3: STING involvement in HSV2 DNA recognition  
Vaginal cells were infected with 5 MOI of HSV2 for 4 hrs or transfected with 20mg HSV2 DNA. Cells 
extracts from unstimulated and also stimulated vaginal cells were analysed for the presence of IRF3 and 
STING by western blotting, using rabbit primary antibody specific for IRF3 or rabbit primary antibody 
specific for STING followed by swine anti-rabbit Ig-HRP (A). To determine the effect of STING in 
IFN-β production, STING expression was knocked down by pshRNA and the cells were again either 
infected with HSV2 or transfected with HSV2 DNA or c-di-AMP as a control and examined for IFN-β 
secretion (B). The data represents the mean ± SD of three independent experiments. 
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4.3 PRR Trafficking in Response to HSV2 Infection 
To verify the involvement of TLR2 in HSV2 infection confocal microscopy was used. 
Co-localisation of HSV2 with MyD88, a signalling adaptor essential for TLR 
signalling was observed when cells were stimulated with HSV2, whereas there was no 
TLR2 and MyD88 co-localisation in unstimulated cells or when cells were stimulated 
with DNA confirming TLR2 signalling in the presence of virus particles (Figure 4.4A). 
In order to detect the mechanism of HSV2 detection by DNA sensors, purified HSV2 
DNA conjugated to Alexa-488 was transfected into vaginal cells. The subcellular 
localization of HSV2 DNA over time was observed using confocal microscopy. 
Endosomal compartments were labelled with EEA-1 specific antibody followed by 
goat-anti mouse Ig-Alexa546. Calreticulin specific antibody followed by goat-anti 
mouse Ig-Alexa546 was used to label the endoplasmic reticulum (ER), whereas 
TOPRO nuclear stain was used to stain the cell nucleus. The viral DNA was showed to 
co-localise within the endosomes within 1h. This was confirmed by the statistical 
analysis, which showed an R(obs) of 0.915, indicating that there was significant 
correlation between HSV2 DNA and the endosomes. The HSV2 DNA subsequently 
translocated to the cytoplasm (statistical analysis revealed an R(obs) of 0.858, which 
suggests strong co-localisation between HSV2 DNA and calreticulin). Finally it 
reached the cell nucleus within 4 hrs. Data shows strong co-localisation between 
HSV2 DNA and IFI16 (Figure 4.4B).  
To gain functional insights into the viral DNA specificity we used drugs that disrupted 
endosomal pathways, such as monensin, an ionophore that neutralizes acidic 
intracellular compartments and leads to defects in vesicular budding as well as 
Brefeldin A (BFA), which blocks transport between the rough endoplasmic reticulum 
(ER) and Golgi complex (Figure 4.4C). The data showed that disruption of the 
endosomes as well as the ER and Golgi complex disrupted the viral DNA 
 104 
colocalization and resulted in re-distribution of the viral DNA in the cell cytoplasm, 
thus verifying that its intracellular trafficking and localisation into intracellular 
organelles is specific and that there was no significant correlation between HSV2 
DNA and the endosomes nor the ER. 
PRR distribution was also investigated in the presence of DNA, co-localisation of 
DNA with TLR9 in the endosomes and MyD88 recruitment was initially observed 
followed by colocalization with STING and DAI in the ER. IFI16 was shown to be 
located in the cell nucleus in vaginal cells. Within 3hrs HSV2 DNA accumulated in 
the cell nucleus and localised with IFI16 (Figure 4.4D). Therefore revealing that 
HSV2 DNA can be recognised by different DNA sensors located in different cell 
compartments, which contribute to a synergic innate immune response to this virus. 
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Figure 4.4: PRR trafficking in response to HSV2 infection Vaginal cells were either unstimulated or 
stimulated with HSV2 (50 PFU) or transfected with HSV2 DNA. The cells were fixed 1 h post 
stimulation and labelled with antibody specific for TLR2 followed by Alexa 546-Fab goat specific Ig 
and MyD88 specific antibody, followed by Alexa 488-Fab rabbit specific Ig (A). 
Vaginal cells were transfected with HSV2 DNA-Alexa 488 for 1 h, 2 h, and 4 h post transfection cells 
were fixed and permeabilised using PBS/0.02% BSA/0.02% Saponin. The endosomes were stained with 
an anti EEA-1 primary antibody (EEA-1 is an early endosomal marker). The Endoplasmic reticulum 
(ER) was stained with an antibody specific for calreticulin conjugated to Alexa 546. IFI16 was labelled 
with an anti IFI16 specific antibody followed by Alexa 546-Fab goat specific Ig. TOPRO nuclear stain 
was also were used for nuclear visualisation (B).  
In order to gain functional insights into the viral DNA specificity, cells were pre-treated with monensin, 
(10 µM) or Brefeldin A (BFA) (10 µg/ml) and stimulated with DNA-Alexa 488 in the presence of these 
drugs. The endosomes and ER were labelled as described above (C).   
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In addition vaginal cells were transfected with HSV2 DNA-Alexa 488 for 1 h, 2 h, and 4 h post 
transfection cells were fixed and permeabilised using PBS/0.02% BSA/0.02% Saponin. TLR9, STING, 
were labelled with specific primary antibodies followed by the Alexa 546-Fab goat specific Ig. IFI16, 
DAI and MyD88 were labelled with specific primary antibodies followed by the Alexa 633-Fab rabbit 
specific Ig (D). Isotype controls normal rabbit IgG followed by Alexa 633-Fab rabbit specific Ig, 
normal rabbit IgG followed by Alexa 546-Fab goat specific Ig and mouse IgG2 followed by Alexa 488-
Fab mouse specific Ig are also shown (E). Cells were imaged using a Zeiss 510 confocal microscope. 
Bars 10 mm. The data presented are representative images from four independent experiments. 
 
4.4 Immunomodulation of HSV2 Infection Using PRR Agonists  
Herpes simplex virus (HSV) infections are efficiently treated with antiviral drugs such 
as acyclovir (ACV), however resistance has been reported mainly among 
immunocompromised patients therefore there is an urgent need of alternative potential 
therapies. New studies such as Krepstakies et al, using synthetic peptide inhibitors as 
alternative therapies have shown that they can effectively block attachment and entry 
of herpes viruses, hepatitis B virus (HBV), and hepatitis C virus (HCV), and human 
immunodeficiency virus (HIV) (Krepstakies et al., 2012). 
TLR agonists could also show some promise in reducing HSV2 infection in the genital 
tract. Thus TLR2 agonists Pam2CSK4 synthetic diacylated lipoprotein, FSL-1 
synthetic diacylated lipoprotein and Pam3CSK4 synthetic triacylated lipoprotein were 
used, as well as CpG DNA in order to activate TLR9. The use of cyclic dinucleotides, 
c-di-AMP and c-di-GMP were also used to activate STING.  
Therefore we screened these agonists to determine whether they could specifically 
inhibit HSV2 infection. Two quantitative methods were utilized to determine the effect 
of these agonists on HSV2 replication. Flow cytometry was initially used to determine 
HSV2 replication. Vaginal cells were seeded at a density of 1.5 ×106/well in a six well 
plate and incubated overnight until cells were confluent. Cells were cultured in media 
containing different concentration of Pam2CSK4, Pam3CSK4, FSL-1, CpG DNA, c-di-
GMP or c-di-AMP for 60 min and subsequently challenged with HSV2. After virus 
internalisation for 1hr at 37 C in 5% CO2 incubator, free virus was removed and 
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replaced with fresh medium and cells were incubated for 18 h. HSV2 replication was 
determined by flow cytometry staining using anti-HSV2 ICP5 antibody (Figure 4.5A). 
Plaque assay was also performed in a 6-well plate format. Vaginal cells were seeded at 
density of 1.5 ×106/well and incubated overnight until cells were 100% confluent. 
Cells were similarly treated with different agonists. Control cells were not treated. 
After treatment, cells were challenged with HSV2 at 50 pfu/well. 
After adsorption for 1 h at 37 ◦C in 5% CO2 humidified incubator, free virus was 
removed and replaced with a mixture of complete medium and 1% agarose. Cells were 
incubated for 72 hours and then stained with 1% crystal violet and plaques were 
counted. Results were shown as number of plaques (Figure 4.5B). Our data showed 
that all agonists used reduced viral replication. However the most significant inhibition 
was when Pam3CSK4 was used as well as CpGDNA and cyclic dinucleotides thus 
indicating that PRR ligands could possibly have a therapeutic use in HSV2 genital 
infection. 
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Figure 4.5: TLR agonists block HSV2 replication.  
Two quantitative methods were utilized to determine the effects of different PRR agonists on HSV2 
replication. Pa3CSK4 was used at 100ng/ml to 300 ng/ml. Pa2CSK4 was used at 50ng/ml to 150ng/ml, 
FSL-1 was used at 50ng/ml to 150ng/ml. CPG DNA was used at 100nM to 300nM and c-di-GMP as 
well as c-di-AMP at 2mg/ml to 6mg/ml. Vaginal cells were seeded at density of 1.5×106/well in a six 
well plate and incubated overnight until cells were confluent. Cells were cultured in media containing 
different concentrations of agonists for 60 min. Control cells were cultured in just media. Then the cells 
were challenged with HSV2 at [5 moi] and were incubated for 18 h. HSV2 replication was determined 
by flow cytometry staining using anti- anti-HSV2 ICP5 antibody and the appropriate secondary 
conjugated to FITC. Isotype controls were also used. Fluorescence was detected using a FACSCalibur 
counting 10, 000 cells not gated (A). 
 In addition, the replication of HSV2 was also determined using the classical plaque assay in vaginal 
cells as described in the results section. The data were counted as number of plaques (B). The data 
represents the mean ± SD of four independent experiments. 
 
4.5 Conclusions 
HSV-2 infects the genital tract of men and women, resulting in self-limiting lesions 
that can serve as portals for acquisition of secondary infection. In rare cases, primary 
HSV infection can also lead to encephalitis, hepatitis, and ocular keratitis and be 
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transmitted to newborns with considerable morbidity and mortality (Beauman, 
2005;Gupta et al., 2007). 
There is currently no vaccine available against HSV2. HSV2 infections are treated 
with antiviral drugs such as acyclovir (ACV), however, resistance has been reported, 
mainly among immunocompromised patients. Strains resistant to ACV are almost 
always cross-resistant to other TK-dependent drugs such as penciclovir and 
famciclovir (Morfin and Thouvenot, 2003). Therefore there is a developing need for 
alternative therapeutic strategies to the traditional HSV antiviral therapy in order to 
suppress or restrict the infection.  
In this study primary human vaginal cells were used and we looked at the involvement 
of different PRRs in HSV2 vaginal innate immune responses. The results showed that 
TLR2 recognizes HSV2 and shuttles from the cell membrane to the Golgi where it co-
localises with MyD88 a signalling adaptor essential for TLR signalling and cytokine 
production. In addition the DNA sensors TLR9 as well as DAI and IFI16 also 
recognise the viral DNA and trigger IFN α/β secretion. TLR9 moves from early 
endosomes and re-distributes in the endoplasmic reticulum (ER) upon HSV2 infection. 
While STING is located in the cytoplasma and ER in unstimulated vaginal cells and 
upon HSV2 DNA stimulation it co-localises with ER translocon components TRAP 
and seC61β (Ishikawa and Barber, 2008). In the experiments, IFI16 was shown to be 
located in the cytoplasm and cell nucleus in vaginal cells. Upon HSV2 DNA 
stimulation IFI16 accumulates more in the cell nucleus. Therefore it seems that 
different PRRs are strategically placed in different cell locations to detect virus 
invasion and replication in order to activate cytokine secretion and protect the host.  
Thus it was investigated whether agonists/ligands for these specific PRRs could 
provide protection against HSV2 infection. Previous studies using TLR agonists have 
shown promise in reducing infection in mice (Gill et al., 2006;Rose et al., 2009).  
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In this study experiments were performed in human vaginal epithelial cells as a model 
of HSV2 infection instead of mice or human dendritic cells like previous studies. 
Contrary to Ashkar et al. there was no TLR3 upregulation nor IFN inhibition when 
poly I:C was used possibly the effect observed in their study on dendritic cells was 
tissue/cell specific and since we are using vaginal epithelial cells it seems that TLR3 
was not involved.  
Lipopeptides were used as TLR2 agonists, CpG DNA as TLR9 agonist as well as for 
the first time cyclic dinucleotides for STING, a signalling adaptor essential for DAI 
and IFI16 activation and triggering IFN type I. The data showed a significant viral 
inhibition especially in the presence of TLR2/6 agonists Pam3CSK4 and FSL1 as well 
as in the presence of cyclic dinucleotides, thus indicating that a combination of 
different agonists especially ones that trigger different cytokines could provide a wider 
spectrum prophylaxis to the host.   
As a result of my findings, it is obvious that the agonists/ligands are successful in 
diminishing the HSV2 replication in vaginal cells. Cells, which were treated with 
certain type of agonist/ligand, had less HSV2 ICP5 expression and the number of the 
plaques caused by the virus was decreased. This also means virus could infect less 
neighbouring number of cells. These agonists magnify the immune response in the cell 
by acting on the immune receptors only, thus they do not cause any harm to the host 
unlike current anti-viral drugs. During the treatment of primary HSV2 infections 
combination of these agonists/ligands will provide an efficient and less harmful 
theraphy for the patients. 
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CHAPTER 5: DNA SENSOR INVOLVEMENT IN 
CYTOMEGALOVIRUS RECOGNITION  
5.1 Introduction 
Cytomegalovirus (human herpes virus 5(HHV-5)) is from the Herpesviridae family it 
belongs to the beta-Herpesviridae subfamily. Beta-herpesviruses are double-stranded 
DNA viruses as well however they target the lymphatic system unlike alpha-
herpesviruses (Hewlett, 2004). Human cytomegalovirus (HCMV) infection symptoms 
can be flu like symptoms, which might be not distinguishable by the infected person. 
Moreover muscle pain; sore throat and high temperature are other symptoms due to 
the HCMV. However the damage of the viral infection can be more serious, if the 
person has a weak immune system or if there is a congenital transmission, this can 
lead to the organ failure, blindness and mental disabilities in the infected person. Thus 
the transmission of the virus from mother to the unborn causes more severe effects 
(Pass, 1985).  
The symptoms of the virus are very flu like symptoms thus it can be hard to identify 
the viral infection, however the immune system detects the virus in the body, and 
initiates the antiviral response. HCMV engagement of pattern recognition receptors 
(PRR), such as TLRs and cytosolic DNA sensors (DeFilippis et al., 2010a;Varani et al., 
2007), initiates the host immune response through activation of elaborate signalling 
programs. The ensuing inflammatory response is further sustained and amplified 
through cytokines, such as IL6, IFNα/β and IL-1β (Boehme et al., 2006;Boyle et al., 
1999;Compton et al., 2003), activating signalling pathways greatly overlapping those 
utilized by TLRs. The central hypothesis of this study is that a HCMV is detected by 
specific TLRs as well as DNA sensors and triggers IFNα/β and IL-6-induced 
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signalling along the MyD88 to NF-κB pathway. To test this hypothesis HCMV innate 
immune responses was initially investigated in Hela cells. It was demonstrated that 
TLR2 plays a role in IL6 secretion During the viral entry TLR2 picks up the viral 
glycoproteins gB and/or gH on the lipid bilayer and triggers NFkB activation and IL6 
secretion After the entry of the virus TLR9 and DAI recognize the genomic DNA and 
initiate the STING pathway to start type I interferon release.  
5.2 Results 
After examining the immune response against HSV2 infection, another member of the 
Herpesviridae family was used to compare the host’s innate immune response We 
wanted to determine whether the same immune receptors that recognize HSV2 also 
play a role in HCMV innate immune recognition. Indirect immunofluorescence was 
use to determine receptor expression levels in infected cells or cells stimulated with 
genomic HCMV DNA. Thus HeLa cells were stimulated with HCMV or HCMV DNA 
at different time points beginning from 1h up to 32h which is a complete virus cycle 
since HCMV has a lengthy infectious cycle compared with other viruses. The 
expression levels were compared to unstimulated samples.  If HCMV was detected 
there would be an upregulation in receptor expression levels. 
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5.2.1 PRR Expression Levels in Response to HCMV and viral 
DNA 
 
 
Figure 5.1: Pattern recognition receptor responses to HCMV infection. HeLa cells were stimulated 
with 5 MOI of HCMV at different time points and then PRR expression was determined by using a 
specific primary antibody for each receptor of interest followed by the appropriate secondary 
conjugated to FITC. The expression levels were represented by the mean fluorescence intensity 
determined by flow cytometry. The data represents the mean ± SD of three independent experiments. 
 
 
The HeLa cells were stimulated with HCMV and it was observed that there was a 
gradual increase in the expression level of TLR2 where it reaches to the maximum at 
the 6th hour. This increase is probably due to the recognition of the glycoproteins on 
the lipid bilayer of HCMV. This level drops off to the minimum at the 12th hour, 
which can be during the latent phase of the virus when the replication cycle is shut. In 
addition to the upregulation of TLR2, there is an upregulation in the expression levels 
of DAI and TLR9 probably because they detect the HCMV genomic DNA, which is 
consistent with other studies showing the involvement of these receptors in viral DNA 
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recognition (DeFilippis et al., 2010a;Varani et al., 2007). DAI expression increases 
from the 4th hour until 32 hours where we have a complete virus cycle. TLR9 
expression is also upregulated. However as a result of HCMV stimulation we did not 
see any increase in the AIM-2 inflammasome expression as it was reported in other 
studies (Rathinam et al., 2010). 
 
 
Figure 5.2: Pattern recognition receptor responses to HCMV DNA stimulation. HeLa cells were 
stimulated with 20 µg/ml of purified DNA at different time points and then PRR expression was 
determined by using a specific primary antibody for each receptor of interest followed by the 
appropriate secondary conjugated to FITC. The expression levels were represented by the mean 
fluorescence intensity determined by flow cytometry. The data represents the mean ± SD of three 
independent experiments. 
 
HCMV DNA triggers TLR9 expression as well as DAI expression  but to a lesser 
effect during the first hour of the infection, however it does not have an effect on 
AIM-2 and IFI-16. Possibly the viral DNA reaches to the endosomes first and then in 
the 2nd hour of the infection the viral DNA is accumulated in the cytoplasm leading to 
high expressions of DAI in HeLa cells.  Furthermore the expression levels of DNA 
sensors AIM-2 and IFI-16 seems to become slightly increased after the 4th hour 
however they are not really significant when compared with TLR9 and DAI.  
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5.2.2 Signalling cascades upon Infection with HCMV and viral 
DNA 
After the expression of PRRs was upregulated at specific time points during the viral 
entry in HeLa cells, the downstream signalling cascade molecules of those receptors 
were examined to see which mechanism does HCMV and HCMV dsDNA trigger in 
the cell. 
NF-κβ production after HCMV stimulation 
                    
          
                      
 
Figure 5.3: Immunostimulatory effect of HCMV on HeLa cells. HeLa cells were left unstimulated or 
were stimulated with 5 MOI of HCMV at different time points. The cell lysate obtained from each 
stimulation, was used for SDS-PAGE gel electrophoresis and western blot analysis using primary 
antibodies for phospho-IkkB followed by the appropriate secondary antibodies conjugated to HRP (A). 
Loading controls for equal loading are shown by Ponceau S staining (B). The gels are representatives of 
three independent experiments. 
 
Cell lysate from different time points of HCMV infection were used to determine 
phosphor-IkkB, which signifies NF-κβ production. From the data above it is obvious 
that there is NF-κβ activation which results from TLR recognition, with highest 
activation between 4th -18th hour time interval of the infectious cycle.  
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HCMV DNA stimulation  results in NF-kB activation 
  
 
                                                           
Figure 5.4: Immunostimulatory effect of HCMV DNA on HeLa cells. HeLa cells were left 
unstimulated or stimulated with 20µg/ml HCMV dsDNA at different time points. The cell lysate 
obtained from each stimulation was used for SDS-PAGE gel electrophoresis and western blot analysis 
using primary antibodies for phospho-Ikkβ followed by the appropriate secondary antibodies 
conjugated to HRP. The gels are representatives of three independent experiments.  
 
Hela cells were stimulated with HCMV DNA and the cell lysate was examined for the 
presence of phosphor-IkkB. The results show that phosphor-IkkB was present thus 
confirming NF-kB activation and TLR involvement. 
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DAI synthesis after HCMV DNA stimulation   
 
 
 
 
Figure 5.5: Immunostimulatory effect of HCMV DNA on HeLa cells. HeLa cells were left 
unstimulated or stimulated with 20µg/ml HCMV dsDNA at different time points. The cell lysate from 
each stimulation was used for SDS-PAGE gel electrophoresis and western blot analysis using primary 
antibodies DAI, followed by the appropriate secondary antibodies conjugated to HRP. Loading control 
for β- actin is also shown. The gels are representatives of three independent experiments. 
 
Cells were stimulated with HCMV DNA and then DAI expression was examined. The 
DAI expression due to HCMV DNA was the highest during the first and the second 
hour of the infection. This decreases in the 4th and the 6th hour however it is not 
stopped completely. 
 
5.2.3 IFN-β, IL-6 and IL-1β Production 
HEK IFN-β, HEK-IL-6 and HEK-IL-1β reporter cell lines were used to determine 
whether HCMV or HCMV DNA could trigger cytokine secretion. Supernatants of 
cells which were infected with HCMV or with HCMV DNA at different times points, 
were incubated with the HEK-Blue cells between 18-24 hrs. After the addition of 
Quanti-Blue and incubation period between 30min-6hrs, samples were tested with the 
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spectrophotometer and the SEAP production levels were determined (Figures 5.6, 5.7, 
5.8, 5.9, 5.10, 5.11).  
HEK IFN-β cells incubated with HCMV stimulated HeLa cell supernatants (Figure 
5.6). 
 
Figure 5.6: Levels of IFN-β  secretion in HeLa cells. HeLa cells were stimulated with 5 MOI of 
HCMV, at different time points. The supernatants were harvested with HEK IFN-β cells incubated 
between 18-24hr and assayed for IFN-β secretion by measuring the levels of SEAP in the supernatant 
using the Quanti-Blue assay.  The SEAP levels were determined via spectrophotometer at 655nm. The 
data represents the mean ± SD of three independent experiments. 
 
 
Due to HCMV infection signalling cascades can trigger type I interferon production in 
the cell. Our results show that there is an increase in IFN-β production starting from 
the first 30 minutes of viral entry. This reaches to the highest in the 2nd and 30th hour. 
The increase is due to the increase in the synthesis of TLR9 and DAI, as they are the 
main PRRs which trigger the signalling pathway to initiate type I interferon production 
in the cell. In the 10th hour lower levels of IFN-β production might be because of the 
viral proteins trying to inhibit the interferon pathway to stop the antiviral response in 
the cell.   
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
1.6 
1.8 
2 
O
D
65
5 
 120 
 
 
HEK IL-6 reporter cells incubated with supernatant from HCMV infected HeLa cells 
(Figure 5.7). 
 
Figure 5.7: Levels of IL-6 secretion in HeLa cells. HeLa cells were stimulated with 5 MOI of HCMV, 
at different time points. The supernatants were harvested with HEK IL-6 cells incubated between 18-
24hr and assayed for IL-6 secretion by measuring the levels of SEAP in the supernatant using the 
Quanti-Blue assay.  The SEAP levels were determined via spectrophotometer at 655nm. The data 
represents the mean ± SD of three independent experiments. 
 
 
The IL-6 production in the cell is mainly dependent on the TLR2 and TLR9. The 
expression levels of IL-6 is quite high especially in the beginning (30 minutes) which 
is logical since TLR2 is on the cell surface and will immediately detect the virus, 
followed by increases in the 6th and 12th hour, throughout these time points TLR9, 
TLR2 and DAI expression is the highest between the 4th- 6th hour, which possibly 
means that viral detection is the highest in between these time points. In addition to 
TLRs there is the possibility that other innate immune sensors such as DEAD box 
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proteins might function during the recognition of the HCMV leading to the production 
of IL-6.  
HEK IL-1β cells incubated with HCMV stimulated HeLa cell supernatants (Figure 
5.8). 
 
Figure 5.8: Levels of IL-1β  secretion in HeLa cells. HeLa cells were stimulated with 5 MOI of 
HCMV, at different time points. The supernatants were harvested with HEK IL-1β cells incubated 
between 18-24hr and assayed for IL-1β secretion by measuring the levels of SEAP in the supernatant 
using the Quanti-Blue assay.  The SEAP levels were determined via spectrophotometer at 655nm. The 
data represents the mean ± SD of three independent experiments. 
 
 
The IL-1β production is triggered during HCMV infection as well. However we have 
not seen any AIM2 upregulation.  It is possible that IL-1β production could be 
triggered by a different inflammasome to AIM2. The amount of IL-1β reaches the 
highest during the 32 hours when there is a viral accumulation in the cell cytoplasm, 
which is around 1.5 pg/ml.  
HEK IFN-β cells incubated with purified HCMV DNA stimulated HeLa cell 
supernatants (Figure 5.9). 
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Figure 5.9: Levels of IFN-β  secretion in HeLa cells. HeLa cells were stimulated with 20µg/ml 
HCMV DNA, at different time points. The supernatants were harvested with HEK IFN-β cells 
incubated between 18-24hr and assayed for IFN-β secretion by measuring the levels of SEAP in the 
supernatant using the Quanti-Blue assay.  The SEAP levels were determined via spectrophotometer at 
655nm. The data represents the mean ± SD of three independent experiments. 
 
 
When we looked at IFN-β production in response to viral DNA we saw that it reaches 
the maximum during the 4th hour and decreases to around 0.9 pg/ml in the 24th hour of 
the stimulation with the viral DNA. We see almost the same pattern of the IFN-β 
production from the viral stimulation thus the IFN-β production is triggered mainly by 
the recognition of the viral DNA. 
HEK IL-6 cells incubated with purified supernatants from Hela cells stimulated with 
HCMV DNA (Figure 5.10). 
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Figure 5.10: Levels of IL-6 secretion in HeLa cells. HeLa cells were stimulated with 20µg/ml HCMV 
DNA, at different time points. The supernatants were harvested with HEK IL-6 cells incubated between 
18-24hr and assayed for IL-6 secretion by measuring the levels of SEAP in the supernatant using the 
Quanti-Blue assay.  The SEAP levels were determined via spectrophotometer at 655nm. The data 
represents the mean ± SD of three independent experiments. 
 
From the data we can see that IL-6 production is also triggered by viral DNA 
stimulation. This is probably due to TLR9 detection. 
HEK IL-1β cells incubated with supernatants from HeLa cell supernatants stimulated 
with HCMV DNA (Figure 5.11). 
 
Figure 5.11: Levels of IL-1β  secretion in HeLa cells. HeLa cells were stimulated with 20µg/ml 
HCMV DNA, at different time points. The supernatants were harvested with HEK IL-1β cells incubated 
between 18-24hr and assayed for IL-1β secretion by measuring the levels of SEAP in the supernatant 
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using the Quanti-Blue assay.  The SEAP levels were determined via spectrophotometer at 655nm. The 
data represents the mean ± SD of three independent experiments. 
 
Surprisingly, IL-1β production is triggered by HCMV DNA. This shows that 
inflammasome activation occurs in response to HCMV DNA.  
5.3 Silencing of TLRs, DAI and RIG-I 
5.3.1 TLRs and DAI innate immune Response to HCMV and 
HCMV DNA 
PRRs were silenced in HeLa cells to determine the effect that they had in HCMV 
innate immune recognition by investigating cytokine secretion in HEK IFN-β, HEK-
IL-6 and HEK-IL-1β reporter cell lines. TLR2, TLR9, DAI were knocked down in 
HeLa cells. The level of knockdown efficiency was 90%. Cells were stimulated with 
either HCMV or HCMV DNA. Supernatants of the cell cultures were obtained from 
different times points, and they were incubated with the HEK-Blue cells between 18-
24 hrs. After the addition of Quanti-Blue and incubation period between 30min-6hrs, 
samples were tested with the spectrophotometer and the SEAP production levels were 
determined.  
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Figure 5.12: IL-1β  synthesis of wt HeLa cells as well as shTLR2 HeLa cells infected with HCMV 
(moi 5), at different time points. The supernatants were harvested with HEK IL-1β cells incubated 
between 18-24hr and assayed for IL-1β secretion by measuring the levels of SEAP in the supernatant 
using the Quanti-Blue assay.  The SEAP levels were determined via spectrophotometer at 655nm. The 
data represents the mean ± SD of three independent experiments. 
 
 
When TLR2 expression is knocked down in Hela cells we can see a complete 
inhibition of IL-1β secretion thus revealing that TLR2 is essential for IL-1β secretion 
and provides signal 1 for inflammasome activation in HCMV infection.   
 
Figure 5.13: IL-1β  synthesis of wt HeLa cells as well as shTLR2 HeLa cells stimulated with 
HCMV DNA. HeLa cells were stimulated with 20µg/ml HCMV DNA, at different time points. The 
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supernatants were harvested with HEK IL-1β cells incubated between 18-24hr and assayed for IL-1β 
secretion by measuring the levels of SEAP in the supernatant using the Quanti-Blue assay. The SEAP 
levels were determined via spectrophotometer at 655nm. The data represents the mean ± SD of three 
independent experiments. 
 
Unexpectedly there is some IL-1β production triggered by HCMV DNA in shTLR2 
HeLa cells. This is probably because in high concentrations of viral DNA other PRRs 
might compensate for signal 1 in the absence of TLR2 for inflammasome activation. 
 
IL-6 synthesis in shTLR2 after HCMV stimulation in HeLa cells 
 
 
Figure 5.14: IL-6 synthesis of shTLR2 HeLa cells infected with HCMV. HeLa cells were infected 
with HCMV, (moi 5) at different time points. The supernatants were harvested with HEK IL-6 cells 
incubated between 18-24hr and assayed for IL-6 secretion by measuring the levels of SEAP in the 
supernatant using the Quanti-Blue assay.  The SEAP levels were determined via spectrophotometer at 
655nm. The data represents the mean ± SD of three independent experiments. 
 
 
When TLR2 was knocked down IL-6 secretion was completely abrogated thus IL-6 
production in HSV2 infection is TLR dependent. 
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In order to see the involvement of TLR9, HeLa wt cells as well as shTLR9 HeLa cells 
(Figure 5.15) were stimulated with viral DNA and IFN-β production was measured.   
 
Figure 5.15: IFN-β  synthesis of wt HeLa cells and shTLR9 HeLa cells stimulated with HCMV 
DNA. Cells were stimulated with 20µg/ml HCMV DNA, at different time points. The supernatants 
were harvested with HEK IFN-β cells incubated between 18-24hr and assayed for IFN-β secretion by 
measuring the levels of SEAP in the supernatant using the Quanti-Blue assay.  The SEAP levels were 
determined via spectrophotometer at 655nm. The data represents the mean ± SD of three independent 
experiments. 
 
 
From the results it is shown that inhibition of TLR9 in HeLa cells, does not have such 
a pronounced effect on IFN-β production, TLR9 silencing does not stop IFN-β 
secretion completely. With the involvement of other PRRs during the detection of the 
viral DNA, low levels of IFN-β are still observed. 
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When DAI is inhibited there is a pronounced IFN-β reduction thus DAI is the main 
PRR triggering type I IFNs (Figure 5.16). 
 
 
Figure 5.16: IFN-β  synthesis of wt HeLa cells and shDAI HeLa cells stimulated with HCMV DNA. 
Cells were stimulated with 20µg/ml HCMV DNA, at different time points. The supernatants were 
harvested with HEK IFN-β cells incubated between 18-24hr and assayed for IFN-β secretion by 
measuring the levels of SEAP in the supernatant using the Quanti-Blue assay.  The SEAP levels were 
determined via spectrophotometer at 655nm. The data represents the mean ± SD of three independent 
experiments. 
 
5.3.2 Signalling cascades in TLR and DNA sensor Silenced 
HeLa cells 
 
To determine the effect of TLR9 and DAI in HCMV DNA recognition, NF-kB 
activation was investigated. 
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Figure 5.17: Immunostimulatory effect of HCMV DNA on HeLa cells before and after TLR9 
silencing. Cells left unstimulated or were stimulated with 20µg/ml HCMV dsDNA at different time 
points. The cell lysate obtained from each stimulation was used for SDS-PAGE gel electrophoresis and 
western blot analysis using primary antibodies for phospho-IkkB followed by the appropriate secondary 
antibodies conjugated to HRP. Loading controls for β-actin are also shown. The data represents the 
mean of three independent experiments. 
 
The data suggests that silencing of TLR9 has an effect on the NF-κβ activation since 
we can see less phospho-IkkB in the shTLR9 cells. TLR9 seems to be an important 
sensor for HCMV DNA.  
 
 
Figure 5.18: Immunostimulatory effect of HCMV DNA on HeLa cells before and after DAI 
silencing. Cells were unstimulated or stimulated with 20µg/ml HCMV dsDNA at different time points. 
The cell lysate obtained from every stimulation was used for SDS-PAGE gel electrophoresis and 
western blot analysis using primary antibodies for Phospho-IkkB followed by the appropriate secondary 
antibodies conjugated to HRP. Loading controls for β-actin are also shown. The data represents the 
mean of three independent experiments. 
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From the data above we can see that silencing of DAI had an effect on NF-κβ 
activation but not as pronounced as TLR9. Thus overall the data lead us to believe that 
TLR9 and DAI recognize HCMV DNA and can trigger a synergic NF-kB activation. 
5.4 Conclusion 
The results have shown that HCMV is recognized by a plethora of PRRs, which are 
TLR2, TLR9 and DAI. The viral DNA stimulations have shown that TLR9 and DAI 
detected HCMV genome, whereas there was almost no detection by AIM-2 and IFI-16. 
According to the western blot results, HCMV was a strong activator of the 
transcription factor NF-κβ, especially the genomic HCMV DNA. 
DAI production was also observed in the cells after stimulations with HCMV genomic 
DNA, this was quite high especially during the 2nd and 4th hours. 
As a result of this activation the production of IFN-β, IL-6 and IL-1β was observed.  
From silencing experiments we can see that IL-6 production is TLR2 dependent as 
well as IL-1β secretion, probably TLR2 triggers signal 1 in inflammasome activation. 
However, there was no indication that the inflammasome recruited was AIM2 
dependent. Thus, NLRs may play a role in HCMV detection. This could be addressed 
in a future study. 
Finally, from the silencing experiments we can conclude that type I IFN secretion is 
TLR9 and DAI dependent. 
The innate immune system plays an important role in controlling herpesvirus 
infections and maintaining the balance between the virus and the host. This study 
revealed the host sensing mechanism in HCMV infection. It is clear that detection of 
classical PAMPs is central to immune surveillance. Recognition of the virus starts 
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from the beginning as soon as it interacts with the cell surface receptors, then it y 
moves to the endosomes, endoplasmic reticulum and in to cytoplasm. 
Recognition of foreign DNA in intracellular compartments or in the cytoplasm sounds 
an alarm bell to the host cells signalling pathogenic invasion. In response, innate 
immune DNA-sensing pathways launch an antimicrobial cytokine and type I IFN 
response. It seems that TLR9 and DAI are major players in viral DNA detection and 
triggering host response. It remains to be determined, however, how the virus 
counteracts TLR and DAI activity and shifts the balance toward viral evasion and its 
consequent growth. 
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Chapter 6: 
Discussion 
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Immunity is the mechanism that organisms use to defend themselves against foreign 
microorganisms. This system gives the chance to identify between self and non-self 
particles and to trigger a signalling cascade to eliminate the specific unknown 
substance from the organism. Skin and mucosal membranes are the very first 
protective parts of the human body, which pathogens have to pass. These barriers are 
supported by the second defensive mechanism, which includes temperature, pH and 
soluble factors. The final mechanism is far more specific than the first two barriers, 
which is the innate immune system. This mechanism includes a broad spectrum of 
receptors, signalling adaptor molecules, transcription factors that cause a big immune 
response in the cells to eliminate the pathogen. Innate immunity is specific however it 
doesn’t have a memory whereas acquired immunity has a memory (Kumar et al., 
2011). 
Janeway in the Cold Spring Harbor Symposia was the first one to refer to innate 
immune receptors and pathogen associated molecular patterns and since 1989 
scientific research has revealed extensive information about the immune system and 
about these receptors (Janeway, 1989). PRR were discovered one after another and the 
way ‘how’ the immune system operates in response to viral infection was beginning to 
be understood. The Toll gene was first discovered in drosophila, (Anderson et al., 
1985;Chuang and Ulevitch, 2001;Chuang and Ulevitch, 2000;Gay and Keith, 
1991;Lemaitre et al., 1996;Medzhitov et al., 1997;Rock et al., 1998;Takeuchi et al., 
1999b). Ligands from different pathogens were identified for every TLR and the 
signalling pathways were studied in detail (Yamamoto et al., 2003;Yamamoto et al., 
2002). It was shown that TLR9 has evolved to detect CpG DNA commonly found in 
bacteria and viruses and to initiate the production of IFN and other cytokines (Hemmi 
et al., 2000). In addition several other PRR were discovered which were involved in 
DNA virus detection such as DAI; (previously also known as DLM1 and ZBP1) was 
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the first molecule to be reported that might function as a cytoplasmic DNA receptor 
(Takaoka et al., 2007). This IFN-inducible protein increased the production of pro-
inflammatory cytokines and type I IFNs when overexpressed. AIM2 has also been 
shown to be essential for mediating inflammatory responses involving IL-1β following 
the sensing of microbial DNA (Hornung et al., 2009). IFI16, another PYHIN family 
protein, has been shown to be an intracellular sensor of HSV‑1 DNA that stimulates 
the expression of IFN-β and pro‑inflammatory genes during infection with this virus 
(Unterholzner et al., 2010). Recently, a molecule referred to as STING was 
demonstrated as being vital for recognizing cytoplasmic DNA and for activating the 
production of innate immune genes in response to a variety of DNA pathogens and 
even certain RNA viruses (Ishikawa et al., 2009).  
Herpesviruses are a large family of DNA viruses, which can cause diseases in humans. 
Although TLRs have been shown to have a role in the sensing of herpesvirus 
infections, the fact that viruses replicate and persist intracellularly suggested that PRRs 
that function in the intracellular environment to detect viral DNA PAMPs also 
contribute to innate immune recognition of these viruses (Malmgaard et al., 2004). In 
this project the mechanism of HSV2 and HCMV in innate immune recognition and the 
host’s innate immune response to herpes urogenital infection were studied. HCMV is 
an opportunistic pathogen associated with significant morbidity and mortality in 
immunocompromised hosts and HSV2 is the most frequent cause of genital 
ulcerations and infections. 
Our data revealed that these viruses are detected by a plethora of PRRs, TLR2 detects 
both viruses and in addition to TLR2, TLR9 is involved in viral dsDNA sensing. In 
addition DAI and to a lesser extent IFI16 in primary vaginal cells can trigger cytokine 
secretion to protect the host from these viruses. There is currently no vaccine available 
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against neither HSV2 nor HCMV. HSV2 infections are treated with antiviral drugs 
such as acyclovir (ACV) and HCMV infections with ganciclovir however, resistance 
has been reported, mainly among immunocompromised patients (Morfin and 
Thouvenot, 2003). Therefore there is a developing need for alternative therapeutic 
strategies to the traditional Herpes virus antiviral therapy in order to suppress or 
restrict the infection.  
Innate immune activation is crucial during the period of acute infection to limit early 
virus replication and to promote the development of an appropriate specific acquired 
immunity. Knowledge of these innate immune mechanisms is therefore of the outmost 
importance if new therapeutic approaches are to be developed. 
In this study we used HeLa cells and primary human vaginal cells and looked at the 
involvement of different PRRs in HSV2 or HCMV vaginal innate immune responses. 
Our results showed that TLR2 recognizes HSV2 and HCMV and shuttles from the cell 
membrane to the Golgi where it co-localises with MyD88 a signalling adaptor 
essential for TLR signalling and cytokine production. In addition the DNA sensors 
TLR9 as well as DAI also recognises the viral DNA and trigger IFN α/β secretion. 
TLR9 moves from early endosomes and re-distributes in the endoplasmic reticulum 
(ER) upon HSV2 infection. While STING is located in the cytoplasma and ER in 
unstimulated vaginal cells and upon HSV2 DNA stimulation it colocalizes with ER 
translocon components TRAP and seC61β (Ishikawa and Barber, 2008). In our 
experiments, IFI16 was shown to be located in the cytoplasm and cell nucleus in 
vaginal cells. Upon HSV2 DNA stimulation IFI16 accumulates more in the cell 
nucleus. Therefore it seems that different PRRs are strategically placed in different 
cell locations to detect virus invasion and replication in order to activate cytokine 
secretion and protect the host.  
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Inflammasome activation and IL-1β secretion is also seen in innate immune responses 
to HCMV and HSV2 in HeLa cells. Surprisingly however this response is AIM2 
independent leading us to speculate that IL-1β secretion maybe triggered by an NLR 
instead. 
HCMV and HSV2 cause chronic persistant infection acyclovir, penciclovir, 
ganciclovir and foscarnet are current antiviral drugs used for herpesvirus-infected 
patients. These drugs target the viral DNA polymerase inhibiting the viral replication 
in the host cell. Acyclovir, valacyclovir and penciclovir are used as antiviral treatment 
for HSV infections. The active form of acyclovir inhibits the DNA polymerase leading 
to the termination of the viral DNA strand formation. The drug is first activated 
selectively by viral thymidine kinase in the cells, infected with HSV (Elion, 
1993;Elion et al., 1999). Penciclovir and valacyclovir function the same way as 
acyclovir.  Unfortunately these drugs that are activated through thymidine kinase, do 
not work with HCMV infections as this type of virus lacks thymidine kinase in its 
structure. However another antiviral agent ganciclovir targets HCMV UL97 kinase 
and can be used for HCMV infections. Ganciclovir slows down the elongation process 
of the viral DNA strand by interacting with the viral proteins as well, whereas 
foscarnet does not need this interaction with these viral proteins for activation (Gilbert 
et al., 2002). It directly binds to the DNA polymerase pyrophosphate-binding site to 
stop the elongation of the viral DNA molecule. Foscarnet is utilised as a second-line 
drug during herpes virus infections. Unfortunately high doses of these antiviral drugs 
can lead to side effects in infected patients. High doses of acyclovir, cidofovir and 
foscarnet can be destructive to the kidney cells (nephrotoxicity), furthermore they can 
damage the brain cells if taken for long periods (Haefeli et al., 1993;Lowance et al., 
1999;Wagstaff and Bryson, 1994;Wagstaff et al., 1994). These drugs can also weaken 
the immune system by reducing the neutrophil levels in the blood (Safrin et al., 1997). 
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Circulation problems can also occur for example valacyclovir can lead to thrombi 
formation in small blood vessels (Ormrod et al., 2000) . However drug toxicities are 
not the only clinical limitation; antiviral drug resistance is another problem that 
clinicians are facing.  
Antiviral drug resistance is common in HSV infections due to mutations in TK, which 
can cause loss of function or change in the functioning of the protein (Coen and 
Schaffer, 1980;Morfin and Thouvenot, 2003). Additions or deletions at guanine and 
cytosine residues are the reason for TK dysfunctioning (Gaudreau et al., 1998;Morfin 
et al., 2000). Although acyclovir and penciclovir are no longer effective however it is 
possible for these emerging mutants to respond to foscarnet and cidofovir as these 
drugs work via DNA polymerase. DNA polymerase is a highly conserved protein, 
which has an important function during the replication cycle and thus mutations in this 
protein is less common (Gilbert et al., 2002). However some cases have been reported 
about foscarnet and cidofovir resistance due to possible DNA polymerase mutations 
(Chen et al., 2000;Wyles et al., 2005). Vidarabine has selectivity for HSV DNA 
polymerase inhibiting the HSV activity, however clinical trials have shown that this 
drug was unsuccessful in HIV-infected patients (De Clercq, 1984;Safrin et al., 1991).  
Ganciclovir and valganciclovir are also drugs used for HCMV infections, however 
resistance to these drugs has been reported as well (Erice et al., 1989). This resistance 
against the drugs is due to mutations in HCMV UL97 kinase gene (Chou et al., 2002). 
Unfortunately chronic HCMV antiviral therapy can induce multiple mutations of 
UL97 gene and of UL54 DNA polymerase, causing cross-resistance not only to 
ganciclovir but also to foscarnet and cidofovir (Chou et al., 1997;Smith et al., 1997). 
Frequent numbers of severe and fatal cases of drug resistant HCMV have been 
reported.  
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In order to treat immunocompromised patients infected with resistant HCMV strains, 
drugs that are used for other diseases are also being tested. Hematopoietic stem cell 
transplant patients, who were under immunosuppressive therapy, had less chance of 
getting HCMV infection (Cutler et al., 2004;Marty et al., 2007). Leflunomide is a drug 
used in rheumatoid arthritis therapy, which showed an inhibitory effect on HCMV 
replication both in vitro and in vivo (Waldman et al., 1999). Artesunate is used for 
malaria treatment and its’ inhibitory effect on HCMV was demonstrated in vivo and in 
vitro studies (Efferth et al., 2008;Kaptein et al., 2006). These drugs could be effective 
on HCMV infection however the drug efficacy or potential side-effects in chronic 
patients are not yet fully determined 
Targeting TLRs or other PRRS involved in viral infections is a promising field for 
HCMV and HSV management and infection control There are clearly many options 
and possibilities for targeting TLRs or other PRRs, because the key function of TLRs 
is to induce cytokines, which could be very potent in clearing an infection 
TLR agonists are widely used to optimize vaccine efficacy, taking advantage of their 
powerful adjuvancity.  
Monophosphoryl lipid A (MPL), a TLR4 agonist is used as a vaccine adjuvant because 
it binds to TLR4 triggering the TRAM/TRIF pathway in the cell (Mata-Haro et al., 
2007)., Pam3CSK4 and MALP-2 are also TLR2 agonists that can be utilised to 
enhance TLR-2 activity (Ishii and Akira, 2007;Lombardi et al., 2008). The data from 
our study also sheds light into the effect of these TLR2 agonists in viral infections. 
Agonists of TLR3 and TLR7-9 have also yielded very promising results for treating 
viral infections. TLR7/8 agonists have reached phase 3 trials. When monocytes from 
HIV patients were stimulated with resiquimod a TLR7 agonist, IL-12 secretion was 
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augmented while TNF production was decreased compared to the control group. 
Additionally, HIV replication in cultured monocytes was inhibited (Nian et al., 2012). 
Another TLR7/8 agonist imiquimod leads to cytokine production and can be used for 
treating genital and perianal human papilloma virus lesions. It is also effective as a 
topical treatment in recurrent acyclovir-resistant HSV sores and lesions and unlike 
other anti-viral drugs it is nontoxic for the patient (Martinez et al., 2006). 
TLR9 agonists cytosine-phosphate-guanosine oligodinucleotide (CPG-ODN) are being 
used as vaccine adjuvant for cancer and infectious diseases (Vollmer and Krieg, 2009). 
Agatolimod is a CPG-ODN aiming at TLR9, triggering the dentritic cell and B cell 
activity, leading to cytotoxic T cell activation initiating anti tumor activity in the host. 
Therapeutic strategies focusing on TLR9-mediated immunomodulation are currently 
being implemented for chronic viral infections, such as chronic hepatitis C (HCV). 
TLR9 agonists stimulate plasmacytoid dendritic cells to produce large amounts of type 
I IFN, especially IFNα, which is the backbone of therapy for HCV. Indeed, IFNα 
powerfully inhibits viral replication and promotes innate and adaptive host immune 
response (Hartmann et al., 2003;Libri et al., 2009). 
The use of antagonists is less successful compared to TLR agonists, as they might 
block the activity of other TLRs as well, very few could reach phase 3 trials. E5564 
(eritoran) a TLR4 antagonist, which blocks TNFα synthesis, was tested for sepsis and 
septic shock therapy, after promising results in phase 1 and phase 2 trials, it failed in 
phase 3 clinical trials (Opal et al., 2013)  
Thus all these new studies reveal that targeting TLRs is a promising field for bacterial 
and viral management and infection control. Therefore we also proceeded to 
investigate whether agonists/ligands for specific PRRs involved in Herpes virus 
recognition could provide protection against infection. Previous studies using TLR 
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agonists had shown promise in reducing infection. It had been previously shown that 
TLR2 agonists vaginally-applied prior to infection increased resistance to HSV-2 
infection in mice (Rose et al., 2009). Surprisingly Poly I:C a synthetic RNA that is a 
TLR3 agonist applied 24 h prior to viral inoculation significantly increased resistance 
to genital HSV2 infection in mice, however TLR4 agonists had no effect (Ashkar et al., 
2004). In addition, TLR9-stimulating CpG oligonucleotides have been shown to 
induce strong local and systemic immune responses in laboratory rabbits.  
In this study we performed experiments in human vaginal epithelial cells as a model of 
HSV2 infection instead of mice or human dendritic cells like previous studies. 
Contrary to Ashkar et al. we found no TLR3 upregulation nor IFN inhibition when 
poly I:C was used possibly the effect observed in their study on dendritic cells was 
tissue/cell specific and since we are using vaginal epithelial cells it seems that TLR3 
was not involved. We have used lipopeptides as TLR2 agonists, CpG DNA as TLR9 
agonist as well as for the first time cyclic dinucleotides for STING. Our data showed a 
significant viral inhibition especially in the presence of TLR2/6 agonists Pam3CSK4 
and FSL1 as well as in the presence of cyclic dinucleotides, thus indicating that a 
combination of different agonists especially ones that trigger different cytokines could 
provide a wider spectrum prophylaxis to the host. However, the intricate network of 
cytokine signalling in response to agonist stimulation needs to be well defined and 
these agonists would ideally be more effective prior to or just after a high-risk sexual 
encounter to prevent herpesvirus infection. Overall the use of PRRs agonists for 
prophylactic and therapeutic use is likely to increase in the future and should continue 
to be at the forefront of immunotherapy research. 
Our data thus identify that vaginal and HeLa cells express both robust levels of TLRs 
as well as DNA sensors which have evolved to complement TLR recognition either 
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through distinct ligand recognition or cell location and thus protect the host from 
herpesvirus infection. 
Novel therapies can be generated based on TLR agonists. The dosage of these PRR 
agonists, mono or combined therapies with different drugs should be determined based 
on experimentations on animal models and after clinical studies. This will also be 
helpful for determining toxicity of these drugs as well as taking into a consideration 
the patients’ health history, and genetic information.      
Additional genetic investigation is needed about drug resistant viruses, so that this data 
can be used for further improvement of these drug therapies. Detailed information 
about the viral mechanism and genetic mutations on these viral proteins will be useful 
to create drugs aiming at different parts of the viral replication cycle also increasing 
the selectivity for conserved viral proteins that are functioning during this process. The 
priority should be a substance with less toxicity and more antiviral efficiency, as the 
majority of the current antiviral drugs are harmful for the patient in the long term. 
Several therapies can be combined together to increase the success of the treatment 
and the precision of a novel therapy can be determined via clinical trials.       
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Glossary: 
A 
Agonist: chemical which binds to the receptor to activate it leading to a biological 
response. 
α-TIF: Viral protein functioning during the transcription of the viral genome. 
Association of this protein with host cell proteins initiates immediate-early gene 
synthesis. 
Antibody: Produced by B-lymphocytes, made up of two regions; Fc region and Fab 
region. Fab region recognizes the antigen and Fc binds to Fc receptors. 
Antigen: Molecule that induces the immune response. 
Antiviral drug: Drugs that have an inhibitory effect on the replication of the virus 
without damaging the host cell. 
Apoptosis: Programmed cell death, initiated by an inflammasome complex. 
Apoptosis-associated spec-like protein containing a CARD (ASC): Protein encoded by 
PYCARD gene.  Pyrin domain functions in the receptor interaction and CARD 
domain functions during the caspase activation leading to inflammasome complex 
formation and apoptosis.  
Assay: test. 
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B 
B-lymphocytes: Immune cells that produce antibodies. 
Baltimore scheme: Virus classification system created by David Baltimore that 
seperates the viruses depending on the type of genome they consist of.  
bp: Specific nucleobases pair up with each other in the DNA by forming hydrogen 
bonds.  
Brefeldin A: Antibiotic produced by fungi that inhibits the protein transportation 
between the endoplasmic reticulum and the golgi. 
 
C 
Capsid: Viral protein structure surrounding the viral genome and the core.  
Capsomere: Viral capsid protein subunits. 
Centrifugation: Process which involves rapid rotation creating a centrifugal force, 
leading to seperation of the different molecules from each other. 
Cytokine: Proteins which function in the behaviour of the cell. 
Cytometric bead array (CBA): A test used to quantify specific molecule in a sample 
with the help of an antibody.  
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D 
Denature: A change in the structure of a molecule. 
Dendritic cells: Antigen presenting cells, received from bone marrow. 
Dimethyl sulfoxide (DMSO): obtained by oxidation of dimethyl sulfide, it dissolves 
polar and nonpolar bonds. It is used as a cryoprotectant to reduce cell death during 
freezing.  
DNA ligase: Enzyme that functions in the DNA replication and repair, by forming a 
phosphodiester bond. 
DNA polymerase: Enzyme that create the new DNA strand.  
dsDNA: Double-stranded DNA 
dsRNA: Double-stranded RNA 
 
E 
Encephalitis: brain inflammation 
Endonuclease: enzyme that initiates the hydrolysis of nucleic acids. 
Endocytosis: Engulfing of the molecules by the cells. 
Endoplasmic reticulum: A eukaryotic cell organelle that is responsible for lipid, 
membrane and protein synthesis.  
Envelope: Lipid layer surrounding the viral capsid and tegument part.  
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F 
Fc region: C-terminal of an antibody, where it interacts with the Fc receptors. 
Fluorescein isothiocyanate (FITC): Derivative of fluorescein molecule, with the 
excitation and emission spectrum wavelengths of 495mn and 519 nm respectively.  
 
G 
Genome: The genetic information of the organism either present as a DNA or RNA.  
Glycoproteins: Polypeptide chains and oligosaccharide chains form membrane 
proteins. Viral glycoproteins function in the cell adhesion and are located on the lipid 
bilayer outer part of the virus. 
Golgi apparatus: A eukaryotic cell organelle located near the cell nucleus, responsible 
for vesicular protein transport. 
Growth factors: Proteins that signals the growth, proliferation of the cell. 
 
H 
Helix: A spiral 
Hepatitis virus: Viruses that cause liver inflammation.  
Herpesvirus: Large dsDNA viruses that cause latent, recurring infections. 
Horseradish peroxidase (HRP): An enzyme obtained from horseradish that catalyzes 
the chemiluminescent substrate (ECL). This reaction produces light; this is used in 
enhanced chemiluminescence.  
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Human immunodeficiency virus: A member of retroviruses, ssRNA virus that causes 
AIDS. 
 
I 
Icosahedron: A polyhedron with 20 faces and 30 edges.  
Immunofluorescence: Microscopic observation of a protein of interest through 
facilitating a specific fluorescent-conjugated antibody for that protein.  
Incubation period: The period of time taken after the initial infection of the cells until 
the appearance of the symptoms in the host cell. 
Inducible genes:  Gene that is expressed due to environmental change or at the end of 
an activated signalling cascade in the cell. 
Interference: The disruption of a specific gene expression by a different gene, via 
interfering with messenger RNA molecules. 
Interferon (IFN): Proteins that are secreted by an infected cell to trigger the antiviral 
response in other cells. 
Interleukin (IL): Proteins that are secreted by immune cells to stimulate the T and B-
cell development and differentiation. 
 
K 
Kb: Kilobases is used to specify the size of the DNA or RNA molecule. 1 Kilobases is 
equal to 1000 bases. 
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L 
Latency-associated transcripts (LATS): Transcripts that interact with the cellular 
histones to initiate latency period of the virus. 
Latent infection: Infection that cannot be detected in the cell or no apparent clinical 
signs are observed on the patient.  
Limulus amebocyte lysate (LAL) test: Test is used to determine the amount of 
endotoxins in a solution. LAL is obtained from horseshoe crab and it reacts with LPS 
and endotoxin from gram-negative bacteria. 
 Luria/Lysogeny broth (LB): Medium that is rich in nutrients, used for the growth of 
bacteria. 
 
M 
Macrophage: Mononuclear cells that are phagocytes. They function in the innate 
immunity secreating inflammatory cytokines and they can initiate adaptive immunity. 
Major histocompatibility antigen: Cell membrane molecules, which are responsible for 
presenting the antigen sequences to T-cells. 
Meningitis: inflammation of the protective tissue around the brain and the spinal cord. 
Monensin: Polyether antibiotic obtained from bacteria, it can transport the ions 
through cellular and subcellular membranes. It blocks the protein transport and 
destroys the vesicular budding. 
Monoclonal antibodies: Antibodies, which are the same, because the same immune 
cells have produced them. 
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Multiplicity of infection (MOI): The ratio of the infectious agents to the cells. 
 
N 
Neurotropic virus: Viruses that infect nerve cells. 
 
O 
Open reading frame (ORF): The part of the genome that doesn’t have stop codon. 
 
P 
Paraformaldehyde (PFA): Polyoxymethylene, which is depolymerised to 
formaldehyde to be used as a fixative for microscopy examinations. 
Passage: Subculturing that is achieved by separating fully confluent cells into a new 
flask with a fresh growth medium, extending the cell life and increasing the number of 
the cells. 
Pathogen: Disease causing microorganisms that trigger the immune system in the host. 
Phosphate buffered saline (PBS): Isotonic buffer made of salt, it is non-toxic to the 
cells. 
Phycoerythrin (PE): Pigment that is obtained from algae and cryptophytes. They 
consist of phycobiliproteins that give off light. 
Plaque-forming unit (PFU): The number of the infectious particles that can form 
plaques per unit volume. 
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Polyclonal: Antibodies, which are clones of multiple immune cells. 
Primary cells: Cells that are obtained from the tissue origin.  
 
R 
Reactivation: Reoccurrence of an infection after a latency period.  
Receptor: A protein that sits on the cell surface or inside the cell, responsible for the 
recognition of certain sequences on other specific proteins (cellular or extracellular) to 
trigger certain signalling cascades in the host. 
 
S 
Standart deviation (SD): A measure to determine the total variation between certain set 
of data. 
Secreted embryonic alkaline phosphatase (SEAP): Short form of human placental 
alkaline phosphatase, which is secreted out of the cell. It can be detected through HEK 
Blue detection Media.  
Symptoms: Change of a normal state to unusual condition which can be diagnosed by 
the patient.  
 
T 
T lymphocytes: A type of white blood cell that function in the host immunity against 
certain antigen after an infection. 
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Tegument: The section between the viral capsid and envelope, consists of viral 
proteins. 
TEMED: A chemical compound used in polyacrylamide gel electrophoresis to initiate 
the polymerization for the formation of the gel. 
Thymidine kinase: An enzyme that functions in the synthesis of DNA, found in 
herpesviruses and some other DNA viruses. 
Transcription: Synthesis of primary transcript RNA from DNA or RNA template by 
RNA polymerase. 
Transfection: Introducing nucleic acids into the eukaryotic cells by using transfection 
chemical reagents.  
Transformation: Genetic change of the cell as a result of the uptake of an exogenous 
DNA. 
Translocation:  The transport of the viral genome to a different part of the cell. 
 
U 
Ubiquitin: A small amino acid sequence tag on a protein, which marks the degradation 
point by proteosome. 
 
V 
Vaccination: Initiating an immune response in humans via introducing an inactive or a 
part of a pathogen, before the individuals are infected with that specific pathogen. 
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Vesicle: Small circular organelles made of lipid bilayer, consisting of fluid or 
infectious particles during an infectious disease.  
Virion: A whole virus particle. 
Virulence: an amount of the pathogenicity of an organism.  
Virus passage: A number of the rounds of virus replication to generate viral stocks in 
the laboratory.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 152 
Reference List: 
A. G. Vahlne and J. Blomberg. Purification of Herpes Simplex Virus. J Gen Virol, vol. 
22: 297-302, 1974 
AHMAD-NEJAD, P., HÄCKER, H., RUTZ, M., BAUER, S., VABULAS, R. M. & 
WAGNER, H. 2002. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like 
receptors at distinct cellular compartments. Eur J Immunol, 32, 1958-68. 
AKHTAR, J. & SHUKLA, D. 2009. Viral entry mechanisms: cellular and viral 
mediators of herpes simplex virus entry. FEBS J, 276, 7228-36. 
ALAIN, T., LUN, X., MARTINEAU, Y., SEAN, P., PULENDRAN, B., 
PETROULAKIS, E., ZEMP, F. J., LEMAY, C. G., ROY, D., BELL, J. C., THOMAS, 
G., KOZMA, S. C., FORSYTH, P. A., COSTA-MATTIOLI, M. & SONENBERG, N. 
2010. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-
dependent type I IFN production. Proc Natl Acad Sci U S A, 107, 1576-81. 
ALDROUBI, A., CHANG, H. T., ZAKHAROV, S. F. & CHRAMBACH, A. 1995. 
Determination of optimally resolving gel concentration and migration time (path) in 
gel electrophoresis. Anal Biochem, 231, 432-6. 
ALEXOPOULOU, L., HOLT, A. C., MEDZHITOV, R. & FLAVELL, R. A. 2001. 
Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like 
receptor 3. Nature, 413, 732-8. 
ANDERSON, K. V., BOKLA, L. & NÜSSLEIN-VOLHARD, C. 1985. Establishment 
of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the 
Toll gene product. Cell, 42, 791-8. 
ANDRADE, W. A., SOUZA, M. O. C., RAMOS-MARTINEZ, E., NAGPAL, K., 
DUTRA, M. S., MELO, M. B., BARTHOLOMEU, D. C., GHOSH, S., 
 153 
GOLENBOCK, D. T. & GAZZINELLI, R. T. 2013. Combined action of nucleic acid-
sensing Toll-like receptors and TLR11/TLR12 heterodimers imparts resistance to 
Toxoplasma gondii in mice. Cell Host Microbe, 13, 42-53. 
ANTINONE, S. E., SHUBEITA, G. T., COLLER, K. E., LEE, J. I., HAVERLOCK-
MOYNS, S., GROSS, S. P. & SMITH, G. A. 2006. The Herpesvirus capsid surface 
protein, VP26, and the majority of the tegument proteins are dispensable for capsid 
transport toward the nucleus. J Virol, 80, 5494-8. 
ASHKAR, A. A., YAO, X. D., GILL, N., SAJIC, D., PATRICK, A. J. & 
ROSENTHAL, K. L. 2004. Toll-like receptor (TLR)-3, but not TLR4, agonist protects 
against genital herpes infection in the absence of inflammation seen with CpG DNA. J 
Infect Dis, 190, 1841-9. 
BAINES, J. D. & ROIZMAN, B. 1992. The UL11 gene of herpes simplex virus 1 
encodes a function that facilitates nucleocapsid envelopment and egress from cells. J 
Virol, 66, 5168-74. 
BEAUMAN, J. G. 2005. Genital herpes: a review. Am Fam Physician, 72, 1527-34. 
BEGO, M. G., MERCIER, J. & COHEN, E. A. 2012. Virus-activated interferon 
regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene 
independently of interferon signaling. J Virol, 86, 3513-27. 
BENEDETTI, J., COREY, L. & ASHLEY, R. 1994. Recurrence rates in genital herpes 
after symptomatic first-episode infection. Ann Intern Med, 121, 847-54. 
BOCHUD, P. Y., MAGARET, A. S., KOELLE, D. M., ADEREM, A. & WALD, A. 
2007. Polymorphisms in TLR2 are associated with increased viral shedding and 
lesional rate in patients with genital herpes simplex virus Type 2 infection. J Infect Dis, 
196, 505-9. 
 154 
BOEHME, K. W., GUERRERO, M. & COMPTON, T. 2006. Human cytomegalovirus 
envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. 
J Immunol, 177, 7094-102. 
BOWMAN, B. R., BAKER, M. L., RIXON, F. J., CHIU, W. & QUIOCHO, F. A. 
2003. Structure of the herpesvirus major capsid protein. EMBO J, 22, 757-65. 
BOYLE, K. A., PIETROPAOLO, R. L. & COMPTON, T. 1999. Engagement of the 
cellular receptor for glycoprotein B of human cytomegalovirus activates the 
interferon-responsive pathway. Mol Cell Biol, 19, 3607-13. 
BRINKMANN, M. M., SPOONER, E., HOEBE, K., BEUTLER, B., PLOEGH, H. L. 
& KIM, Y. M. 2007. The interaction between the ER membrane protein UNC93B and 
TLR3, 7, and 9 is crucial for TLR signaling. J Cell Biol, 177, 265-75. 
BRYANT, C. E., SPRING, D. R., GANGLOFF, M. & GAY, N. J. 2010. The 
molecular basis of the host response to lipopolysaccharide. Nat Rev Microbiol, 8, 8-14. 
BÜRCKSTÜMMER, T., BAUMANN, C., BLÜML, S., DIXIT, E., DÜRNBERGER, 
G., JAHN, H., PLANYAVSKY, M., BILBAN, M., COLINGE, J., BENNETT, K. L. 
& SUPERTI-FURGA, G. 2009. An orthogonal proteomic-genomic screen identifies 
AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol, 10, 266-72. 
BURDETTE, D. L., MONROE, K. M., SOTELO-TROHA, K., IWIG, J. S., ECKERT, 
B., HYODO, M., HAYAKAWA, Y. & VANCE, R. E. 2011. STING is a direct innate 
immune sensor of cyclic di-GMP. Nature, 478, 515-8. 
BURNS, K., JANSSENS, S., BRISSONI, B., OLIVOS, N., BEYAERT, R. & 
TSCHOPP, J. 2003. Inhibition of interleukin 1 receptor/Toll-like receptor signaling 
through the alternatively spliced, short form of MyD88 is due to its failure to recruit 
IRAK-4. J Exp Med, 197, 263-8. 
 155 
CAI, M., LI, M., WANG, K., WANG, S., LU, Q., YAN, J., MOSSMAN, K. L., LIN, 
R. & ZHENG, C. 2013. The herpes simplex virus 1-encoded envelope glycoprotein B 
activates NF-κB through the Toll-like receptor 2 and MyD88/TRAF6-dependent 
signaling pathway. PLoS One, 8, e54586. 
CAI, W. H., GU, B. & PERSON, S. 1988. Role of glycoprotein B of herpes simplex 
virus type 1 in viral entry and cell fusion. J Virol, 62, 2596-604. 
CAMPBELL, M. E., PALFREYMAN, J. W. & PRESTON, C. M. 1984. Identification 
of herpes simplex virus DNA sequences which encode a trans-acting polypeptide 
responsible for stimulation of immediate early transcription. J Mol Biol, 180, 1-19. 
CAO, Z., HENZEL, W. J. & GAO, X. 1996. IRAK: a kinase associated with the 
interleukin-1 receptor. Science, 271, 1128-31. 
CARFÍ, A., WILLIS, S. H., WHITBECK, J. C., KRUMMENACHER, C., COHEN, G. 
H., EISENBERG, R. J. & WILEY, D. C. 2001. Herpes simplex virus glycoprotein D 
bound to the human receptor HveA. Mol Cell, 8, 169-79. 
CARPETTE, D. R. 2011. Introduction to SDS-PAGE. [Online]. Department of 
Biochemistry and Cell Biology.Rice University Available: 
http://www.ruf.rice.edu/~bioslabs/studies/sds-page/gellab2.html [Accessed 03/05 
2014]. 
CHEN, D. H., JIANG, H., LEE, M., LIU, F. & ZHOU, Z. H. 1999. Three-dimensional 
visualization of tegument/capsid interactions in the intact human cytomegalovirus. 
Virology, 260, 10-6. 
CHEN, Y., SCIEUX, C., GARRAIT, V., SOCIÉ, G., ROCHA, V., MOLINA, J. M., 
THOUVENOT, D., MORFIN, F., HOCQUELOUX, L., GARDERET, L., ESPÉROU, 
H., SÉLIMI, F., DEVERGIE, A., LELEU, G., AYMARD, M., MORINET, F., 
 156 
GLUCKMAN, E. & RIBAUD, P. 2000. Resistant herpes simplex virus type 1 
infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect 
Dis, 31, 927-35. 
CHI, J. H., HARLEY, C. A., MUKHOPADHYAY, A. & WILSON, D. W. 2005. The 
cytoplasmic tail of herpes simplex virus envelope glycoprotein D binds to the 
tegument protein VP22 and to capsids. J Gen Virol, 86, 253-61. 
CHOU, S., MAROUSEK, G., GUENTZEL, S., FOLLANSBEE, S. E., POSCHER, M. 
E., LALEZARI, J. P., MINER, R. C. & DREW, W. L. 1997. Evolution of mutations 
conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus 
disease. J Infect Dis, 176, 786-9. 
CHOU, S., WALDEMER, R. H., SENTERS, A. E., MICHELS, K. S., KEMBLE, G. 
W., MINER, R. C. & DREW, W. L. 2002. Cytomegalovirus UL97 phosphotransferase 
mutations that affect susceptibility to ganciclovir. J Infect Dis, 185, 162-9. 
CHOWDARY, T. K., CAIRNS, T. M., ATANASIU, D., COHEN, G. H., 
EISENBERG, R. J. & HELDWEIN, E. E. 2010. Crystal structure of the conserved 
herpesvirus fusion regulator complex gH-gL. Nat Struct Mol Biol, 17, 882-8. 
CHUANG, T. & ULEVITCH, R. J. 2001. Identification of hTLR10: a novel human 
Toll-like receptor preferentially expressed in immune cells. Biochim Biophys Acta, 
1518, 157-61. 
CHUANG, T. H. & ULEVITCH, R. J. 2000. Cloning and characterization of a sub-
family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw, 
11, 372-8. 
COEN, D. M. & SCHAFFER, P. A. 1980. Two distinct loci confer resistance to 
acycloguanosine in herpes simplex virus type 1. Proc Natl Acad Sci U S A, 77, 2265-9. 
 157 
COMPTON, T., KURT-JONES, E. A., BOEHME, K. W., BELKO, J., LATZ, E., 
GOLENBOCK, D. T. & FINBERG, R. W. 2003. Human cytomegalovirus activates 
inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol, 77, 4588-
96. 
COMPTON, T., NOWLIN, D. M. & COOPER, N. R. 1993. Initiation of human 
cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. 
Virology, 193, 834-41. 
COPELAND, A. M., NEWCOMB, W. W. & BROWN, J. C. 2009. Herpes simplex 
virus replication: roles of viral proteins and nucleoporins in capsid-nucleus attachment. 
J Virol, 83, 1660-8. 
CUNNINGHAM, A. L., DIEFENBACH, R. J., MIRANDA-SAKSENA, M., 
BOSNJAK, L., KIM, M., JONES, C. & DOUGLAS, M. W. 2006. The cycle of human 
herpes simplex virus infection: virus transport and immune control. J Infect Dis, 194 
Suppl 1, S11-8. 
CUTLER, C., KIM, H. T., HOCHBERG, E., HO, V., ALYEA, E., LEE, S. J., FISHER, 
D. C., MIKLOS, D., LEVIN, J., SONIS, S., SOIFFER, R. J. & ANTIN, J. H. 2004. 
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease 
prophylaxis after matched related donor peripheral blood stem cell transplantation. 
Biol Blood Marrow Transplant, 10, 328-36. 
CZAUDERNA, F., SANTEL, A., HINZ, M., FECHTNER, M., DURIEUX, B., 
FISCH, G., LEENDERS, F., ARNOLD, W., GIESE, K., KLIPPEL, A. & 
KAUFMANN, J. 2003. Inducible shRNA expression for application in a prostate 
cancer mouse model. Nucleic Acids Res, 31, e127. 
 158 
DE CLERCQ, E. 1984. The antiviral spectrum of (E)-5-(2-bromovinyl)-2'-
deoxyuridine. J Antimicrob Chemother, 14 Suppl A, 85-95. 
DEFILIPPIS, V. R., ALVARADO, D., SALI, T., ROTHENBURG, S. & FRÜH, K. 
2010a. Human cytomegalovirus induces the interferon response via the DNA sensor 
ZBP1. J Virol, 84, 585-98. 
DEFILIPPIS, V. R., SALI, T., ALVARADO, D., WHITE, L., BRESNAHAN, W. & 
FRÜH, K. J. 2010b. Activation of the interferon response by human cytomegalovirus 
occurs via cytoplasmic double-stranded DNA but not glycoprotein B. J Virol, 84, 
8913-25. 
DELALE, T., PAQUIN, A., ASSELIN-PATUREL, C., DALOD, M., BRIZARD, G., 
BATES, E. E., KASTNER, P., CHAN, S., AKIRA, S., VICARI, A., BIRON, C. A., 
TRINCHIERI, G. & BRIÈRE, F. 2005. MyD88-dependent and -independent murine 
cytomegalovirus sensing for IFN-alpha release and initiation of immune responses in 
vivo. J Immunol, 175, 6723-32. 
DESAI, P., SEXTON, G. L., HUANG, E. & PERSON, S. 2008. Localization of 
herpes simplex virus type 1 UL37 in the Golgi complex requires UL36 but not capsid 
structures. J Virol, 82, 11354-61. 
DEYOUNG, K. L., RAY, M. E., SU, Y. A., ANZICK, S. L., JOHNSTONE, R. W., 
TRAPANI, J. A., MELTZER, P. S. & TRENT, J. M. 1997. Cloning a novel member 
of the human interferon-inducible gene family associated with control of 
tumorigenicity in a model of human melanoma. Oncogene, 15, 453-7. 
DI GIOVINE, P., SETTEMBRE, E. C., BHARGAVA, A. K., LUFTIG, M. A., LOU, 
H., COHEN, G. H., EISENBERG, R. J., KRUMMENACHER, C. & CARFI, A. 2011. 
 159 
Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1. 
PLoS Pathog, 7, e1002277. 
DIEBOLD, S. S., KAISHO, T., HEMMI, H., AKIRA, S. & REIS E SOUSA, C. 2004. 
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded 
RNA. Science, 303, 1529-31. 
DÖHNER, K., WOLFSTEIN, A., PRANK, U., ECHEVERRI, C., DUJARDIN, D., 
VALLEE, R. & SODEIK, B. 2002. Function of dynein and dynactin in herpes simplex 
virus capsid transport. Mol Biol Cell, 13, 2795-809. 
DOLAN, A., JAMIESON, F. E., CUNNINGHAM, C., BARNETT, B. C. & 
MCGEOCH, D. J. 1998. The genome sequence of herpes simplex virus type 2. J Virol, 
72, 2010-21. 
DOUGLAS, M. W., DIEFENBACH, R. J., HOMA, F. L., MIRANDA-SAKSENA, M., 
RIXON, F. J., VITTONE, V., BYTH, K. & CUNNINGHAM, A. L. 2004. Herpes 
simplex virus type 1 capsid protein VP26 interacts with dynein light chains RP3 and 
Tctex1 and plays a role in retrograde cellular transport. J Biol Chem, 279, 28522-30. 
DUBIN, G. & JIANG, H. 1995. Expression of herpes simplex virus type 1 
glycoprotein L (gL) in transfected mammalian cells: evidence that gL is not 
independently anchored to cell membranes. J Virol, 69, 4564-8. 
EFFERTH, T., ROMERO, M. R., WOLF, D. G., STAMMINGER, T., MARIN, J. J. & 
MARSCHALL, M. 2008. The antiviral activities of artemisinin and artesunate. Clin 
Infect Dis, 47, 804-11. 
ELION, G. B. 1993. Acyclovir: discovery, mechanism of action, and selectivity. J 
Med Virol, Suppl 1, 2-6. 
 160 
ELION, G. B., FURMAN, P. A., FYFE, J. A., DE MIRANDA, P., BEAUCHAMP, L. 
& SCHAEFFER, H. J. 1999. The selectivity of action of an antiherpetic agent, 9-(2-
hydroxyethoxymethyl) guanine. Reproduced from Proc. Natl. Acad. Sci. USA 74, 
5716-5720 (1977). Rev Med Virol, 9, 147-52; discussion 152-3. 
ELLIOTT, G., MOUZAKITIS, G. & O'HARE, P. 1995. VP16 interacts via its 
activation domain with VP22, a tegument protein of herpes simplex virus, and is 
relocated to a novel macromolecular assembly in coexpressing cells. J Virol, 69, 7932-
41. 
ERICE, A., CHOU, S., BIRON, K. K., STANAT, S. C., BALFOUR, H. H. & 
JORDAN, M. C. 1989. Progressive disease due to ganciclovir-resistant 
cytomegalovirus in immunocompromised patients. N Engl J Med, 320, 289-93. 
FARNSWORTH, A., WISNER, T. W., WEBB, M., ROLLER, R., COHEN, G., 
EISENBERG, R. & JOHNSON, D. C. 2007. Herpes simplex virus glycoproteins gB 
and gH function in fusion between the virion envelope and the outer nuclear 
membrane. Proc Natl Acad Sci U S A, 104, 10187-92. 
FEIRE, A. L., ROY, R. M., MANLEY, K. & COMPTON, T. 2010. The glycoprotein 
B disintegrin-like domain binds beta 1 integrin to mediate cytomegalovirus entry. J 
Virol, 84, 10026-37. 
FERNANDES-ALNEMRI, T., YU, J. W., DATTA, P., WU, J. & ALNEMRI, E. S. 
2009. AIM2 activates the inflammasome and cell death in response to cytoplasmic 
DNA. Nature, 458, 509-13. 
FIELD, H. J. & WILDY, P. 1978. The pathogenicity of thymidine kinase-deficient 
mutants of herpes simplex virus in mice. J Hyg (Lond), 81, 267-77. 
 161 
FORRESTER, A., FARRELL, H., WILKINSON, G., KAYE, J., DAVIS-POYNTER, 
N. & MINSON, T. 1992. Construction and properties of a mutant of herpes simplex 
virus type 1 with glycoprotein H coding sequences deleted. J Virol, 66, 341-8. 
FORTIN, J. F., BARBEAU, B., HEDMAN, H., LUNDGREN, E. & TREMBLAY, M. 
J. 1999. Role of the leukocyte function antigen-1 conformational state in the process 
of human immunodeficiency virus type 1-mediated syncytium formation and virus 
infection. Virology, 257, 228-38. 
FU, Y., COMELLA, N., TOGNAZZI, K., BROWN, L. F., DVORAK, H. F. & 
KOCHER, O. 1999. Cloning of DLM-1, a novel gene that is up-regulated in activated 
macrophages, using RNA differential display. Gene, 240, 157-63. 
FUCHS, W., KLUPP, B. G., GRANZOW, H., HENGARTNER, C., BRACK, A., 
MUNDT, A., ENQUIST, L. W. & METTENLEITER, T. C. 2002a. Physical 
interaction between envelope glycoproteins E and M of pseudorabies virus and the 
major tegument protein UL49. J Virol, 76, 8208-17. 
FUCHS, W., KLUPP, B. G., GRANZOW, H., OSTERRIEDER, N. & 
METTENLEITER, T. C. 2002b. The interacting UL31 and UL34 gene products of 
pseudorabies virus are involved in egress from the host-cell nucleus and represent 
components of primary enveloped but not mature virions. J Virol, 76, 364-78. 
GALEN, B., CHESHENKO, N., TUYAMA, A., RAMRATNAM, B. & HEROLD, B. 
C. 2006. Access to nectin favors herpes simplex virus infection at the apical surface of 
polarized human epithelial cells. J Virol, 80, 12209-18. 
GAUDREAU, A., HILL, E., BALFOUR, H. H., ERICE, A. & BOIVIN, G. 1998. 
Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex 
viruses from immunocompromised patients. J Infect Dis, 178, 297-303. 
 162 
GAUDREAULT, E., FIOLA, S., OLIVIER, M. & GOSSELIN, J. 2007. Epstein-Barr 
virus induces MCP-1 secretion by human monocytes via TLR2. J Virol, 81, 8016-24. 
GAY, N. J. & KEITH, F. J. 1991. Drosophila Toll and IL-1 receptor. Nature, 351, 
355-6. 
GILBERT, C., BESTMAN-SMITH, J. & BOIVIN, G. 2002. Resistance of 
herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug 
Resist Updat, 5, 88-114. 
GILL, N., DEACON, P. M., LICHTY, B., MOSSMAN, K. L. & ASHKAR, A. A. 
2006. Induction of innate immunity against herpes simplex virus type 2 infection via 
local delivery of Toll-like receptor ligands correlates with beta interferon production. J 
Virol, 80, 9943-50. 
GUPTA, R., WARREN, T. & WALD, A. 2007. Genital herpes. Lancet, 370, 2127-37. 
HAEFELI, W. E., SCHOENENBERGER, R. A., WEISS, P. & RITZ, R. F. 1993. 
Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir 
overdose. Am J Med, 94, 212-5. 
HARTMANN, G., BATTIANY, J., POECK, H., WAGNER, M., KERKMANN, M., 
LUBENOW, N., ROTHENFUSSER, S. & ENDRES, S. 2003. Rational design of new 
CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in 
plasmacytoid dendritic cells. Eur J Immunol, 33, 1633-41. 
HAYASHI, F., SMITH, K. D., OZINSKY, A., HAWN, T. R., YI, E. C., GOODLETT, 
D. R., ENG, J. K., AKIRA, S., UNDERHILL, D. M. & ADEREM, A. 2001. The 
innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. 
Nature, 410, 1099-103. 
 163 
HEIL, F., HEMMI, H., HOCHREIN, H., AMPENBERGER, F., KIRSCHNING, C., 
AKIRA, S., LIPFORD, G., WAGNER, H. & BAUER, S. 2004. Species-specific 
recognition of single-stranded RNA via toll-like receptor 7 and 8. Science, 303, 1526-
9. 
HELDWEIN, E. E., LOU, H., BENDER, F. C., COHEN, G. H., EISENBERG, R. J. & 
HARRISON, S. C. 2006. Crystal structure of glycoprotein B from herpes simplex 
virus 1. Science, 313, 217-20. 
HEMMI, H., KAISHO, T., TAKEUCHI, O., SATO, S., SANJO, H., HOSHINO, K., 
HORIUCHI, T., TOMIZAWA, H., TAKEDA, K. & AKIRA, S. 2002. Small anti-viral 
compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. 
Nat Immunol, 3, 196-200. 
HEMMI, H., TAKEUCHI, O., KAWAI, T., KAISHO, T., SATO, S., SANJO, H., 
MATSUMOTO, M., HOSHINO, K., WAGNER, H., TAKEDA, K. & AKIRA, S. 
2000. A Toll-like receptor recognizes bacterial DNA. Nature, 408, 740-5. 
HEROLD, B. C., VISALLI, R. J., SUSMARSKI, N., BRANDT, C. R. & SPEAR, P. 
G. 1994. Glycoprotein C-independent binding of herpes simplex virus to cells requires 
cell surface heparan sulphate and glycoprotein B. J Gen Virol, 75 ( Pt 6), 1211-22. 
HEWLETT, E. K. W. A. M. J. 2004. Basic Virology, Oxford, UK, Blackwell 
Science,Inc. 
HIDMARK, A., VON SAINT PAUL, A. & DALPKE, A. H. 2012. Cutting edge: 
TLR13 is a receptor for bacterial RNA. J Immunol, 189, 2717-21. 
HOCHREIN, H., SCHLATTER, B., O'KEEFFE, M., WAGNER, C., SCHMITZ, F., 
SCHIEMANN, M., BAUER, S., SUTER, M. & WAGNER, H. 2004. Herpes simplex 
 164 
virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -
independent pathways. Proc Natl Acad Sci U S A, 101, 11416-21. 
HONDA, K., OHBA, Y., YANAI, H., NEGISHI, H., MIZUTANI, T., TAKAOKA, A., 
TAYA, C. & TANIGUCHI, T. 2005a. Spatiotemporal regulation of MyD88-IRF-7 
signalling for robust type-I interferon induction. Nature, 434, 1035-40. 
HONDA, K., YANAI, H., NEGISHI, H., ASAGIRI, M., SATO, M., MIZUTANI, T., 
SHIMADA, N., OHBA, Y., TAKAOKA, A., YOSHIDA, N. & TANIGUCHI, T. 
2005b. IRF-7 is the master regulator of type-I interferon-dependent immune responses. 
Nature, 434, 772-7. 
HORAN, K. A., HANSEN, K., JAKOBSEN, M. R., HOLM, C. K., SØBY, S., 
UNTERHOLZNER, L., THOMPSON, M., WEST, J. A., IVERSEN, M. B., 
RASMUSSEN, S. B., ELLERMANN-ERIKSEN, S., KURT-JONES, E., LANDOLFO, 
S., DAMANIA, B., MELCHJORSEN, J., BOWIE, A. G., FITZGERALD, K. A. & 
PALUDAN, S. R. 2013. Proteasomal degradation of herpes simplex virus capsids in 
macrophages releases DNA to the cytosol for recognition by DNA sensors. J Immunol, 
190, 2311-9. 
HORNUNG, V., ABLASSER, A., CHARREL-DENNIS, M., BAUERNFEIND, F., 
HORVATH, G., CAFFREY, D. R., LATZ, E. & FITZGERALD, K. A. 2009. AIM2 
recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with 
ASC. Nature, 458, 514-8. 
HORNUNG, V. & LATZ, E. 2010. Intracellular DNA recognition. Nat Rev Immunol, 
10, 123-30. 
 165 
HUBER, M. T. & COMPTON, T. 1998. The human cytomegalovirus UL74 gene 
encodes the third component of the glycoprotein H-glycoprotein L-containing 
envelope complex. J Virol, 72, 8191-7. 
HUBER, M. T., WISNER, T. W., HEGDE, N. R., GOLDSMITH, K. A., RAUCH, D. 
A., ROLLER, R. J., KRUMMENACHER, C., EISENBERG, R. J., COHEN, G. H. & 
JOHNSON, D. C. 2001. Herpes simplex virus with highly reduced gD levels can 
efficiently enter and spread between human keratinocytes. J Virol, 75, 10309-18. 
HUTCHINSON, L., BROWNE, H., WARGENT, V., DAVIS-POYNTER, N., 
PRIMORAC, S., GOLDSMITH, K., MINSON, A. C. & JOHNSON, D. C. 1992. A 
novel herpes simplex virus glycoprotein, gL, forms a complex with glycoprotein H 
(gH) and affects normal folding and surface expression of gH. J Virol, 66, 2240-50. 
IRMIERE, A. & GIBSON, W. 1983. Isolation and characterization of a noninfectious 
virion-like particle released from cells infected with human strains of cytomegalovirus. 
Virology, 130, 118-33. 
ISHII, K. J. & AKIRA, S. 2007. Toll or toll-free adjuvant path toward the optimal 
vaccine development. J Clin Immunol, 27, 363-71. 
ISHII, K. J., COBAN, C., KATO, H., TAKAHASHI, K., TORII, Y., TAKESHITA, F., 
LUDWIG, H., SUTTER, G., SUZUKI, K., HEMMI, H., SATO, S., YAMAMOTO, 
M., UEMATSU, S., KAWAI, T., TAKEUCHI, O. & AKIRA, S. 2006. A Toll-like 
receptor-independent antiviral response induced by double-stranded B-form DNA. Nat 
Immunol, 7, 40-8. 
ISHII, K. J., KAWAGOE, T., KOYAMA, S., MATSUI, K., KUMAR, H., KAWAI, T., 
UEMATSU, S., TAKEUCHI, O., TAKESHITA, F., COBAN, C. & AKIRA, S. 2008. 
 166 
TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA 
vaccines. Nature, 451, 725-9. 
ISHIKAWA, H. & BARBER, G. N. 2008. STING is an endoplasmic reticulum 
adaptor that facilitates innate immune signalling. Nature, 455, 674-8. 
ISHIKAWA, H., MA, Z. & BARBER, G. N. 2009. STING regulates intracellular 
DNA-mediated, type I interferon-dependent innate immunity. Nature, 461, 788-92. 
JANEWAY, C. A. 1989. Approaching the asymptote? Evolution and revolution in 
immunology. Cold Spring Harb Symp Quant Biol, 54, 1–13. 
JANSSENS, S. & BEYAERT, R. 2003. Functional diversity and regulation of 
different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell, 
11, 293-302. 
JIANG, Z., NINOMIYA-TSUJI, J., QIAN, Y., MATSUMOTO, K. & LI, X. 2002. 
Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling 
complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate 
TAK1 in the cytosol. Mol Cell Biol, 22, 7158-67. 
JIN, L., WATERMAN, P. M., JONSCHER, K. R., SHORT, C. M., REISDORPH, N. 
A. & CAMBIER, J. C. 2008. MPYS, a novel membrane tetraspanner, is associated 
with major histocompatibility complex class II and mediates transduction of apoptotic 
signals. Mol Cell Biol, 28, 5014-26. 
JIN, T., PERRY, A., JIANG, J., SMITH, P., CURRY, J. A., UNTERHOLZNER, L., 
JIANG, Z., HORVATH, G., RATHINAM, V. A., JOHNSTONE, R. W., HORNUNG, 
V., LATZ, E., BOWIE, A. G., FITZGERALD, K. A. & XIAO, T. S. 2012. Structures 
of the HIN domain:DNA complexes reveal ligand binding and activation mechanisms 
of the AIM2 inflammasome and IFI16 receptor. Immunity, 36, 561-71. 
 167 
KANAYAMA, A., SETH, R. B., SUN, L., EA, C. K., HONG, M., SHAITO, A., 
CHIU, Y. H., DENG, L. & CHEN, Z. J. 2004. TAB2 and TAB3 activate the NF-
kappaB pathway through binding to polyubiquitin chains. Mol Cell, 15, 535-48. 
KAPTEIN, S. J., EFFERTH, T., LEIS, M., RECHTER, S., AUEROCHS, S., 
KALMER, M., BRUGGEMAN, C. A., VINK, C., STAMMINGER, T. & 
MARSCHALL, M. 2006. The anti-malaria drug artesunate inhibits replication of 
cytomegalovirus in vitro and in vivo. Antiviral Res, 69, 60-9. 
KAWAI, T. & AKIRA, S. 2010. The role of pattern-recognition receptors in innate 
immunity: update on Toll-like receptors. Nat Immunol, 11, 373-84. 
KAYE, J. F., GOMPELS, U. A. & MINSON, A. C. 1992. Glycoprotein H of human 
cytomegalovirus (HCMV) forms a stable complex with the HCMV UL115 gene 
product. J Gen Virol, 73 ( Pt 10), 2693-8. 
KELLY, B. J., FRAEFEL, C., CUNNINGHAM, A. L. & DIEFENBACH, R. J. 2009. 
Functional roles of the tegument proteins of herpes simplex virus type 1. Virus Res, 
145, 173-86. 
KERUR, N., VEETTIL, M. V., SHARMA-WALIA, N., BOTTERO, V., 
SADAGOPAN, S., OTAGERI, P. & CHANDRAN, B. 2011. IFI16 acts as a nuclear 
pathogen sensor to induce the inflammasome in response to Kaposi Sarcoma-
associated herpesvirus infection. Cell Host Microbe, 9, 363-75. 
KIJPITTAYARIT, S., EID, A. J., BROWN, R. A., PAYA, C. V. & RAZONABLE, R. 
R. 2007. Relationship between Toll-like receptor 2 polymorphism and 
cytomegalovirus disease after liver transplantation. Clin Infect Dis, 44, 1315-20. 
KIM, T., PAZHOOR, S., BAO, M., ZHANG, Z., HANABUCHI, S., FACCHINETTI, 
V., BOVER, L., PLUMAS, J., CHAPEROT, L., QIN, J. & LIU, Y. J. 2010. Aspartate-
 168 
glutamate-alanine-histidine box motif (DEAH)/RNA helicase A helicases sense 
microbial DNA in human plasmacytoid dendritic cells. Proc Natl Acad Sci U S A, 107, 
15181-6. 
KLUPP, B. G., GRANZOW, H. & METTENLEITER, T. C. 2001. Effect of the 
pseudorabies virus US3 protein on nuclear membrane localization of the UL34 protein 
and virus egress from the nucleus. J Gen Virol, 82, 2363-71. 
KOMURO, A. & HORVATH, C. M. 2006. RNA- and virus-independent inhibition of 
antiviral signaling by RNA helicase LGP2. J Virol, 80, 12332-42. 
KOPER-EMDE, D., HERRMANN, L., SANDROCK, B. & BENECKE, B. J. 2004. 
RNA interference by small hairpin RNAs synthesised under control of the human 7S 
K RNA promoter. Biol Chem, 385, 791-4. 
KREPSTAKIES, M., LUCIFORA, J., NAGEL, C. H., ZEISEL, M. B., 
HOLSTERMANN, B., HOHENBERG, H., KOWALSKI, I., GUTSMANN, T., 
BAUMERT, T. F., BRANDENBURG, K., HAUBER, J. & PROTZER, U. 2012. A 
new class of synthetic peptide inhibitors blocks attachment and entry of human 
pathogenic viruses. J Infect Dis, 205, 1654-64. 
KRIEG, A. M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu 
Rev Immunol, 20, 709-60. 
KRUG, A., FRENCH, A. R., BARCHET, W., FISCHER, J. A., DZIONEK, A., 
PINGEL, J. T., ORIHUELA, M. M., AKIRA, S., YOKOYAMA, W. M. & 
COLONNA, M. 2004a. TLR9-dependent recognition of MCMV by IPC and DC 
generates coordinated cytokine responses that activate antiviral NK cell function. 
Immunity, 21, 107-19. 
 169 
KRUG, A., LUKER, G. D., BARCHET, W., LEIB, D. A., AKIRA, S. & COLONNA, 
M. 2004b. Herpes simplex virus type 1 activates murine natural interferon-producing 
cells through toll-like receptor 9. Blood, 103, 1433-7. 
KRUG, A., ROTHENFUSSER, S., HORNUNG, V., JAHRSDÖRFER, B., 
BLACKWELL, S., BALLAS, Z. K., ENDRES, S., KRIEG, A. M. & HARTMANN, G. 
2001. Identification of CpG oligonucleotide sequences with high induction of IFN-
alpha/beta in plasmacytoid dendritic cells. Eur J Immunol, 31, 2154-63. 
KRUMMENACHER, C., BARIBAUD, F., PONCE DE LEON, M., BARIBAUD, I., 
WHITBECK, J. C., XU, R., COHEN, G. H. & EISENBERG, R. J. 2004. Comparative 
usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical 
isolates of herpes simplex virus. Virology, 322, 286-99. 
KUMAR, H., KAWAI, T. & AKIRA, S. 2011. Pathogen recognition by the innate 
immune system. Int Rev Immunol, 30, 16-34. 
KURT-JONES, E. A., CHAN, M., ZHOU, S., WANG, J., REED, G., BRONSON, R., 
ARNOLD, M. M., KNIPE, D. M. & FINBERG, R. W. 2004. Herpes simplex virus 1 
interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad 
Sci U S A, 101, 1315-20. 
LATZ, E. 2010. The inflammasomes: mechanisms of activation and function. Curr 
Opin Immunol, 22, 28-33. 
LATZ, E., SCHOENEMEYER, A., VISINTIN, A., FITZGERALD, K. A., MONKS, 
B. G., KNETTER, C. F., LIEN, E., NILSEN, N. J., ESPEVIK, T. & GOLENBOCK, 
D. T. 2004. TLR9 signals after translocating from the ER to CpG DNA in the 
lysosome. Nat Immunol, 5, 190-8. 
 170 
LATZ, E., VERMA, A., VISINTIN, A., GONG, M., SIROIS, C. M., KLEIN, D. C., 
MONKS, B. G., MCKNIGHT, C. J., LAMPHIER, M. S., DUPREX, W. P., ESPEVIK, 
T. & GOLENBOCK, D. T. 2007. Ligand-induced conformational changes 
allosterically activate Toll-like receptor 9. Nat Immunol, 8, 772-9. 
LEE, J. H., VITTONE, V., DIEFENBACH, E., CUNNINGHAM, A. L. & 
DIEFENBACH, R. J. 2008. Identification of structural protein-protein interactions of 
herpes simplex virus type 1. Virology, 378, 347-54. 
LEMAITRE, B., NICOLAS, E., MICHAUT, L., REICHHART, J. M. & HOFFMANN, 
J. A. 1996. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the 
potent antifungal response in Drosophila adults. Cell, 86, 973-83. 
LEONI, V., GIANNI, T., SALVIOLI, S. & CAMPADELLI-FIUME, G. 2012. Herpes 
simplex virus glycoproteins gH/gL and gB bind Toll-like receptor 2, and soluble 
gH/gL is sufficient to activate NF-κB. J Virol, 86, 6555-62. 
LI, H., LI, X., WEI, Y., TAN, Y., LIU, X. & WU, X. 2009. HSV-2 induces TLRs and 
NF-kappaB-dependent cytokines in cervical epithelial cells. Biochem Biophys Res 
Commun, 379, 686-90. 
LI, X. D. & CHEN, Z. J. 2012. Sequence specific detection of bacterial 23S ribosomal 
RNA by TLR13. Elife, 1, e00102. 
LIAO, J. C., LAM, R., BRAZDA, V., DUAN, S., RAVICHANDRAN, M., MA, J., 
XIAO, T., TEMPEL, W., ZUO, X., WANG, Y. X., CHIRGADZE, N. Y. & 
ARROWSMITH, C. H. 2011. Interferon-inducible protein 16: insight into the 
interaction with tumor suppressor p53. Structure, 19, 418-29. 
LIBRI, N. A., BARKER, S. J., ROSENBERG, W. M. & SEMPER, A. E. 2009. A 
class C CpG toll-like receptor 9 agonist successfully induces robust interferon-alpha 
 171 
production by plasmacytoid dendritic cells from patients chronically infected with 
hepatitis C. J Viral Hepat, 16, 315-24. 
LIM, W. H., KIRETA, S., RUSS, G. R. & COATES, P. T. 2007. Human plasmacytoid 
dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and 
delay EBV-related mortality in humanized NOD-SCID mice. Blood, 109, 1043-50. 
LIU, J., SHRIVER, Z., POPE, R. M., THORP, S. C., DUNCAN, M. B., COPELAND, 
R. J., RASKA, C. S., YOSHIDA, K., EISENBERG, R. J., COHEN, G., LINHARDT, 
R. J. & SASISEKHARAN, R. 2002. Characterization of a heparan sulfate 
octasaccharide that binds to herpes simplex virus type 1 glycoprotein D. J Biol Chem, 
277, 33456-67. 
LOMBARDI, V., VAN OVERTVELT, L., HORIOT, S., MOUSSU, H., CHABRE, H., 
LOUISE, A., BALAZUC, A. M., MASCARELL, L. & MOINGEON, P. 2008. Toll-
like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific 
tolerance via the sublingual route. Clin Exp Allergy, 38, 1819-29. 
LORET, S., GUAY, G. & LIPPÉ, R. 2008. Comprehensive characterization of 
extracellular herpes simplex virus type 1 virions. J Virol, 82, 8605-18. 
LOWANCE, D., NEUMAYER, H. H., LEGENDRE, C. M., SQUIFFLET, J. P., 
KOVARIK, J., BRENNAN, P. J., NORMAN, D., MENDEZ, R., KEATING, M. R., 
COGGON, G. L., CRISP, A. & LEE, I. C. 1999. Valacyclovir for the prevention of 
cytomegalovirus disease after renal transplantation. International Valacyclovir 
Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med, 340, 1462-
70. 
 172 
LUND, J., SATO, A., AKIRA, S., MEDZHITOV, R. & IWASAKI, A. 2003. Toll-like 
receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic 
cells. J Exp Med, 198, 513-20. 
LUND, J. M., ALEXOPOULOU, L., SATO, A., KAROW, M., ADAMS, N. C., 
GALE, N. W., IWASAKI, A. & FLAVELL, R. A. 2004. Recognition of single-
stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A, 101, 5598-
603. 
MALKIN, J. E., MORAND, P., MALVY, D., LY, T. D., CHANZY, B., DE 
LABAREYRE, C., EL HASNAOUI, A. & HERCBERG, S. 2002. Seroprevalence of 
HSV-1 and HSV-2 infection in the general French population. Sex Transm Infect, 78, 
201-3. 
MALMGAARD, L., MELCHJORSEN, J., BOWIE, A. G., MOGENSEN, S. C. & 
PALUDAN, S. R. 2004. Viral activation of macrophages through TLR-dependent and 
-independent pathways. J Immunol, 173, 6890-8. 
MARTINEZ, V., MOLINA, J. M., SCIEUX, C., RIBAUD, P. & MORFIN, F. 2006. 
Topical imiquimod for recurrent acyclovir-resistant HSV infection. Am J Med, 119, 
e9-11. 
MARTY, F. M., BRYAR, J., BROWNE, S. K., SCHWARZBERG, T., HO, V. T., 
BASSETT, I. V., KORETH, J., ALYEA, E. P., SOIFFER, R. J., CUTLER, C. S., 
ANTIN, J. H. & BADEN, L. R. 2007. Sirolimus-based graft-versus-host disease 
prophylaxis protects against cytomegalovirus reactivation after allogeneic 
hematopoietic stem cell transplantation: a cohort analysis. Blood, 110, 490-500. 
 173 
MATA-HARO, V., CEKIC, C., MARTIN, M., CHILTON, P. M., CASELLA, C. R. & 
MITCHELL, T. C. 2007. The vaccine adjuvant monophosphoryl lipid A as a TRIF-
biased agonist of TLR4. Science, 316, 1628-32. 
MCGEOCH, D. J., COOK, S., DOLAN, A., JAMIESON, F. E. & TELFORD, E. A. 
1995. Molecular phylogeny and evolutionary timescale for the family of mammalian 
herpesviruses. J Mol Biol, 247, 443-58. 
MCGEOCH, D. J., DALRYMPLE, M. A., DAVISON, A. J., DOLAN, A., FRAME, 
M. C., MCNAB, D., PERRY, L. J., SCOTT, J. E. & TAYLOR, P. 1988. The complete 
DNA sequence of the long unique region in the genome of herpes simplex virus type 1. 
J Gen Virol, 69 ( Pt 7), 1531-74. 
MEDZHITOV, R. 2007. Recognition of microorganisms and activation of the immune 
response. Nature, 449, 819-26. 
MEDZHITOV, R., PRESTON-HURLBURT, P. & JANEWAY, C. A. 1997. A human 
homologue of the Drosophila Toll protein signals activation of adaptive immunity. 
Nature, 388, 394-7. 
MELCHJORSEN, J., RINTAHAKA, J., SØBY, S., HORAN, K. A., POLTAJAINEN, 
A., ØSTERGAARD, L., PALUDAN, S. R. & MATIKAINEN, S. 2010. Early innate 
recognition of herpes simplex virus in human primary macrophages is mediated via 
the MDA5/MAVS-dependent and MDA5/MAVS/RNA polymerase III-independent 
pathways. J Virol, 84, 11350-8. 
MELCHJORSEN, J., SIRÉN, J., JULKUNEN, I., PALUDAN, S. R. & 
MATIKAINEN, S. 2006. Induction of cytokine expression by herpes simplex virus in 
human monocyte-derived macrophages and dendritic cells is dependent on virus 
 174 
replication and is counteracted by ICP27 targeting NF-kappaB and IRF-3. J Gen Virol, 
87, 1099-108. 
MEYLAN, E., BURNS, K., HOFMANN, K., BLANCHETEAU, V., MARTINON, F., 
KELLIHER, M. & TSCHOPP, J. 2004. RIP1 is an essential mediator of Toll-like 
receptor 3-induced NF-kappa B activation. Nat Immunol, 5, 503-7. 
MILBRADT, J., AUEROCHS, S. & MARSCHALL, M. 2007. Cytomegaloviral 
proteins pUL50 and pUL53 are associated with the nuclear lamina and interact with 
cellular protein kinase C. J Gen Virol, 88, 2642-50. 
MILLER, M. S., FURLONG, W. E., PENNELL, L., GEADAH, M. & HERTEL, L. 
2010. RASCAL is a new human cytomegalovirus-encoded protein that localizes to the 
nuclear lamina and in cytoplasmic vesicles at late times postinfection. J Virol, 84, 
6483-96. 
MIYAKE, K. 2007. Innate immune sensing of pathogens and danger signals by cell 
surface Toll-like receptors. Semin Immunol, 19, 3-10. 
MOLINA, M., ROMAGUERA, R. A., VALENTINE, J. & TAO, G. 2011. 
Seroprevalence of herpes simplex virus 2 among Hispanics in the USA: National 
Health and Nutrition Examination Survey, 2007-2008. Int J STD AIDS, 22, 387-90. 
MORFIN, F., SOUILLET, G., BILGER, K., OOKA, T., AYMARD, M. & 
THOUVENOT, D. 2000. Genetic characterization of thymidine kinase from acyclovir-
resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow 
transplant recipients. J Infect Dis, 182, 290-3. 
MORFIN, F. & THOUVENOT, D. 2003. Herpes simplex virus resistance to antiviral 
drugs. J Clin Virol, 26, 29-37. 
 175 
MORRISON, E. E., STEVENSON, A. J., WANG, Y. F. & MEREDITH, D. M. 1998a. 
Differences in the intracellular localization and fate of herpes simplex virus tegument 
proteins early in the infection of Vero cells. J Gen Virol, 79 ( Pt 10), 2517-28. 
MORRISON, E. E., WANG, Y. F. & MEREDITH, D. M. 1998b. Phosphorylation of 
structural components promotes dissociation of the herpes simplex virus type 1 
tegument. J Virol, 72, 7108-14. 
MULLARKEY, M., ROSE, J. R., BRISTOL, J., KAWATA, T., KIMURA, A., 
KOBAYASHI, S., PRZETAK, M., CHOW, J., GUSOVSKY, F., CHRIST, W. J. & 
ROSSIGNOL, D. P. 2003. Inhibition of endotoxin response by e5564, a novel Toll-
like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther, 304, 1093-102. 
MURUVE, D. A., PÉTRILLI, V., ZAISS, A. K., WHITE, L. R., CLARK, S. A., 
ROSS, P. J., PARKS, R. J. & TSCHOPP, J. 2008. The inflammasome recognizes 
cytosolic microbial and host DNA and triggers an innate immune response. Nature, 
452, 103-7. 
NEERINCX, A., LAUTZ, K., MENNING, M., KREMMER, E., ZIGRINO, P., 
HÖSEL, M., BÜNING, H., SCHWARZENBACHER, R. & KUFER, T. A. 2010. A 
role for the human nucleotide-binding domain, leucine-rich repeat-containing family 
member NLRC5 in antiviral responses. J Biol Chem, 285, 26223-32. 
NIAN, H., GENG, W. Q., CUI, H. L., BAO, M. J., ZHANG, Z. N., ZHANG, M., PAN, 
Y., HU, Q. H. & SHANG, H. 2012. R-848 triggers the expression of TLR7/8 and 
suppresses HIV replication in monocytes. BMC Infect Dis, 12, 5. 
O'NEILL, L. A., GOLENBOCK, D. & BOWIE, A. G. 2013. The history of Toll-like 
receptors - redefining innate immunity. Nat Rev Immunol, 13, 453-60. 
 176 
O'REGAN, K. J., BUCKS, M. A., MURPHY, M. A., WILLS, J. W. & COURTNEY, 
R. J. 2007. A conserved region of the herpes simplex virus type 1 tegument protein 
VP22 facilitates interaction with the cytoplasmic tail of glycoprotein E (gE). Virology, 
358, 192-200. 
OJALA, P. M., SODEIK, B., EBERSOLD, M. W., KUTAY, U. & HELENIUS, A. 
2000. Herpes simplex virus type 1 entry into host cells: reconstitution of capsid 
binding and uncoating at the nuclear pore complex in vitro. Mol Cell Biol, 20, 4922-
31. 
OKABE, Y., KAWANE, K., AKIRA, S., TANIGUCHI, T. & NAGATA, S. 2005. 
Toll-like receptor-independent gene induction program activated by mammalian DNA 
escaped from apoptotic DNA degradation. J Exp Med, 202, 1333-9. 
OLDENBURG, M., KRÜGER, A., FERSTL, R., KAUFMANN, A., NEES, G., 
SIGMUND, A., BATHKE, B., LAUTERBACH, H., SUTER, M., DREHER, S., 
KOEDEL, U., AKIRA, S., KAWAI, T., BUER, J., WAGNER, H., BAUER, S., 
HOCHREIN, H. & KIRSCHNING, C. J. 2012. TLR13 recognizes bacterial 23S rRNA 
devoid of erythromycin resistance-forming modification. Science, 337, 1111-5. 
OPAL, S. M., LATERRE, P. F., FRANCOIS, B., LAROSA, S. P., ANGUS, D. C., 
MIRA, J. P., WITTEBOLE, X., DUGERNIER, T., PERROTIN, D., TIDSWELL, M., 
JAUREGUI, L., KRELL, K., PACHL, J., TAKAHASHI, T., PECKELSEN, C., 
CORDASCO, E., CHANG, C. S., OEYEN, S., AIKAWA, N., MARUYAMA, T., 
SCHEIN, R., KALIL, A. C., VAN NUFFELEN, M., LYNN, M., ROSSIGNOL, D. P., 
GOGATE, J., ROBERTS, M. B., WHEELER, J. L., VINCENT, J. L. & GROUP, A. S. 
2013. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with 
severe sepsis: the ACCESS randomized trial. JAMA, 309, 1154-62. 
 177 
ORMROD, D., SCOTT, L. J. & PERRY, C. M. 2000. Valaciclovir: a review of its 
long term utility in the management of genital herpes simplex virus and 
cytomegalovirus infections. Drugs, 59, 839-63. 
OUYANG, S., SONG, X., WANG, Y., RU, H., SHAW, N., JIANG, Y., NIU, F., ZHU, 
Y., QIU, W., PARVATIYAR, K., LI, Y., ZHANG, R., CHENG, G. & LIU, Z. J. 2012. 
Structural analysis of the STING adaptor protein reveals a hydrophobic dimer 
interface and mode of cyclic di-GMP binding. Immunity, 36, 1073-86. 
PASS, R. F. 1985. Epidemiology and transmission of cytomegalovirus. J Infect Dis, 
152, 243-8. 
PELLETT, P. E., MCKNIGHT, J. L., JENKINS, F. J. & ROIZMAN, B. 1985. 
Nucleotide sequence and predicted amino acid sequence of a protein encoded in a 
small herpes simplex virus DNA fragment capable of trans-inducing alpha genes. Proc 
Natl Acad Sci U S A, 82, 5870-4. 
POLTORAK, A., HE, X., SMIRNOVA, I., LIU, M. Y., VAN HUFFEL, C., DU, X., 
BIRDWELL, D., ALEJOS, E., SILVA, M., GALANOS, C., FREUDENBERG, M., 
RICCIARDI-CASTAGNOLI, P., LAYTON, B. & BEUTLER, B. 1998a. Defective 
LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science, 
282, 2085-8. 
POLTORAK, A., SMIRNOVA, I., HE, X., LIU, M. Y., VAN HUFFEL, C., 
MCNALLY, O., BIRDWELL, D., ALEJOS, E., SILVA, M., DU, X., THOMPSON, P., 
CHAN, E. K., LEDESMA, J., ROE, B., CLIFTON, S., VOGEL, S. N. & BEUTLER, 
B. 1998b. Genetic and physical mapping of the Lps locus: identification of the toll-4 
receptor as a candidate gene in the critical region. Blood Cells Mol Dis, 24, 340-55. 
 178 
POST, L. E., MACKEM, S. & ROIZMAN, B. 1981. Regulation of alpha genes of 
herpes simplex virus: expression of chimeric genes produced by fusion of thymidine 
kinase with alpha gene promoters. Cell, 24, 555-65. 
PRICHARD, M. N. 2009. Function of human cytomegalovirus UL97 kinase in viral 
infection and its inhibition by maribavir. Rev Med Virol, 19, 215-29. 
PYLES, R. B., SAWTELL, N. M. & THOMPSON, R. L. 1992. Herpes simplex virus 
type 1 dUTPase mutants are attenuated for neurovirulence, neuroinvasiveness, and 
reactivation from latency. J Virol, 66, 6706-13. 
QUAN, Y., ZHANG, Y., WANG, S., LEE, N. & KENNEDY, I. R. 2006. A rapid and 
sensitive chemiluminescence enzyme-linked immunosorbent assay for the 
determination of fumonisin B1 in food samples. Anal Chim Acta, 580, 1-8. 
RAHMAN, M. 2006. Introduction to Flow Cytometry [Online]. AbD Serotec Ltd. 
Available: http://static.abdserotec.com/uploads/Flow-Cytometry.pdf [Accessed 25/01 
2013]. 
RATHINAM, V. A., JIANG, Z., WAGGONER, S. N., SHARMA, S., COLE, L. E., 
WAGGONER, L., VANAJA, S. K., MONKS, B. G., GANESAN, S., LATZ, E., 
HORNUNG, V., VOGEL, S. N., SZOMOLANYI-TSUDA, E. & FITZGERALD, K. 
A. 2010. The AIM2 inflammasome is essential for host defense against cytosolic 
bacteria and DNA viruses. Nat Immunol, 11, 395-402. 
REBSAMEN, M., HEINZ, L. X., MEYLAN, E., MICHALLET, M. C., SCHRODER, 
K., HOFMANN, K., VAZQUEZ, J., BENEDICT, C. A. & TSCHOPP, J. 2009. 
DAI/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to 
activate NF-kappaB. EMBO Rep, 10, 916-22. 
 179 
REYNOLDS, A. E., WILLS, E. G., ROLLER, R. J., RYCKMAN, B. J. & BAINES, J. 
D. 2002. Ultrastructural localization of the herpes simplex virus type 1 UL31, UL34, 
and US3 proteins suggests specific roles in primary envelopment and egress of 
nucleocapsids. J Virol, 76, 8939-52. 
ROBERTS, A. P., ABAITUA, F., O'HARE, P., MCNAB, D., RIXON, F. J. & 
PASDELOUP, D. 2009a. Differing roles of inner tegument proteins pUL36 and 
pUL37 during entry of herpes simplex virus type 1. J Virol, 83, 105-16. 
ROBERTS, T. L., IDRIS, A., DUNN, J. A., KELLY, G. M., BURNTON, C. M., 
HODGSON, S., HARDY, L. L., GARCEAU, V., SWEET, M. J., ROSS, I. L., HUME, 
D. A. & STACEY, K. J. 2009b. HIN-200 proteins regulate caspase activation in 
response to foreign cytoplasmic DNA. Science, 323, 1057-60. 
ROCK, F. L., HARDIMAN, G., TIMANS, J. C., KASTELEIN, R. A. & BAZAN, J. F. 
1998. A family of human receptors structurally related to Drosophila Toll. Proc Natl 
Acad Sci U S A, 95, 588-93. 
ROIZMAN, B., GU, H. & MANDEL, G. 2005. The first 30 minutes in the life of a 
virus: unREST in the nucleus. Cell Cycle, 4, 1019-21. 
ROLLER, R. J., ZHOU, Y., SCHNETZER, R., FERGUSON, J. & DESALVO, D. 
2000. Herpes simplex virus type 1 U(L)34 gene product is required for viral 
envelopment. J Virol, 74, 117-29. 
ROOP, C., HUTCHINSON, L. & JOHNSON, D. C. 1993. A mutant herpes simplex 
virus type 1 unable to express glycoprotein L cannot enter cells, and its particles lack 
glycoprotein H. J Virol, 67, 2285-97. 
 180 
ROSE, W. A., MCGOWIN, C. L. & PYLES, R. B. 2009. FSL-1, a bacterial-derived 
toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection. 
Virol J, 6, 195. 
RYCKMAN, B. J. & ROLLER, R. J. 2004. Herpes simplex virus type 1 primary 
envelopment: UL34 protein modification and the US3-UL34 catalytic relationship. J 
Virol, 78, 399-412. 
SAFRIN, S., CHERRINGTON, J. & JAFFE, H. S. 1997. Clinical uses of cidofovir. 
Rev Med Virol, 7, 145-156. 
SAFRIN, S., CRUMPACKER, C., CHATIS, P., DAVIS, R., HAFNER, R., RUSH, J., 
KESSLER, H. A., LANDRY, B. & MILLS, J. 1991. A controlled trial comparing 
foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the 
acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J 
Med, 325, 551-5. 
SAITO, T., HIRAI, R., LOO, Y. M., OWEN, D., JOHNSON, C. L., SINHA, S. C., 
AKIRA, S., FUJITA, T. & GALE, M. 2007. Regulation of innate antiviral defenses 
through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A, 104, 
582-7. 
SAM, M. D., EVANS, B. T., COEN, D. M. & HOGLE, J. M. 2009. Biochemical, 
biophysical, and mutational analyses of subunit interactions of the human 
cytomegalovirus nuclear egress complex. J Virol, 83, 2996-3006. 
SANCHEZ, V., GREIS, K. D., SZTUL, E. & BRITT, W. J. 2000. Accumulation of 
virion tegument and envelope proteins in a stable cytoplasmic compartment during 
human cytomegalovirus replication: characterization of a potential site of virus 
assembly. J Virol, 74, 975-86. 
 181 
SATO, A., LINEHAN, M. M. & IWASAKI, A. 2006. Dual recognition of herpes 
simplex viruses by TLR2 and TLR9 in dendritic cells. Proc Natl Acad Sci U S A, 103, 
17343-8. 
SCHMIEG, F. 2011. Principles of Polyacrylamide Gel Electrophoresis (PAGE). 
[Online]. Department of Biological Sciences,University of Delaware Available: 
http://www.udel.edu/biology/fschmieg/411acrylamide.htm [Accessed 03/05 2014]. 
SCHRÖDER, M., BARAN, M. & BOWIE, A. G. 2008. Viral targeting of DEAD box 
protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J, 27, 
2147-57. 
SCHUMANN, R. R., LEONG, S. R., FLAGGS, G. W., GRAY, P. W., WRIGHT, S. 
D., MATHISON, J. C., TOBIAS, P. S. & ULEVITCH, R. J. 1990. Structure and 
function of lipopolysaccharide binding protein. Science, 249, 1429-31. 
SCHWARTZ, T., BEHLKE, J., LOWENHAUPT, K., HEINEMANN, U. & RICH, A. 
2001. Structure of the DLM-1-Z-DNA complex reveals a conserved family of Z-
DNA-binding proteins. Nat Struct Biol, 8, 761-5. 
SEO, J. Y. & BRITT, W. J. 2007. Cytoplasmic envelopment of human 
cytomegalovirus requires the postlocalization function of tegument protein pp28 
within the assembly compartment. J Virol, 81, 6536-47. 
SHANG, G., ZHU, D., LI, N., ZHANG, J., ZHU, C., LU, D., LIU, C., YU, Q., ZHAO, 
Y., XU, S. & GU, L. 2012. Crystal structures of STING protein reveal basis for 
recognition of cyclic di-GMP. Nat Struct Mol Biol, 19, 725-7. 
SHIMAZU, R., AKASHI, S., OGATA, H., NAGAI, Y., FUKUDOME, K., MIYAKE, 
K. & KIMOTO, M. 1999. MD-2, a molecule that confers lipopolysaccharide 
responsiveness on Toll-like receptor 4. J Exp Med, 189, 1777-82. 
 182 
SHU, C., YI, G., WATTS, T., KAO, C. C. & LI, P. 2012. Structure of STING bound 
to cyclic di-GMP reveals the mechanism of cyclic dinucleotide recognition by the 
immune system. Nat Struct Mol Biol, 19, 722-4. 
SHUKLA, D., LIU, J., BLAIKLOCK, P., SHWORAK, N. W., BAI, X., ESKO, J. D., 
COHEN, G. H., EISENBERG, R. J., ROSENBERG, R. D. & SPEAR, P. G. 1999. A 
novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell, 99, 
13-22. 
SIMPSON, S. A., MANCHAK, M. D., HAGER, E. J., KRUMMENACHER, C., 
WHITBECK, J. C., LEVIN, M. J., FREED, C. R., WILCOX, C. L., COHEN, G. H., 
EISENBERG, R. J. & PIZER, L. I. 2005. Nectin-1/HveC Mediates herpes simplex 
virus type 1 entry into primary human sensory neurons and fibroblasts. J Neurovirol, 
11, 208-18. 
SINGH, V. V., KERUR, N., BOTTERO, V., DUTTA, S., CHAKRABORTY, S., 
ANSARI, M. A., PAUDEL, N., CHIKOTI, L. & CHANDRAN, B. 2013. Kaposi's 
sarcoma-associated herpesvirus latency in endothelial and B cells activates gamma 
interferon-inducible protein 16-mediated inflammasomes. J Virol, 87, 4417-31. 
SMITH, I. L., CHERRINGTON, J. M., JILES, R. E., FULLER, M. D., FREEMAN, 
W. R. & SPECTOR, S. A. 1997. High-level resistance of cytomegalovirus to 
ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. 
J Infect Dis, 176, 69-77. 
SØRENSEN, L. N., REINERT, L. S., MALMGAARD, L., BARTHOLDY, C., 
THOMSEN, A. R. & PALUDAN, S. R. 2008. TLR2 and TLR9 synergistically control 
herpes simplex virus infection in the brain. J Immunol, 181, 8604-12. 
 183 
SPENCER, J. V., NEWCOMB, W. W., THOMSEN, D. R., HOMA, F. L. & BROWN, 
J. C. 1998. Assembly of the herpes simplex virus capsid: preformed triplexes bind to 
the nascent capsid. J Virol, 72, 3944-51. 
SRINIVASULA, S. M., POYET, J. L., RAZMARA, M., DATTA, P., ZHANG, Z. & 
ALNEMRI, E. S. 2002. The PYRIN-CARD protein ASC is an activating adaptor for 
caspase-1. J Biol Chem, 277, 21119-22. 
STEBEN M, S. S. 1997. Genital herpes: the epidemiology and control of a common 
sexually transmitted disease. . Can J.Human Sex, 2, 127-34. 
STETSON, D. B., KO, J. S., HEIDMANN, T. & MEDZHITOV, R. 2008. Trex1 
prevents cell-intrinsic initiation of autoimmunity. Cell, 134, 587-98. 
STETSON, D. B. & MEDZHITOV, R. 2006. Recognition of cytosolic DNA activates 
an IRF3-dependent innate immune response. Immunity, 24, 93-103. 
SUN, W., LI, Y., CHEN, L., CHEN, H., YOU, F., ZHOU, X., ZHOU, Y., ZHAI, Z., 
CHEN, D. & JIANG, Z. 2009. ERIS, an endoplasmic reticulum IFN stimulator, 
activates innate immune signaling through dimerization. Proc Natl Acad Sci U S A, 
106, 8653-8. 
SZILÁGYI, J. F. & CUNNINGHAM, C. 1991. Identification and characterization of a 
novel non-infectious herpes simplex virus-related particle. J Gen Virol, 72 ( Pt 3), 661-
8. 
SZOMOLANYI-TSUDA, E., LIANG, X., WELSH, R. M., KURT-JONES, E. A. & 
FINBERG, R. W. 2006. Role for TLR2 in NK cell-mediated control of murine 
cytomegalovirus in vivo. J Virol, 80, 4286-91. 
 184 
TABETA, K., HOEBE, K., JANSSEN, E. M., DU, X., GEORGEL, P., CROZAT, K., 
MUDD, S., MANN, N., SOVATH, S., GOODE, J., SHAMEL, L., HERSKOVITS, A. 
A., PORTNOY, D. A., COOKE, M., TARANTINO, L. M., WILTSHIRE, T., 
STEINBERG, B. E., GRINSTEIN, S. & BEUTLER, B. 2006. The Unc93b1 mutation 
3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 
and 9. Nat Immunol, 7, 156-64. 
TAKAESU, G., KISHIDA, S., HIYAMA, A., YAMAGUCHI, K., SHIBUYA, H., 
IRIE, K., NINOMIYA-TSUJI, J. & MATSUMOTO, K. 2000. TAB2, a novel adaptor 
protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the 
IL-1 signal transduction pathway. Mol Cell, 5, 649-58. 
TAKAOKA, A., WANG, Z., CHOI, M. K., YANAI, H., NEGISHI, H., BAN, T., LU, 
Y., MIYAGISHI, M., KODAMA, T., HONDA, K., OHBA, Y. & TANIGUCHI, T. 
2007. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate 
immune response. Nature, 448, 501-5. 
TAKEUCHI, O., HOSHINO, K., KAWAI, T., SANJO, H., TAKADA, H., OGAWA, 
T., TAKEDA, K. & AKIRA, S. 1999a. Differential roles of TLR2 and TLR4 in 
recognition of gram-negative and gram-positive bacterial cell wall components. 
Immunity, 11, 443-51. 
TAKEUCHI, O., KAWAI, T., SANJO, H., COPELAND, N. G., GILBERT, D. J., 
JENKINS, N. A., TAKEDA, K. & AKIRA, S. 1999b. TLR6: A novel member of an 
expanding toll-like receptor family. Gene, 231, 59-65. 
TANAKA, Y. & CHEN, Z. J. 2012. STING specifies IRF3 phosphorylation by TBK1 
in the cytosolic DNA signaling pathway. Sci Signal, 5, ra20. 
 185 
TER BRAKE, O., 'T HOOFT, K., LIU, Y. P., CENTLIVRE, M., VON EIJE, K. J. & 
BERKHOUT, B. 2008. Lentiviral vector design for multiple shRNA expression and 
durable HIV-1 inhibition. Mol Ther, 16, 557-64. 
TOROPOVA, K., HUFFMAN, J. B., HOMA, F. L. & CONWAY, J. F. 2011. The 
herpes simplex virus 1 UL17 protein is the second constituent of the capsid vertex-
specific component required for DNA packaging and retention. J Virol, 85, 7513-22. 
TRIANTAFILOU, K., ERYILMAZLAR, D. & TRIANTAFILOU, M. 2014. Herpes 
simplex virus 2-induced activation in vaginal cells involves Toll-like receptors 2 and 9 
and DNA sensors DAI and IFI16. Am J Obstet Gynecol, 210, 122.e1-122.e10. 
TRIANTAFILOU, K., ORTHOPOULOS, G., VAKAKIS, E., AHMED, M. A., 
GOLENBOCK, D. T., LEPPER, P. M. & TRIANTAFILOU, M. 2005. Human cardiac 
inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like 
receptor (TLR) 8-dependent. Cell Microbiol, 7, 1117-26. 
TRIANTAFILOU, K., VAKAKIS, E., KAR, S., RICHER, E., EVANS, G. L. & 
TRIANTAFILOU, M. 2012. Visualisation of direct interaction of MDA5 and the 
dsRNA replicative intermediate form of positive strand RNA viruses. J Cell Sci, 125, 
4761-9. 
TRIANTAFILOU, M., GAMPER, F. G., HASTON, R. M., MOURATIS, M. A., 
MORATH, S., HARTUNG, T. & TRIANTAFILOU, K. 2006. Membrane sorting of 
toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines 
heterotypic associations with CD36 and intracellular targeting. J Biol Chem, 281, 
31002-11. 
UNTERHOLZNER, L., KEATING, S. E., BARAN, M., HORAN, K. A., JENSEN, S. 
B., SHARMA, S., SIROIS, C. M., JIN, T., LATZ, E., XIAO, T. S., FITZGERALD, K. 
 186 
A., PALUDAN, S. R. & BOWIE, A. G. 2010. IFI16 is an innate immune sensor for 
intracellular DNA. Nat Immunol, 11, 997-1004. 
UPTON, J. W., KAISER, W. J. & MOCARSKI, E. S. 2010. Virus inhibition of RIP3-
dependent necrosis. Cell Host Microbe, 7, 302-13. 
UPTON, J. W., KAISER, W. J. & MOCARSKI, E. S. 2012. DAI/ZBP1/DLM-1 
complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted 
by murine cytomegalovirus vIRA. Cell Host Microbe, 11, 290-7. 
VARANI, S., CEDERARV, M., FELD, S., TAMMIK, C., FRASCAROLI, G., 
LANDINI, M. P. & SÖDERBERG-NAUCLÉR, C. 2007. Human cytomegalovirus 
differentially controls B cell and T cell responses through effects on plasmacytoid 
dendritic cells. J Immunol, 179, 7767-76. 
VERTHELYI, D., ISHII, K. J., GURSEL, M., TAKESHITA, F. & KLINMAN, D. M. 
2001. Human peripheral blood cells differentially recognize and respond to two 
distinct CPG motifs. J Immunol, 166, 2372-7. 
VITTONE, V., DIEFENBACH, E., TRIFFETT, D., DOUGLAS, M. W., 
CUNNINGHAM, A. L. & DIEFENBACH, R. J. 2005. Determination of interactions 
between tegument proteins of herpes simplex virus type 1. J Virol, 79, 9566-71. 
VOLLMER, J. & KRIEG, A. M. 2009. Immunotherapeutic applications of CpG 
oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev, 61, 195-204. 
VON EINEM, J., SCHUMACHER, D., O'CALLAGHAN, D. J. & OSTERRIEDER, 
N. 2006. The alpha-TIF (VP16) homologue (ETIF) of equine herpesvirus 1 is essential 
for secondary envelopment and virus egress. J Virol, 80, 2609-20. 
 187 
WAGSTAFF, A. J. & BRYSON, H. M. 1994. Foscarnet. A reappraisal of its antiviral 
activity, pharmacokinetic properties and therapeutic use in immunocompromised 
patients with viral infections. Drugs, 48, 199-226. 
WAGSTAFF, A. J., FAULDS, D. & GOA, K. L. 1994. Aciclovir. A reappraisal of its 
antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs, 47, 153-
205. 
WALD, A. & LINK, K. 2002. Risk of human immunodeficiency virus infection in 
herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis, 185, 
45-52. 
WALDMAN, W. J., KNIGHT, D. A., BLINDER, L., SHEN, J., LURAIN, N. S., 
MILLER, D. M., SEDMAK, D. D., WILLIAMS, J. W. & CHONG, A. S. 1999. 
Inhibition of cytomegalovirus in vitro and in vivo by the experimental 
immunosuppressive agent leflunomide. Intervirology, 42, 412-8. 
WANG, J. B. & MCVOY, M. A. 2011. A 128-base-pair sequence containing the pac1 
and a presumed cryptic pac2 sequence includes cis elements sufficient to mediate 
efficient genome maturation of human cytomegalovirus. J Virol, 85, 4432-9. 
WANG, J. P., KURT-JONES, E. A., SHIN, O. S., MANCHAK, M. D., LEVIN, M. J. 
& FINBERG, R. W. 2005. Varicella-zoster virus activates inflammatory cytokines in 
human monocytes and macrophages via Toll-like receptor 2. J Virol, 79, 12658-66. 
WOLFSTEIN, A., NAGEL, C. H., RADTKE, K., DÖHNER, K., ALLAN, V. J. & 
SODEIK, B. 2006. The inner tegument promotes herpes simplex virus capsid motility 
along microtubules in vitro. Traffic, 7, 227-37. 
 188 
WRIGHT, S. D., RAMOS, R. A., TOBIAS, P. S., ULEVITCH, R. J. & MATHISON, 
J. C. 1990. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS 
binding protein. Science, 249, 1431-3. 
WYLES, D. L., PATEL, A., MADINGER, N., BESSESEN, M., KRAUSE, P. R. & 
WEINBERG, A. 2005. Development of herpes simplex virus disease in patients who 
are receiving cidofovir. Clin Infect Dis, 41, 676-80. 
YAMAMOTO, M., SATO, S., HEMMI, H., HOSHINO, K., KAISHO, T., SANJO, H., 
TAKEUCHI, O., SUGIYAMA, M., OKABE, M., TAKEDA, K. & AKIRA, S. 2003. 
Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. 
Science, 301, 640-3. 
YAMAMOTO, M., SATO, S., MORI, K., HOSHINO, K., TAKEUCHI, O., TAKEDA, 
K. & AKIRA, S. 2002. Cutting edge: a novel Toll/IL-1 receptor domain-containing 
adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor 
signaling. J Immunol, 169, 6668-72. 
YANG, P., AN, H., LIU, X., WEN, M., ZHENG, Y., RUI, Y. & CAO, X. 2010. The 
cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via 
a beta-catenin-dependent pathway. Nat Immunol, 11, 487-94. 
YANG, Y. G., LINDAHL, T. & BARNES, D. E. 2007. Trex1 exonuclease degrades 
ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell, 131, 
873-86. 
YAROVINSKY, F., ZHANG, D., ANDERSEN, J. F., BANNENBERG, G. L., 
SERHAN, C. N., HAYDEN, M. S., HIENY, S., SUTTERWALA, F. S., FLAVELL, R. 
A., GHOSH, S. & SHER, A. 2005. TLR11 activation of dendritic cells by a protozoan 
profilin-like protein. Science, 308, 1626-9. 
 189 
YIN, Q., TIAN, Y., KABALEESWARAN, V., JIANG, X., TU, D., ECK, M. J., 
CHEN, Z. J. & WU, H. 2012. Cyclic di-GMP sensing via the innate immune signaling 
protein STING. Mol Cell, 46, 735-45. 
YONEYAMA, M. & FUJITA, T. 2007. Function of RIG-I-like receptors in antiviral 
innate immunity. J Biol Chem, 282, 15315-8. 
YONEYAMA, M., KIKUCHI, M., MATSUMOTO, K., IMAIZUMI, T., MIYAGISHI, 
M., TAIRA, K., FOY, E., LOO, Y. M., GALE, M., AKIRA, S., YONEHARA, S., 
KATO, A. & FUJITA, T. 2005. Shared and unique functions of the DExD/H-box 
helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol, 175, 
2851-8. 
ZHANG, D., ZHANG, G., HAYDEN, M. S., GREENBLATT, M. B., BUSSEY, C., 
FLAVELL, R. A. & GHOSH, S. 2004. A toll-like receptor that prevents infection by 
uropathogenic bacteria. Science, 303, 1522-6. 
ZHANG, Z., LOUBOUTIN, J. P., WEINER, D. J., GOLDBERG, J. B. & WILSON, J. 
M. 2005. Human airway epithelial cells sense Pseudomonas aeruginosa infection via 
recognition of flagellin by Toll-like receptor 5. Infect Immun, 73, 7151-60. 
ZHANG, Z., YUAN, B., BAO, M., LU, N., KIM, T. & LIU, Y. J. 2011. The helicase 
DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. 
Nat Immunol, 12, 959-65. 
ZHONG, B., YANG, Y., LI, S., WANG, Y. Y., LI, Y., DIAO, F., LEI, C., HE, X., 
ZHANG, L., TIEN, P. & SHU, H. B. 2008. The adaptor protein MITA links virus-
sensing receptors to IRF3 transcription factor activation. Immunity, 29, 538-50. 
 190 
ZHOU, Z. H., CHEN, D. H., JAKANA, J., RIXON, F. J. & CHIU, W. 1999. 
Visualization of tegument-capsid interactions and DNA in intact herpes simplex virus 
type 1 virions. J Virol, 73, 3210-8. 
ZHOU, Z. H., DOUGHERTY, M., JAKANA, J., HE, J., RIXON, F. J. & CHIU, W. 
2000. Seeing the herpesvirus capsid at 8.5 A. Science, 288, 877-80. 
ZUCCHINI, N., BESSOU, G., TRAUB, S., ROBBINS, S. H., UEMATSU, S., 
AKIRA, S., ALEXOPOULOU, L. & DALOD, M. 2008. Cutting edge: Overlapping 
functions of TLR7 and TLR9 for innate defense against a herpesvirus infection. J 
Immunol, 180, 5799-803. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 191 
Appendix 
X10 PBS (500ml)  
• 50g NaCl  
• 1.25g KCl  
• 7.2g Na2HPO4  
• 1.25g KH2PO4  
• 400ml distilled water (dH2O) 
• pH 7.2  
• Top up to 500ml with dH2O  
 
For PBS-Tween, add 10ml Tween-20 (rinse tip in buffer).  
 
X1 PBS (500ml)  
• 50ml x10 PBS  
• 450ml dH2O  
 
X2 PBS (500ml)  
• 100ml x10 PBS  
• 400ml dH2O  
 
X1 PBS/0.02%(w/v) BSA/0.02%(w/v) Saponin/0.02%(w/v) Sodium Azide (NaN3) 
(500ml)  
• 0.02% = 0.02g in 100ml 
• In 500ml need 0.1g  
• 0.1g of each added to 500ml x1 PBS  
 
10% SDS (100ml)  
• 10.0g SDS  
• In 100ml dH2O  
• Mix on a heater / stirrer  
 
4% Paraformaldehyde (4% PFA) (200ml)  
• Add 8.0g PFA powder to approx. 80ml of dH2O in a glass beaker.  
• Heat to 60oC in a fume hood on a heater / stirrer  
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• Add a few drops of 1M NaOH to help dissolve, whilst still on a heater / stirrer  
• When the solid has completely dissolved, top up to 100ml with dH2O, let the 
solution cool to room temperature, add 100ml of x2 PBS  
 
 
0.5M Tris pH 6.8 (250ml)  
• 60.5g in 1000ml (M = Mass / M.wt therefore 0.5 = Mass / 121 therefore Mass 
= 60.5)  
• 15.1g Tris in 250ml dH2O  
• pH to 6.8 with concentrated HCl  
 
X2 SDS-PAGE Reducing Sample Buffer (approx. 40ml)  
• 20ml 0.5M Tris pH 6.8  
• 16ml 10% SDS  
• 10.0g Glycerol  
• 4ml 14.3M β-mercaptoethanol  
• Small spatula with a bit of Bromophenol Blue  
• Stir with spatula till mixed, transfer to bottle  
 
Phenol / Chloroform / Isoamyl Alcohol  
• In fume hood, in a 500ml sterile glass bottle  
•  Add 100ml Phenol + 100ml Chloroform / Isoamyl Alcohol + 100ml dH2O  
• Leave to settle  
• Place in fridge  
 
 
Stripping Buffer (200ml)  
•  1.4ml β-Mercaptoethanol (100mM) 
• 40ml 10% SDS (=2% in 200ml)  
• 1.52g Tris HCl pH6.7 (62.5mM)  
• Top up to 200ml with PBS-T  
DNA Isolation Solutions: 
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STET Buffer (100ml)  
• 8g Sucrose  
• 500µl Triton  
• 10ml EDTA (500mM) pH 8 (adjust with HCl)  
• 1ml Tris pH 8 (1M) (adjust with HCl)  
• Make up to 100ml with dH2O 
 
1M Tris (100ml)  
• 12.1g Tris  
• In 100ml dH2O  
• pH to 8 with HCl  
 
500mM EDTA (=0.5M EDTA) (100ml)  
• 37.22g EDTA  
• In 200ml dH2O  
• pH to 8 with HCl  
 
Sucrose Gradient Buffers:  
 
60% / 30% / 10% in PBS  
• 60g / 30g / 10g Sucrose (powder) into 3 separate conical flasks  
• Top each up to 100ml with PBS  
• Fridge  
 
 
 
SDS-PAGE / Western Blot Solutions:  
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1.5M Tris-HCl pH 8.8 (500ml)  
• 90.85g Tris  
• In 500ml dH2O  
• pH to 8.8 with conc. HCl  
 
X2 Transfer Buffer (1000ml)  
• 4.88g Tris  
• 20ml 10% SDS  
• 400ml Isopropanol (= Propan-2-ol)  
• Make up to 1000ml with dH2O 
• pH to 8.3 with Acetic Acid  
• To get X1 TB  split into 2 beakers, add 500ml dH2O to each  
 
Running Buffer (500ml)   
• 50ml x10 Running Buffer  
• 450ml dH2O  
• [Tris-Glycine pH 8.8]  25mM Tris, 192mM glycine, 0.1% SDS 
• For 10x running buffer:  
• 288g glycine 
• 60.4g tris base  
• 20g SDS  
• 1800ml dH2O  
 
PBS-Tween (2000ml)  
• 200ml x10 PBS into a 1000ml bottle  
• Top up to 1000ml with dH2O  
• Add 2ml PBS-Tween20, dropping the tips into the bottle  
• Mix (shake)  
• Decant 500ml into a new bottle, top both up with 500ml dH2O = 2 x 1000ml 
bottles of PBS-T  
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10% Resolving Gel (for 2 gels)  
• 4.02ml dH2O  
• 2.5ml 1.5M Tris-HCl pH 8.8  
• 100µl 10% SDS  
• 3.33ml Acrylamide/Bis   
• To Polymerise, add:  
o 50µl 10% APS  
o 10µl TEMED  
 
4% Stacking Gel (for 2 gels)  
• 6.1ml dH2O  
• 2.5ml 0.5M Tris-HCl pH 6.8  
• 100µl 10% SDS  
• 1.3ml Acrylamide/Bis  
• To Polymerise, add:  
o 50µl 10% APS  
o 20µl TEMED  
 
Blocking Reagent (40ml)  
• 2g Milk Powder  
• 40ml PBS-T  
 
Agarose Gel Electrophoresis Solutions:  
 
50X ELFO (2M Tris, 50mM EDTA) (1000ml)  
• 242g Tris base  
• 100ml EDTA (0.5M)  
• pH 7.7 with Acetic acid  
• Make up to 1000ml with dH2O  
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1X ELFO (1000ml)  
• 20ml 50X ELFO in 1000ml dH2O  
ELFO Loading Buffer (200ml)  
• 100ml Glycerol  
• 20ml 50X ELFO  
• 80ml dH2O  
• A few mg of Bromophenol Blue  
 
The original amounts for resolving and stacking solutions are shown in the Table 2, 
and Table 3 respectively. 
 
Table 2: This table shows the amounts of each solution used to prepare a resolving solution for one gel.  
 
 
 
 Two Gels One Gel 
Distilled Water 6.1ml 3.05ml 
0.5 M Tris-HCl pH 
6.8 
2.5ml 1.25ml 
10% (w/v) SDS 100µl 50µl 
Acrylamide/Bis 1.3ml 0.65ml 
10% APS 50µl 50µl 
TEMED 10µl 10µl 
   
Total Monomer 10ml  
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Table 3:  This table shows the amounts of each solution to prepare a stacking solution for one gel. 
 
 10% 12% 
Distilled Water 4.02ml 3.5ml 
1.5 M Tris-HCl pH 8.8 2.5ml 2.5ml 
10% (w/v) SDS 100µl 100µl 
Acrylamide/Bis 3.33ml 4.0ml 
10% APS 50.0µl 50.0µl 
TEMED 5.0µl 5.0µl 
   
Total Monomer 10.0ml 10.0 ml 
